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ABSTRACT OF DISSERTATION 
DEVELOPMENT OF NOVEL CHEMICAL TOOLS FOR PROTEASOME BIOLOGY 
& A NEW APPROACH TO 1-AZASPIROCYCLIC RING SYSTEM 
 The proteasome, a multiprotease complex, is clinically validated as an anticancer 
target by the FDA approval of bortezomib and carfilzomib for the treatment of multiple 
myeloma. The emergence of resistance to proteasome inhibitors however remains a major 
clinical challenge. Recently, distinct types of proteasomes termed ‘intermediate 
proteasomes’, which contain unconventional mixtures of catalytic subunits, have been 
implicated with drug resistance of tumor cells. In elucidating the role of intermediate 
proteasomes in drug resistance, a crucial step is to unequivocally determine the subunit 
composition of intermediate proteasomes in cells. With this in mind, the goal of the 
studies reported in this dissertation is to develop novel chemical tools which can facilitate 
the investigation of intermediate proteasomes via two complementary approaches: a 
FRET-based approach and a bifunctional cross-linking approach.
 Chapter 2 describes the structure-based design, synthesis, and characterization of 
a peptide epoxyketone-based fluorescent probe, named as LKS01-B650, which 
selectively targets the immunoproteasome subunit β5i/LMP7. In addition to its utility in 
determining the identity of intermediate proteasomes as FRET-based probe, this imaging 
agent may also serve as a valuable tool in visualizing the immunoproteasome in living 
cells. 
Chapter 3 describes the design and synthesis of various epoxyketone-based 
bifunctional agents. The ability of these bifunctional agents to cross-link different 
catalytic subunits within a proteasome complex is shown by mobility shift assays. 
These bifunctional agents may provide important information in determining the subunit 
composition of proteasomes.  
 Chapter 4 describes a systematic study of the relationship between the proteasome 
inhibitor structure and the inhibitory activity against critical subunits of the proteasome. 
Given the reported role of β5i/LMP7 in autoimmune diseases, this study may provide 
useful insights in developing therapeutic agents for autoimmune diseases as well as other 
diseases. 
 Chapter 5 describes a separate study which is not related to proteasome biology. 
A concise approach to synthesize 1-azaspirocyclic ring systems is developed by utilizing 
a novel semi-pinacol/Beckmann rearrangement. Additionally, an environmentally benign, 
microwave-assisted, and solvent-free self-condensation of carbonyl compounds is 
reported. 
Keywords: Intermediate Proteasome, Activity-Based Fluorescent Probe, Cross-linking 
Agent, 1-Azaspirocyclic Ring System
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Chapter 1: Introduction & Objective of the Study 
 
1.1. Intracellular Protein Degradation 
Intracellular protein synthesis and protein degradation are two complementary processes 
which play important roles in maintaining biological homeostasis. The dynamic state of 
intracellular protein turnover is not only regulated by the rate of protein synthesis, but 
also by the rate of proteolysis. As cellular processes depend on active proteins, 
uncontrolled or inaccurate protein synthesis or degradation is potentially harmful to cells. 
Even a small imbalance in the rate of protein synthesis and degradation can result in 
cellular and tissue atrophy (loss of proteins from cells) or hypertrophy (increase in 
protein contents of cells), which in turn can cause the deregulation of several cellular 
processes (Mitch et al. 1996). To prevent promiscuous protein degradation, cells contain 
complex proteolytic active sites that are carefully compartmentalized either in the 
macromolecular complex known as the proteasome or in organelles such as lysosomes. 
 In all eukaryotic cells, the ubiquitin proteasome pathway (UPP) is responsible for 
the degradation of the majority of intracellular proteins. However, some extracellular 
proteins and cell surface proteins are degraded within lysosomes. The selection of 
proteins to be degraded by lysosomes generally occurs during endocytosis (Lardeux et al. 
1987; Baehrecke et al. 2005). Lysosomes contain several proteases such as cathepsins B, 
H, and D for the degradation of proteins. In mammalian cells, there are other proteolytic 
processes that involve the calpains and caspases. The calpains are cysteine proteases that 
are activated during cellular injury and require Ca2+ for their activity (Goll et al. 2003). 
On the other hand, caspases are aspartate-specific cysteine proteases that are required for 
the degradation of cellular components during apoptosis (Salvesen et al. 1997). 
 
1.2. Ubiquitin proteasome pathway (UPP) 
The importance of the ubiquitin proteasome pathway (UPP) is evident from the 2004 
Noble Prize in Chemistry, which was awarded to Aaron Chiechanover, Avram Hershko, 
and Irwin Rose for their contributions to the discovery of ubiquitin and the understanding 
 
2 
of its role in protein degradation. The UPP is responsible for selective ATP-dependent 
degradation of more than 80% of the intracellular proteins in eukaryotes (Adams, J. 
2004). The primary functions of the UPP are degradation of damaged or unneeded 
proteins and maintaining turnover of short-lived proteins that are essential for many 
cellular regulatory mechanisms. For example, cell growth and gene expression are 
controlled by the proteasomal degradation of transcriptional regulators, e.g. c-Jun, E2F-1 
and β-catenin (Hershko et al. 1998). The degradation of cyclins and inhibitors of cyclin-
dependent kinases is required for the regulation of cell cycle progression (Koepp et al. 
1999). Similarly, the termination of certain transduction cascades is regulated by 
proteasomal degradation of activated protein kinases such as protein kinase C and Src 
tyrosine kinase (Lu et al. 1998; Harris et al. 1999). Furthermore, the ubiquitin proteasome 
pathway (UPP) plays an important role in maintaining other cellular processes such as 
inflammation (Palombella et al. 1998), muscle atrophy (Mitch et al. 1996), immune 
responses (Rock et al.1999) and metabolic pathways (Hampton et al. 1996; Murakami et 
al. 1992). Also, the UPP selectively breaks down mutant and misfolded proteins 
(Schubert et al. 2000).  
 The whole process of protein degradation by the UPP involves two consecutive 
and distinct steps. The first step involves the labeling of a protein for degradation by 
covalent attachment of ubiquitin to the protein target (ubiquitination). In the second step, 
a complex proteolytic system known as the proteasome degrades the ubiquitinated 
protein into smaller peptides (degradation). 
 
1.2.1. Ubiquitination 
The key player in the ubiquitination process is ubiquitin (Ub) which is a highly conserved 
protein of 76 amino acids. Ubiquitin contains a glycine residue (G76) at its C-terminal 
end that serves as the site of covalent conjugation with the nucleophilic ?-amino group of 
a Lys residue of the target substrate (Vijay-Kumar et al. 1985).  
A cascade of three enzymes (E1, E2 and E3) is required for the conjugation of a 
ubiquitin (Ub) monomer or a polyubiquitin (poly-Ub) chain onto the protein destined for 
degradation (Figure 1.1). This process is initiated by the activation of the C-terminal G76 
of ubiquitin by the ubiquitin-activation enzyme, E1. This single E1 enzyme uses one ATP 
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to generate a highly reactive E1-Ub thioester intermediate (Handley et al. 1991). After 
activation, the Ub thioester is transferred to the ubiquitin-conjugating enzyme E2 (Jentsch 
et al. 1992; Scheffner et al. 1993; Zheng et al. 2000). E3 enzymes bind to protein 
substrate and thus these ligases are mainly responsible for substrate specificity (Hershko 
et al. 1986). The E2 enzyme conjugates with E3 ligase, which catalyses the transfer of Ub 
chain to the substrate and forms an isopeptide bond between the Lys of the protein 
substrate and G76 of Ub (Hershko et al. 1986; Reiss et al. 1989, Huang et al. 1999). 
 
Figure 1.1 Conjugation of ubiquitin to a protein substrate by the E1-E2-E3 
enzymatic cascade. 
Ub also contains seven lysine residues (K63, K48, K33, K29, K27, K11 and K6) 
that are used to create polyubiquitin chains. The covalent linkage between the C-terminal 
G76 and lysine residue of the previous ubiquitin results in ubiquitin polymerization. The 
nature of this linkage decides the fate of the substrate (Spence et al. 2000). For example, 
only G76-K48-linked chains are destined for degradation by proteasome (Chau et al. 
1989). On the other hand, K63-G76-linked chains are believed to play an important role 
in DNA repair, endocytosis and translational regulation (Hofmann et al. 1999). 
 
1.2.2. Protein Degradation by the 26S Proteasome 
In the second step of the ubiquitin proteasome pathway (UPP), the polyubiquitinated 
protein substrate is recognized and degraded by the 26S proteasome. The crystal structure 
of the 26S proteasome from the archaeon Thermoplasma acidophilum showed that it is 
composed of two substructures: the central barrel-shaped 20S proteasome that contains 
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multiple proteolytic sites and the 19S regulatory particles assembled at either or both 
ends of the 20S proteasome (Lowe et al. 1995) (Figure 2). Each 19S regulatory particle 
(RP) is composed of 18 subunits. Two subunits of the 19S RP with poly-ubiquitin chain 
binding domains are responsible for recognition of polyubiquitinated substrates 
(Deveraux et al. 1994; Lam et al. 2002). The 19S RP also contains six ATPases that assist 
in recognition of the ubiquitin-tagged protein and provide the energy required to unfold 
the protein (Kohler et al. 2001). After partial unfolding of the protein substrate, it is 
translocated to the central core of the 26S proteasome that contains the active sites 
responsible for protein degradation. 
The 20S core of the 26S proteasome is a hollow cylinder and it is made up of four 
stacked rings each comprising of α- and β-type subunits arranged in αββα stoichiometry 
(Figure 1.2A). The outer two rings are each made up of seven α-subunits. The α-rings 
play an important role in regulating substrate entry into the 20S core for proteolysis. The 
inner two rings are also each made up of seven β-subunits. In prokaryotic proteasomes, 
all the 14 β-subunits have identical proteolytic activity. While in case of eukaryotic 
proteasome, only β1(Y), β2(Z) and β5(X) of each β-ring are catalytically active, each 
having a unique proteolytic activity (Lowe et al. 1995) (Figure 1.2B). 
 
Figure 1.2  (A) Structural composition of the 26S proteasome and (B) cross-sectional 
view of subunits of a β-rings. 
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 Structural and mutational studies revealed that the β5-subunit is responsible for 
chymotrypsin-like (CT-L) activity and cleaves peptide bonds preferentially after bulky 
hydrophobic residues (Groll et al. 1997; Heinemeyer et al. 1997; Groll et al. 1999). The 
β1-subunit has caspase-like (C-L) activity i.e. it cleaves peptide bonds after acidic 
residues; and β2 cleaves after basic residues, consistent with trypsin-like (T-L) activity. 
Because of these three activities, the proteasome has the ability to degrade most of the 
amino acid sequences found in intracellular proteins (Orlowski et al. 1990; Orlowski et 
al. 2000, Arendt et al. 1997). The substrate specificity of different catalytic sites was 
explained by structural analysis of their substrate specific (S1) pockets (Groll et al. 1997). 
Residue 45 in the S1-pocket of each catalytic subunit mainly contributes to its cleavage 
preference. The presence of Arg45 in the β1 S1 pocket provides it with a basic character, 
which in turn favors the cleavage of peptide bonds after the acidic residues. The Gly 
residue at position 45 makes a wide β2 S1 pocket, resulting in broad substrate specificity 
and preferred cleavage after large basic residues. The β5 subunit contains Met45 in its S1 
pocket, which explains its CT-L activity. 
 Cocrystallization of the Thermoplasma proteasome with the inhibitor Ac-LLnL-al 
showed the covalent attachment of the N-terminal threonine of the catalytic β-subunits 
with the aldehyde of Ac-LLnL-al (Lowe et al. 1995). This, in addition to mutational 
studies, identified the N-terminal Thr1 as the key catalytic residue (Groll et al. 1997, 
Groll et al. 1999). Mechanistically, the hydroxyl group on the N-terminal threonine 
(Thr1-Oγ) is activated by the free amino group (NH2) (Scheme 1.1). The nucleophilic 
attack by this activated hydroxyl then initiates hydrolysis of the peptide bond and thereby 
forms a tetrahedral intermediate. This intermediate is then collapsed into an acyl-enzyme 
ester and the first hydrolysis product. The hydrolysis of the ester bond is catalyzed by a 
neighboring water molecule to produce the C-terminal peptide fragment, thereby 
regenerating the Thr1-Oγ for another reaction. Based on this mechanism, which was 
originally proposed by Groll et. al.1997, the proteasome was classified as a N-terminal 
nucleophilic (Ntn) hydrolase. Aside from Thr1, Asp/Glu17 and Lys33 are also important 
active site residues. Other neighboring side chains such as Ser129, Asp166, and Ser169 
are also required for structural integrity of the proteolytic sites (Lowe et al. 1995; 
Seemuller et al. 1995). 
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Scheme 1.1 The proposed proteolytic mechanism of catalytically active proteasome 
subunit. 
 
1.3. Immunoproteasome 
In addition to the standard/constitutive proteasome, mammalian cells are also capable of 
producing an alternate form of proteasome known as the immunoproteasome, which 
contains a different set of catalytic subunits: β1i /LMP2 (low molecular mass polypeptide 
2), β2i/ MECL1 (multicatalytic endopeptidase complex 1) and β5i/LMP7 (low-molecular 
mass polypeptide 7). The immunoproteasome is normally expressed in immune cells, but 
can also be induced in non-hematopoietic cells following exposure to cytokines such as 
interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α). The exposure of mammalian 
cells to these cytokines induces the synthesis of immunoproteasome-specific catalytic 
subunits β1i/LMP2, β2i/MECL1 and β5i/LMP7 which are preferentially incorporated 
during proteasome assembly to create the immunoproteasome (Strehl et al. 2005) (Figure 
1.3). Several cytokine-independent regulations of immunoproteasomes have also been 
reported. One of them is nitric oxide (NO) which has been shown to upregulate immuno-
subunit expression in endothelial cells (Kotamraju et al. 2006). Other reported regulators 
of immunoproteasomes include heat shock (Callahan et al. 2006), H2O2 (Ding et al. 2003) 
and hyperglycemia (Zu et al. 2010). 
 
7 
  
Figure 1.3 Formation of Immunoproteasome 
 The catalytic subunits of immunoproteasome have been associated with enhanced 
chymotrypsin like (CT-L) and trypsin like (T-L) activities and reduced caspase like (C-L) 
activity. This leads to the production of a completely different spectrum of degraded 
peptides as compared to what result from the constitutive proteasome. Initially, the main 
function of immunoproteasome in the cells was thought to be the generation of peptides 
required for the major histocompatibility complex (MHC) class I antigen presentation.  
However, studies in mice lacking LMP2 and LMP7 have suggested that the 
immunoproteasome plays only a minor role in antigen presentation (Fehling et al. 1994, 
Van Kaer et al. 1994). Recent studies have demonstrated the involvement of 
immunoproteasomes in regulating of cytokine production in immune cells (Hensley et al. 
2010). Additionally, several studies have also suggested a key role of 
immunoproteasomes in T-cell differentiation (Muchamuel et al. 2009), survival (Chen et 
al. 2001; Basler et al. 2006), and proliferation (Caudill et al. 2006).  
In addition to its roles in the immune system, recent studies have revealed the 
non-immune functions of immunoproteasome, such as anti-oxidative stress (Pickering et 
al. 2010), prevention of protein aggregation (Seifert et al. 2010) and muscle remolding 
(Cai et al. 2008, Zu et al. 2010). Importantly, recent studies have associated the 
immunoproteasome to cells with disease states such as cancer (Altun et al. 2005), 
neurodegenerative disease (Diaz-Hernandez et. al. 2004; Mishto et al. 2006), autoimmune 
diseases (Basler et al. 2010; Muchamuel et al. 2009), and cardiovascular disease (Yang et 
al. 2009; Zu et al. 2010). In line with these reports, the immunoproteasome is currently 
being investigated as a therapeutic target in cancer, and autoimmune diseases. 
 
8 
1.4. Assembly of the Proteasome & the Concept of Intermediate Proteasome 
In vertebrates, proteasome assembly is a highly ordered process and involves the 
formation of two symmetrical half proteasomes, each containing one α and one β-ring. 
Studies in Trypanosoma brucei and E. coli suggested that the process of proteasome 
assembly begins with α-ring formation (Yao et al. 1999; Gerards et al. 1997). Two 
dimeric proteasome assembly chaperones (PAC1-PAC2 and PAC3-PAC4) assist in this 
process. Knockdown experiments showed that PAC1-PAC2 complex not only assists in 
α-ring assembly but also prevents dimerization of α-rings (Hirano et al. 2005). The 
PAC1-PAC2 heterodimer has been shown to stick to the proteasome precursor (α1-7-
PAC1-PAC2) until the formation of the fully matured 20S proteasome (Hirano et al. 
2005). The primary role of the PAC3-PAC4 complex is to maintain the correct subunit 
orientation of the α-ring by inhibiting inappropriate binding of α-subunits (Yashiroda et 
al. 2008).  
 The α-ring directly serves as a platform for the binding of β subunits. The three 
catalytic subunits (β1, β2 and β5) and non-catalytic β6 and β7 are synthesized as 
precursors having a propeptides at their N-termini. These propeptides are only removed 
at the final stage of the proteasome assembly to expose the catalytic Thr of β1, β2 and β5. 
The β subunits are recruited onto the α ring in an ordered set of steps, which is directed 
by the mutual interactions of their propeptides (Hirano et al. 2008). β ring formation is 
initiated by proteasome maturation protein (POMP) (Ramos et al. 1998; Witt et al. 2000). 
First, the β2 subunit is recruited to the α ring and is followed by the sequential addition of 
β3 and β4 subunits to form the 13S proteasome complex. Next, β5 is added, followed by 
the β6-subunit. β1 can be recruited at any time after incorporation of β2 and β3. Finally, 
β7-subunit is added to complete the assembly of the β ring and thereby construct the 16S 
proteasome (α1-7β1-7-PAC1-PAC2-POMP) (Hirano et al. 2008). 
 The dimerization of two 16S half proteasomes is triggered by the incorporation of 
β7 and insertion of its C-terminal tail into a groove between β1 and β2 of the opposite 
ring (Marques et al. 2007; Hirano et al. 2008). After the correct dimerization of the half 
proteasomes, the propeptides at the N-terminus of β subunits are removed by an 
intramolecular autolysis mechanism. This step results in activation of the N-terminal Thr 
residues of catalytic subunits (β1, β2 and β5), which degrade POMP and PAC1-PAC2 to 
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complete the formation of the mature 20S proteasome (α1-7β1-7β1-7α1-7) (Hirano et al. 
2005; Ramos et al. 1998). To protect unregulated protein degradation by the matured 
catalytic subunits in the 20S proteasome, the propeptides on α-subunits serve as a gate for 
entry into the chamber. 
 Similar to the constitutive proteasome, the immunoproteasome subunits are also 
assembled in a defined order. However, in immunoproteasome assembly, there is an early 
incorporation of β1i subunit on to the α-ring (Nandi et al. 1997). Subunit β1i is required 
for the incorporation of β2i, although β1i can be incorporated in the absence of β2i 
(Groettrup et al. 1997). The propeptide of β5i was found to be necessary for cleaving the 
propeptide of β1i and β2i (Kingsbury et al. 2000). Therefore, after the addition of β3 and 
β4, β5i (LMP7) is preferentially incorporated over β5 (Griffin et al. 1998). This 
cooperative assembly of the three inducible subunits (β1i, β2i and β5i) favors their 
common incorporation to form the immunoproteasome. 
 Recently, there have been several reports which suggest the formation of 
proteasomes having a non-standard mixture of catalytic subunits of the constitutive- and 
immuno-proteasome (Figure 1.4). The existence of these so called “intermediate 
proteasomes” was first reported by Burkhardt et al. (2000). In this study, subtypes of the 
20S proteasome were purified and separated by chromatographic means. Analysis of the 
rat spleen suggested the presence of small amounts of intermediate proteasomes (β1-β2-
β5i and β1-β2i-β5i). The activity of these subtypes against fluorogenic proteasome 
substrates was found to be different, suggesting the unique activities and/or function of 
these subtypes in vivo (Burkhardt et al. 2000). Later, another study suggested the 
formation of proteasome subtype β1-β2i-β5i, although the existence of proteasomes 
containing β2i without β1i does not agree with the proposed model of cooperative 
proteasome assembly (De et al. 2003). Also, β5i was found to be expressed in β1i- and 
β2i-deficient cells, suggesting the formation of subtype β1-β2-β5i (De et al. 2003; Basler 
et al. 2006). In 2007, Drews et al. developed a new protocol for in-solution isoelectric 
focusing of multiprotease complexes. They observed differences in pI values of cardiac 
and hepatic proteasomes and noted: “These data suggest the possibility of mixed 20S 
proteasome assembly, a departure from the currently hypothesized two subpopulations: 
constitutive and immuno forms.” More recently, Guillaume et al. (2010) isolated two 
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major intermediate proteasomes (β1-β2-β5i and β1i-β2-β5i), which are found to be 
responsible for the processing of certain tumor antigens of clinical interest. 
 As a matured 20S proteasome is made up of two β-rings, we cannot rule out the 
existence of two rings with different subunit composition (i.e. asymmetric intermediate 
proteasome). As Klare et al. noted in 2007: “Our study showed that subunit replacement 
can be confined to one half of the proteasome cylinder, resulting in the formation of 
intermediate-type proteasomes with “asymmetric” subunit composition.” Given that β5i 
is required for the existence of β1i and β2i, theoretically there are 13 subtypes of 
proteasome possible as suggested by Klare et al. 2007. 
 
Figure 1.4. Different proteasome subtypes 
1.5. History of proteasome inhibitors 
Initially, proteasome inhibitors were developed to understand the functional role of the 
proteasomes in the cell. As explained earlier, the key step in protein degradation by the 
proteasome is the nucleophilic attack of the hydroxyl group of Thr1 (Thr1-Oγ) on peptide 
bonds of proteins (Scheme 1.1). Therefore, most of the proteasome inhibitors developed 
so far target the N-terminal Thr1 of the catalytic subunits of the proteasome (Figure 1.5). 
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The most important proteasome inhibitors can be classified into five different classes: 
peptide aldehydes, peptide vinyl sulfones, peptide boronates, β-lactones and peptide 
epoxyketones. 
Peptide aldehydes were the first class of proteasome inhibitors to be developed. 
Because of the similar catalytic activities of serine/cysteine protease and the proteasome, 
initially known inhibitors of these proteases were explored as proteasome inhibitors. A 
serine and cysteine protease, Leupeptin (1), was shown to inhibit the T-L activity of the 
proteasome (Wilk et al. 1983). Later, calpain inhibitors I/II were found to inhibit the CT-
L activity of the proteasome (Orlowski et al. 1990). Co-crystallization of caplain inhibitor 
I (Ac-Leu-Leu-nLeu-CHO) with the yeast proteasome showed hemiacetal bond 
formation between the active Thr1-Oγs and the aldehyde group of inhibitor (Scheme 2A) 
(Groll et al. 1997). Many peptide aldehydes have been developed so far, and MG115 (Z-
Leu-Leu-nVal-CHO, 2), MG132 (Z-Leu-Leu-Leu-CHO) and PSI (Z-Ile-Glu(OtBu)-Ala-
Leu-CHO) were found to be selective and potent inhibitors of CT-L activity of the 
proteasome (Lee et al. 1996, Rock et al. 1994). All of these aldehyde pharmacophore-
based inhibitors also target other proteases in cells and thus they have limited therapeutic 
potential. Still, peptide aldehydes are the most widely used inhibitors for studying 
proteasome biology. 
 Several additional electrophilic groups were explored as a pharmacophores for 
proteasome inhibitors. The ability of the vinyl sulfone group, acting as a Michael 
acceptor, to bind to the hydroxyl group of Thr1 was first explored by Bogyo’s lab 
(Scheme 1.2B).  Bogyo and co-workers showed that peptide vinyl sulfones, Nip-Leu-
Leu-Leu-VS (9) and Tyr-Leu-Leu-Leu-VS, bind to catalytic β-subunits of the proteasome 
(Bogyo et al. 1997 and 1998). Later, Ada-Ahx3-Leu-Leu-Leu-VS (10) was found to be 
the most potent vinyl sulfone-based inhibitor of the proteasome and was shown to inhibit 
all the catalytically active sites of both the constitutive and immunoproteasome. This 
compound was further labeled with a radioisotope, biotin, and fluorescent groups and the 
resulting derivatives were successfully used to study the mechanism of proteasome action 
(Kessler et al. 2001). However, the peptide vinyl sulfones are also known to target the 
thiol groups of cysteine proteases, limiting their  applications as molecular probes in 
proteasome biology. 
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Peptide boronic acids were known to inhibit serine proteases such as 
chymotrypsin (Kettner et al. 1984; Weber et al. 1995), so it was postulated that they 
might potentially inhibit the chymotrypsin- like (CT-L) activity of the proteasome. Adam 
and co-workers investigated a few peptide boronates such as MG262 (Z-Leu-Leu-Leu-
boronate, 8) and found them to be very potent inhibitors with much slower dissociation 
rates as compared to aldehyde-based inhibitors (Adams et al. 1998). Interestingly, these 
peptide boronates were found to inhibit the proteasome reversibly (Gardner et al. 2000). 
As compared to aldehyde and vinyl sulfones, the peptide boronates were found to be poor 
inhibitors of cysteine proteases (Adams et al. 1998). The selectivity of boronates towards 
the proteasome was postulated to arise from the interaction between the lone pair of the 
hydroxyl group of Thr1-Oγ and the empty p-orbital on the boron atom of the inhibitor 
(Scheme 1.2C). This selectivity of boronates made them attractive targets for drug 
development. Further medicinal efforts resulted into the development of the first-in-class 
proteasome inhibitor drug, bortezomib, which was subsequently approved by the FDA 
for the treatment of multiple myeloma (see Sec. 1.6 for detail). 
 Lactacystin (3) was the first natural product reported as a selective inhibitor of the 
proteasome with a non-peptide backbone. It was originally discovered as a metabolite of 
Streptomyces lactacystinaeus and found to induce neuritogenesis in neuroblastoma cells 
(Omura et al. 1991). Later, radiolabeled derivatives of lactacystin demonstrated its ability 
to bind predominantly to the β5 subunit of mammalian proteasomes, irreversibly 
inhibiting CT-L activity. The T-L and C-L activities were also found to be blocked, but at 
much slower rates (Fenteany et al. 1995). However, in vivo studies demonstrated that 
lactacystin itself does not inhibit proteasomal activites (Corey et al. 1999). Kinetic 
analysis suggested that lactacystin is hydrolysed into clasto-lactacystin β-lactone (4) at 
pH 8, and then the β-lactone reacts with the catalytic Thr1 of the proteasome (Scheme 
1.2D) (Dick, L. R. 1996). This mechanism of action of lactacystin was confirmed by X-
ray diffraction analysis of the yeast proteasome complexed with clasto-lactacystin β-
lactone (Groll et al. 1997).  Even though the β-lactones were found to be  more selective 
inhibitors of proteasomes compared to peptide aldehydes, their unstable nature at neutral 
pH, complex synthesis, and ability to bind to other proteases discouraged further 
medicinal chemistry efforts. 
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Figure 1.5. Classification of proteasome inhibitors based on their pharmacophores 
(blue). 
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Scheme 1.2  Mechanism of proteasome inhibition by different classes of inhibitors. 
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Another important class of proteasome inhibitors are the peptidyl epoxyketones.  
Crews and coworkers reported eponemycin (5) and epoxomicin (6), two peptidyl α’,β’-
epoxyketone natural products, as selective inhibitors of the proteasome (Meng et al. 1999 
and 1999b). Eponemycin was originally isolated from Streptomyces hygroscopicus and 
was later found to bind to the β1i, β5i and β5 subunits of the proteasome (Meng et al. 
1999). On the other hand, epoxomicin was found to primarily target the CT-L activity of 
the proteasome and bind to β2, β2i, β5 and β5i. Further studies demonstrated that 
epoxomicin does not inhibit other proteases such as papin, calpin, trypsin, chymotrypsin 
or cathepsins (Meng et al. 1999b). The unusually high specificity of epoxomicin was 
explained by crystal structure analysis. Co-crystallization of epoxomicin with the yeast 
proteasome showed the formation of a six-membered morpholine ring system between 
the epoxyketone pharmacophore of epoxomicin and the N-terminal Thr1 of proteasome 
catalytic subunits (Groll et al. 2000). Mechanistically, the formation of this unique 
morpholino ring can be explained by the nucleophilic attack of Thr1-Oγ on the carbonyl 
group of the epoxyketone to form a hemiacetal intermediate. This positions the free 
amine group at N-terminus perfectly to carry out ring opening of the epoxide to form the 
morpholino ring (Scheme 1.2D). The high specificity of epoxomicin towards the 20S 
proteasome encouraged the synthesis of second generation α’,β’-epoxyketones. One of 
the most promising compounds, PR-171 or carfilzomib, has been recently approved by 
the FDA for the treatment of relapsed multiple myeloma (see Sec. 1.6 for detail).                                       
 
1.6. Clinically Relevant Proteasomes Inhibitors 
Increased understanding of the ubiquitin proteasome pathway (UPP) resulted into the 
identification of the proteasome as a target for cancer treatment. Proteasome inhibitors 
were found to induce cell death in malignant cell lines (Imajoh-Ohmi et al. 1995; 
Shinohara et al. 1996), which was not surprising given that the proteasome-mediated 
degradation of proteins helps regulate a veriety of cellular processes. Interestingly, 
malignant cells were found to be preferentially affected by proteasome inhibition, 
suggesting a higher dependence of tumor cells on the UPP (An et al. 1998; Orlowski et 
al. 1998; Masdehors et al. 2000). These studies provided the rational for the development 
of proteasome inhibitors as anti-cancer drugs.  
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1.6.1 Reversible Inhibitors 
After building on strong preclinical rational and encouraging results from clinical trials, 
bortezomib (PS-341 or VelcadeTM) became the first proteasome inhibitor to be approved 
by US Food and Drug Administration (FDA) for the treatment of relapsed multiple 
myeloma and mantle cell lymphoma (Figure 1.6). During clinical trials, bortezomib 
alone caused an overall response rate of 41-43% in relapsed and refractory multiple 
myeloma (Richardson et al. 2007; Orlowski et al. 2007). Several phase II clinical trials 
confirmed the activity of bortezomib in non-Hodgkin’s lymphoma (O’Connor et al. 2005; 
Goy et al. 2005; Belch et al. 2007). Currently, bortezomib is being tested in combinations 
with other drugs for the treatment of other types of cancer. 
 
Figure 1.6. Classification of proteasome inhibitors under clinical trials based on 
their mode of action. 
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Structurally, bortezomib (11) is a dipeptide boronate proteasome inhibitor that 
targets, specifically and reversibly, the CT-L activity of the 20S proteasome (Lightcap et 
al. 2000). It has also been shown to target the C-L activity of the proteasome, but with 
lower affinity (Demo et al. 2007). A recent study using subunit-specific fluorogenic 
substrates showed that bortezomib inhibits the β1i, β5 and β5i subunits of the proteasome 
with IC50 values of 5.5 nM, 8.2 nM and 3.3 nM, respectively (Blackburn et al. 2010). 
 Despite its clinical success in myeloma and mantle cell lymphoma, bortezomib 
therapy has several disadvantages. First, due to the poor bioavailability of bortezomib, it 
requires twice-weekly or weekly intravenous administration and thus patients must go to 
special clinics regularly. Additionally, some serious side effects of bortezomib have been 
observed, such as thrombocytopenia, neutroprnia, and gastrointestinal disorders. The 
development of reversible but severe peripheral neuropathy has also been observed in 
more than one-third of bortezomib-treated patients. These side effects are mainly 
associated with off-target activity of bortezomib. Arastu-Kapur et. al. (2011) recently 
demonstrated that some serine proteases, such as cathepsin A/G, chymase, HtrA2/omi 
and dipeptidyl peptidase II, are inhibited by bortezomib. These proteases are required for 
neuronal cell survival, and their inhibition by bortezomib treatment causes neurotoxicity, 
tremor, and reduced nerve conduction velocity. Furthermore, despite encouraging 
preclinical data, the response to bortezomib treatment in patients with non-small cell lung 
cancer (NSCLC) and other solid tumors has been very disappointing. In addition to this 
inherent resistance, acquired resistance to bortezomib treatment is also a major clinical 
concern. 
 The limitations of bortezomib treatment have provided a wide range of 
opportunities for the development of a second generation of proteasome inhibitordrugs. 
Currently, there are two additional boronic acid-based proteasome inhibitors under 
clinical trials, namely Delanzomib/CEP-18770 (12) and Ixazomib/MLN9074 (13) 
(Kupperman et al. 2010, Sanchez et al. 2010, Piva et al. 2008). Preclinical studies with 
these proteasome inhibitors have demonstrated their enhanced anti-tumor activity 
compared to bortezomib. Additionally, an advantage of these drug candidates is their oral 
route of administration, which offers more flexible dosing and convenience for the 
patient. However, since the mechanism of action of both of these second-generation 
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boronates is similar to that of bortezomib, it is unlikely that these inhibitors will 
overcome bortezomib resistance. 
1.6.2 Irreversible Inhibitors 
As previously mentioned, α’,β’-epoxyketones inhibit proteasome activity in a highly 
selective manner because of the unique interaction of the epoxyketone pharmacophore 
and the N-terminal Thr residues of the catalytic subunits of the proteasome (Scheme 
1.2E). An extensive medicinal chemistry effort led to the development of the first 
epoxyketone based drug, Carfilzomib (14) (Figure 1.6). Carfilzomib is a tetrapeptide 
derivative of the natural product epoxomycin (Figure 4). Compared to bortezomib, 
carfilzomib is a more selective and potent inhibitor of the CT-L activity of the 
proteasome (Parlati et al. 2009, Kuhn et al. 2007). It has been shown that carfilzomib 
binds to both β5 and β5i catalytic subunits of the proteasome (Parlati et al. 2009). Several 
studies have shown the ability of carfilzomib to induce cell death in bortezomib-resistant 
cells (Kuhn et al. 2007; Demo et al. 2007). After successful Phase 3 clinical trials, 
carfilzomib was approved by the FDA for the treatment of relapsed multiple myeloma in 
July, 2012.  
Carfilzomib’s increased specificity results in decreased off-target activity in 
comparison with bortezomib. The most common side effects of carfilzomib treatment 
include pneumonia, thrombocytopenia, pyrexia and GradeI/II gastrointestinal problems, 
but, importantly, no peripheral neurotoxicity was observed. Another major limitation of 
carfilzomib is its poor bioavailability and therefore its requirement of intravenous or 
subcutaneous routes of administration. To address these limitations, an orally 
bioavailable proteasome inhibitor (ONX0912 or Oprozomib or PR-047) is already in 
phase 1 clinical trials. ONX0912 (15) is a tripeptide epoxyketone-based inhibitor that 
inhibits both β5 and β5i with IC50 values of 36nM and 82nM (Zhau et al. 2009). 
ONX0912 is now being evaluated as a monotherapy for the treatment of hematological 
malignancies and some solid tumors. 
 Since most of these proteasome inhibitors are peptide-based, they can be degraded 
by endogenous peptidases and proteases. Thus, researchers are also developing 
proteasome inhibitors without peptide backbones. One such irreversible non-peptidyl 
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proteasome inhibitor is NPI-0052/Marizomib (16). The pharmacophore of NPI-0052 is a 
β-lactone, and the mechanism of action is the same as explained earlier (Scheme 1.2D). 
NPI-0052 has been shown to inhibit the CT-L and T-L activities of the proteasome faster 
than bortezomib (Chauhan et al. 2005). Additionally, NPI-0052 showed activity in 
bortezomib-resistant tumor cells (Chauhan et al. 2005).  Currently, NPI-0052 is under 
evaluation in Phase I clinical trials for the treatment of multiple myeloma and solid 
tumors. Despite encouraging preclinical and phase I clinical studies, the half-life of NPI-
0052 is less than 5 minutes, which may limit its therapeutic potential. 
 Another interesting approach to overcome side effects of proteasome inhibitors is 
to target the immunoproteasomes. All of the proteasome inhibitors currently under 
clinical trials target both the constitutive and immunoproteasome. Although 
immunoproteasome expression is predominantly limited to immune cells, recent studies 
have demonstrated high expression levels of immunoproteasome catalytic subunits (β1i, 
β2i and β5i) in various cancer cell lines. Therefore, it is possible that immunoproteasome-
specific inhibitors could improve the side effects by sparing most noncancerous cells 
which do not contain immunoproteasomes.  
 
1.7. Intermediate Proteasomes and Drug Resistance 
The approval of the proteasome inhibitors, bortezomib and carfilzomib, by the FDA has 
validated the proteasome as an anticancer target. Even though these two drugs have 
shown very encouraging clinical responses, intrinsic and acquired resistance to 
proteasome inhibitors has remained a major clinical concern. Despite multiple 
mechanisms so far identified, there appears no major unifying mechanism which can 
account for intrinsic or acquired resistance to proteasome inhibitors. A better 
understanding of the mechanism of this resistance would be helpful in developing more 
effective therapies. Interestingly, there are some reports which have associated 
intermediate proteasomes with resistance to proteasome inhibitors. For example, unique 
subtypes of intermediate proteasomes with differential sensitivities to proteasome 
inhibitors have been identified in the murine heart and liver (Gomes et al. 2009; Kloss et 
al. 2010). Additionally, when treated with proteasome inhibitors, cancer cells were found 
to alter the expression of certain proteasome catalytic subunits (Fuchs et al. 2008; Busse 
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et al. 2008, Ruchrich et al. 2009), indicating the formation of different proteasome 
subtypes in response to proteasome inhibitors. Recently, specific intermediate 
proteasomes have been identified in cancer cells of differing sensitivity to proteasome 
inhibitors (Wang et al. 2011, Guillaume et al. 2010). 
All these previous reports and preliminary experiments conduct in ou lab (data not 
reported in this dissertation) have suggested that the presence and/or formation of 
different intermediate proteasomes may underlie a unique mechanism of resistance to 
proteasome inhibitors. With this in mind, we hypothesize that intermediate 
proteasomes contribute to cellular adaptation to adverse conditions, such as 
exposure to proteasome inhibitors. A major challenge in testing our hypothesis is that 
there is no appropriate means currently available to identify different proteasome 
subtypes in cells. 
1.8. Our Approaches to Identify Intermediate Proteasome 
Most of the current research in proteasome biology is focused on two conventional forms 
of the proteasome (constitutive- and immuno-proteasomes). Despite growing interest in 
intermediate proteasomes, there is a significant knowledge gap in understanding the role 
of intermediate proteasomes in cells.  A crucial step to study the role of intermediate 
proteasomes in drug-resistant cells is to determine proteasome subunit composition and 
specific subtypes present in these cells. Traditional techniques, such as western blotting 
and ELISA, can only assess the overall subunit levels in a preparation of proteasomes 
rather than actual composition or the specific proteasome subtypes present in cells. 
Recently, Guillaume et al. (2010) have reported the first method to identify intermediate 
proteasomes using a set of subunit-specific antibodies. Although this method directly 
shows the existence of intermediate proteasomes, the procedure has serious limitations. 
First, it requires three sequential immunoprecipitation steps, which are difficult to 
perform for each and every cell line. Also, this procedure may identify only a sub-
population of intermediate proteasomes present in cells. Therefore, there is a need to 
develop novel chemical tools/approaches to identify intermediate proteasomes. The 
identification of these proteasome subtypes in a series of cancer cell lines will allow us to 
investigate whether specific subtypes are associated with intrinsic and acquired resistance 
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to proteasome inhibitors. Currently, Dr. Kim’s lab is investigating two complementary 
approaches to identify intermediate proteasomes: a FRET-based approach and a chemical 
cross-linking approach utilizing bifunctional agents. 
1.8.1. FRET Approach 
Fluorescence resonance energy transfer or Fӧrster resonance energy transfer (FRET) has 
emerged as a sensitive tool for elucidating the various structures and dynamics of 
different biomolecular systems. FRET is a spectroscopic process which involves a non-
radiative transfer of energy from an excited donor fluorophore to an acceptor fluorophore 
over long distances (10-100 Å) (Figure 1.7). This energy transfer requires a resonance 
between singlet-singlet electronic transitions of the two fluorophores, generated by 
dipolar coupling between the transition moments of donor and acceptor. The efficiency of 
energy transfer during the FRET process depends on the distance and relative orientation 
of the donor and acceptor, as well as the spectral properties of the two fluorophores. The 
first practical description of FRET was reported by Theodor Fӧrster in 1946. Since then, 
due to its relative simplicity and ability to follow the dynamics of individual complexes 
with high sensitivity, FRET has been extensively used for studying  protein structures, 
protein-nucleic acids interactions, DNA structures, RNA folding and many other systems.  
 
  
Figure 1.7  (A) Utilization of FRET to study proteasome biology and (B) molecular 
assembly of the 20S proteasome. 
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As FRET provides a unique tool for studying molecular interactions with sub-
nanometer sensitivity, we envisioned that a FRET-based method could also be used for 
determining different proteasome subtypes in cells.  The X-ray structural analysis of the 
yeast 20S proteasome revealed the intermolecular distances between Thr1Oϒ residues of 
the catalytic subunits of the 20S proteasome complex (Figure 1.7B).  These 
intermolecular distances are within the range (<100 Å) of FRET detection. Additionally, 
the confinement of the catalytic residues on the interior of the proteasome will facilitate 
the detection of FRET only when the two targeted subunits are present within the same 
proteasome complex (Figure 1.7A). Therefore, if we label the catalytic subunits with 
different fluorescent probes, the identity of non-standard mixtures of catalytic subunits 
(intermediate proteasomes) can be easily detected utilizing the FRET process. 
The application of a FRET-based approach in proteasome biology requires the 
specific labeling of different catalytic subunits of proteasomes with donor/acceptor 
fluorescent pairs. However, the lack of appropriate fluorescent probes selective for the 
different catalytic subunits of proteasomes limits our options. Therefore, to explore the 
utility of a FRET-based method in the context of proteasome biology, there is a need to 
develop activity-based fluorescent probes targeting specific proteasome subunits. 
1.8.2 Chemical Cross-linking Approach Utilizing Bifunctional Agents 
Complementary to the FRET-based method, we decided to use a more traditional 
chemical cross-linking approach to analyze the subunit composition of proteasomes. This 
approach involves the formation of a covalent bridge between two different proteins in 
close proximity. It utilizes bifunctional agents containing two chemical groups that are 
reactive towards specific functional groups on proteins. The bifunctional cross-linking 
agents have proved to be very useful to study the tertiary and quaternary structure of 
proteins and to identify the spatial arrangements of subunits in oligomeric proteins. 
Over a period of time, Dr. Kim’s lab has developed epoxyketone based inhibitors 
selective for different catalytic subunits of proteasomes. These selective inhibitors could 
be used to design and synthesize several bifunctional agents.  Based on the previously-
determined intermolecular distances between catalytic subunits within the 20S 
proteasome complex (Figure 1.7B), bifunctional agents with appropriate spacer arm 
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lengths to covalently cross-link two different catalytic subunits within the same 
proteasome complex could be developed. Western blotting analysis of the reaction 
products of the proteasome and these bifunctional reagents could provide a direct and 
rapid method to identify different proteasome. 
 
Figure 1.8 Our approach to cross-link to different catalytic subunits within a 
proteasome complex utilizing bifunctional probes. 
1.9. Specific Aims 
Aim 1. To develop fluorescently labeled molecular probes selectively targeting the 
catalytically active immunoproteasome subunits. This study will require structure-
based design, synthesis, and characterization of activity-based fluorescent probes capable 
of labeling catalytic subunits of the immunoproteasome. Given the implication of 
immunoproteasomes in cancer and inflammatory diseases, these imaging probes will 
provide a valuable tool to analyze the functions and dynamics of the immunoproteasome 
in disease states. Additionally, these fluorescent probes can be used in FRET studies to 
identify different intermediate proteasome subtypes. The details of these studies are 
reported in chapter 2. 
 
Aim 2. To develop bifunctional agents capable of cross-linking two catalytic 
subunits within the 20S proteasome complex. In this study, we will design and 
synthesize a few epoxyketone pharmacophore-based bifunctional molecules by utilizing 
the knowledge gained by inhibitor screening in our lab. The ability of these bifunctional 
agents to cross-link different catalytic subunits of the proteasome will be tested using 
mobility shift assays. The results obtained will provide a proof of concept of cross-
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linking two proteasome catalytic subunits using bifunctional agents, which may serve as 
a direct and convincing method to identify intermediate proteasomes. The details of these 
studies are reported in chapter 3. 
Aim 3. To develop a selective inhibitor of the β5i/LMP7 subunit of the 
immunoproteasome. In this study, we plan to synthesize a small library of peptidyl-
epoxyketone-based compounds based on the reference compound IPSI, with the goal of 
identifying a selective inhibitor of the LMP7 subunit of the immunoproteasome. The 
synthesized compounds will be screened for their ability to selectively target LMP7 using 
proteasome activity assays. As recent studies have associated elevated levels of the 
LMP7-subunits with some pathological disorders such as cancer and autoimmune 
disease, a selective inhibitor of LMP7-subunit may provide a therapeutic potential for 
targeting LMP7 in cancer and rheumatoid arthritis. The details of these studies are 
reported in chapter 4. 
 
Aim 4. To develop a new and concise approach to synthesize 1-azaspirocyclic ring 
systems. This is a completely different study which is not related to proteasomes (Aim 1-
3). In this study, we will design and develop a new, concise and more flexible route for 
the construction of 1-azaspirocyclic ring systems. These structural motifs are present in 
various natural products that are structurally complex and show interesting biological 
activities. We plan to utilize Lewis catalyzed semi-pinacol rearrangement and acid 
mediated Beckmann rearrangement to synthesize 1-azaspriocyclic ring systems. Our 
approach may lead to the development of new, novel, or more efficient synthetic 
reactions. The details of these studies are reported in chapter 5. 
 
 
 
 
 
 
 
Copyright © Lalit Kumar 2012 
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Chapter 2: Development of activity-based fluorescent probes targeting the 
β5i/LMP7 catalytic subunits of the immunoproteasome† 
 
2.1 Overview of the Study 
To investigate our FRET-based approach for the identification of intermediate 
proteasomes, we require activity-based fluorescent probes which are selective towards 
different catalytic subunits of the immunoproteasome. The primary goal of the study 
reported in this chapter is to develop fluorescently-labeled molecular probes selective for 
the immunoproteasome catalytic subunit β5i/LMP7. A structure-based design and 
synthesis of the fluorescently-labeled compound LKS01-B650 is described here. The 
western blot analysis and in-gel fluorescence assay demonstrates the ability of LKS01-
B650 to selectively label β5i/LMP7. The utility of this imaging agent to visualize 
β5i/LMP7 in living cells is demonstrated in various localization studies. In addition to 
their utility for FRET-based studies, these fluorescent probes may serve as valuable 
imaging agents for the real-time investigation of immunoproteasome functions in living 
cells.  
2.2. Introduction 
2.2.1. Activity Based Probes 
Over the past 20-30 years, the advancement in the field of global genomics and 
proteomics has allowed us to understand the functions of genes and proteins in complex 
networks within a cell. The field of genomics includes the study of all of the genes of a 
cell or tissue and the relationship of those genes with each other and with adverse 
environmental effects (Venter et al. 2001).  A raw genome sequence data is informative 
____________________ 
† A report of this work has been published. Portions taken in part from:  Lalit Kumar Sharma, 
Na-Ra Lee, Eun-Ryoung Jang, Beilei Lei, Chang-Guo Zhan, Wooin Lee, Kyung Bo Kim. 
ChemBioChem 2012, 13, 1899-1903. 
† The work reported in this chapter was conducted in collaboration with Wooin Lee and 
Chang-Guo Zhan at College of Pharmacy, University of Kentucky. 
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(Reiss 2001), but it often fails to provide insight into the functional roles of specific gene 
products.  
To address the complexity arisen from genome sequences, the field of proteomics 
was established. Proteomics is the analysis of the functional regulation of all of the 
proteins in a given proteome (Wasinger et al. 1995). The traditional proteomics 
methodology is based on two dimensional gel electrophoresis (2-DE) combined with 
protein staining and mass spectrometry. Other techniques which are used for purification 
and identification of proteins, include geLC-MS/MS, DIGE, MudPIT, ICAT etc. These 
proteomic methods allow for global analysis of protein abundance but they are still 
unable to analyze the activity and the function of the proteins/enzymes. 
In cells, most enzymes are often synthesized as inactive zymogens that require 
activation by proteolytic cleavage to carry out specific biological processes. To 
differentiate the functions of active and inactive form of enzymes, a new division of 
proteomics, known as activity-based proteomics, was established. This method utilizes 
small molecules designed to target the active sites of enzymes. As these activity-based 
probes (ABPs) are able to covalently label the active site of enzymes, they are highly 
selective and allow specific labeling of active enzymes while inactive enzymes remain 
unlabeled (Kidd et al. 2001).  
 
Figure 2.1 General structure of activity-based probes (ABPs) having three basic 
components: warhead (green), linker (blue) and tag (red). 
ABPs are composed of three main structural elements: the reactive group 
(warhead), linker and chemical tag (Figure 2.1) (Kidd et al. 2001). The warhead of the 
ABPs consists of a reactive functional group which is capable of forming a covalent bond 
with the active site of the enzyme. The linker is generally used to separate the reactive 
 
27 
group from the tag and in some cases it also enhances the specificity of the probe. The 
chemical tag of the ABPs enables the visualization and/or purification of the labeled 
protein. The most commonly used chemical tags include radioisotopes, fluorescent dyes 
and biotin. 
The application of fluorophores as chemical tags was the most exciting 
development in the field of activity-based proteomics. Fluorophores are generally safe as 
compared to radioisotopes and show comparable sensitivity. Also, various types of 
fluorophores are commercially available and span a long range of emission spectra from 
blue to near-infra red (NIR).  Fluorescently-labeled ABPs, being highly selective, allow 
us to monitor the activity of enzymes in living cells or organisms, in real time and with 
spatial resolution. 
2.2.2. Activity Based Probes & Proteasome Biology 
For proteasome biology, the application of activity based probes can be particularly 
useful since there are two forms of β subunits present in cells: catalytically inactive, 
immature precursor forms and active, mature forms (Chapter 1, Sec 1.4). Initially, the 
catalytic β-subunits of proteasomes are genetically expressed with N-terminal 
propeptides. These β-propeptides assist in subunit folding and molecular assembly of the 
20S proteasome, but their presence directly blocks the proteolytic active sites (Figure 
2.2). Only during the final step of assembly of the 20S proteasome, these propeptides are 
cleaved off to expose the catalytic Thr residues of β1, β2 and β5. 
 
Figure 2.2  Strucuture of N-terminal Thr1 in precursor and matured β-ubunits. 
Thus, the immature β subunits undergo maturation only in the fully assembled 
proteasome complex (Figure 2.2). Investigating the localization pattern of the 
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catalytically active immunoproteasome using immunofluorescence labeling is very 
difficult, since antibodies often detect both catalytically active and propeptide-containing 
inactive forms of proteasome subunits 
General proteasome inhibitors containing active-site-targeting pharmacophores, 
such as the vinyl sulfone (Bogyo et. al. 1997) or epoxyketone functional groups (Groll et 
al. 2000), can be used as activity-based probes because of their ability to target only the 
catalytically active β subunits in the fully assembled proteasome. The use of these 
pharmacophores led to the design of the first generation of activity-based fluorescent 
probes targeting proteasomes. In 2006, Verdoes et. al. reported a BODIPY-labeled vinyl 
sulfone-based ABP (MV151) (17), which  binds to all catalytic subunits of the 
proteasome in living cells. The same research group designed a more selective 
fluorescent probe, BODIPY-epoxomicin (18), which was shown to covalently modify β1 
and β5 subunits of the proteasome. 
 
Figure 2.3  Structures of commonly used proteasome targeting ABPs (MV151 and 
BODIPY-labeled epoxomicin). 
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 Both of these fluorescently labeled proteasome targeting ABPs proved to be very 
useful in functional studies of active proteasomes in tissues and for subunit-specific 
inhibitor screening (Berkers et al. 2007, Ovaa et al. 2007). However, due to high 
structural homology between the immunoproteasome and the constitutive proteasome 
(Huber et al. 2012), these probes typically target both proteasome subtypes, adding to the 
difficulty in deciphering the distinct functions of the immunoproteasome. Therefore, in 
order to properly study the functional intricacies of the immunoproteasome, it is 
necessary to develop a new generation of molecular probes specific for 
immunoproteasome subunits. The goal of the study described in this chapter is to 
develop fluorescently-labeled ABPs that selectively bind the catalytically active 
β5i/LMP7 subunit of the immunoproteasome to allow its visualization in living cells. 
Given the implication of immunoproteasomes in cancer and inflammatory diseases 
(Chapter 1, Sec. 1.3), these imaging probes can potentially be implemented as an imaging 
agents to monitor the activity and subcellular localization of the immunoproteasome in 
disease states. Also, these fluorescently labeled ABPs can be further used in FRET-based 
studies to identify different intermediate proteasomes (as explained in Chapter 1, 
Sec1.8.1). 
2.3 Results and Discussion 
2.3.1. Structure-based design of LMP7-specific fluorescent probe 
In 2009, Parlati et. al. reported a peptide epoxy-ketone based molecular inhibitor (IPSI) 
as a selective inhibitor of the LMP7 subunit in a dose-dependent manner. We decided to 
use IPSI (19) to design a LMP7-specific fluorescent molecular probe. First, we needed to 
understand the binding pattern of IPSI and LMP7 subunit of immunoproteasome. So, we 
performed in silico molecular modeling utilizing the 3D model of the 
immunoproteasome. 
 Our molecular modeling studies of LMP7:IPSI complex structure indicated 
that the tryptophan side chain at P2 site of IPSI is exposed towards the surface of LMP7 
through the open channel extending from the active site. Therefore, the tryptophan group 
at P2 segment of IPSI is most likely not involved in any specific interaction with LMP7, 
thus providing a potential anchor to introduce a fluorophore without disrupting the 
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specific IPSI:LMP7 interaction  (Figure 2.4). Based on these predictions, we decided to 
introduce a Lysine group at a P2 site of IPSI and the free amine functional group was 
envisioned to derivatize with a fluorophore at the P2 position (Scheme 2.1). 
 
        
 
Figure 2.4 Chemical structure of (A) IPSI and (B) its predicted LMP7 binding 
mode. The LMP7:IPSI binding structure depicted here was the last snapshot of the 
molecular dynamics (MD) simulation of the LMP7:IPSI complex in water. ‡ The blue or 
white circle highlights the tryptophan group at P2, which is modified to yield LKS01. 
(This figure is taken from our published work L. K. Sharma et al. ChemBioChem 2012, 
13, 1899) 
 
 
 
Scheme 2.1 Design strategy of LMP7-specific fluorescent probe based on molecular 
modeling studies. 
(A) (B) 
____________________ 
‡ Molecular modeling study was performed by Beilei Lei of Dr. Zhang’s group. 
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2.3.2. Synthesis and Binding Selectivity of compound LKS01 (1) 
As depicted in Scheme 2.2, the structure of LKS01 (20) can be retrosynthetically divided 
into two fragments 21 and 22 that could be reassembled easily to the desired compound. 
This convergent approach would allow us to synthesize material in large scale as 
compared to linear approach. The left fragment 21 can be further dissected into three 
amino-acid/acid precursors that could be coupled utilizing the well-established peptide 
bond formation reaction. We envisioned that right fragment 22 could be assembled from 
a readily available NH-protected L-phenylalanine derivative via sequential conversion of 
acid to weinreb amide, then to α,β-unsaturated ketone and final epoxidation would give 
the desired epoxide. 
 
 
 
Scheme 2.2  Our retrosynthetic analysis to synthesize LKS01. 
Based on the synthetic plan, we initially focused on the synthesis of tripeptide 
(21). As indicated in Scheme 2.3, the tert-butyl protected derivative of tripeptide 21 was 
assembled in three steps staring from H-Lys(Z)-OBut (23). HOBt/HBTU-promoted 
coupling of 23 with Fmoc-D-Ala-OH afforded access to dipeptide 24 in 96% yield. Here, 
HOBT and HBTU were used to control the racemization. Next, the sequential treatment 
of 24 with 20% piperidine in DMF (Fmoc removal) followed by coupling with 3-
methylindene-2-carboxylic acid furnished the desired 25 in 95% isolated yield. 
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Scheme 2.3  Synthesis of left fragment (25) of LKS01. Reagents and conditions: (a) 
Fmoc-D-Ala-OH (1 equiv), HBTU (1.5 equiv), HOBt (1.5 equiv), DIPEA (5 equiv), 
DCM, rt, 3 hr, 96%; (c) 20% piperidine, 2 hr; (g) 3-Methylindene-2-carboxylic acid (1 
equiv), HBTU (1.5 equiv), HOBt (1.5 equiv), DIPEA (5 equiv), DCM, rt, 3 hr, 95% for 2 
steps. 
 
With tripeptide 25 in hand, we turned our attention towards the preparation of 
epoxyketone fragment 22. The current procedure reported in the literature which was 
generally used to synthesize the peptide epoxyketone is shown in Scheme 2.4. It involved 
first the construction of enone 26, which was then reduced by sodium 
borohydride/cerium chloride to get a mixture of two separable diastereomers. The 
absolute configuration of desired allylic alcohol 27 was determined by treatment of 27 
with 1M HCl/dioxane, followed by carbonyl diimidazole mediated cyclization. The 
resulted oxazolidinone 30 is analyzed by Nuclear Overhauser Effect (NOE) and absolute 
configuration is assigned accordingly. 
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Scheme 2.4  Current procedure to synthesize epoxyketone and determination the 
absolute stereochemistry using NMR. 
The epoxidation of 27 was achieved by VO(acac)2-TBHP system or MCPBA to 
get epoxyalcohol 28 as a single diastereomer in low yield. Finally, oxidation of 28 
yielded the desired epoxyketone 29. To determine the absolute configuration of the 
epoxide, nucleophilic ring opening of epoxide in epoxyalcohol 28 was done and the 
resulted diol 31 was cyclized with diimidazole. The cyclic carbonate 32 thus obtained is 
analyzed by spectroscopic means to assign the absolute configuration. 
Due to the lack of an efficient method for the synthesis of epoxy-ketone and a 
complex procedure for determination of absolute configuration, we decided to modify the 
current procedure. We began the synthesis of required epoyketone derivative with the 
reaction of Boc-Phe-OH (33) with N,O-dimethylhydroxylamine hydrochloride which 
provided Weinreb amide 34 in 98% yield. Treatment of 34 with isopropenyl magnesium 
bromide delivered the corresponding α,β-unsaturated ketone 35 in 84% yield. Several 
epoxidation methods such as H2O2/NaOH, mcpba, HBO3 etc., were investigated and the 
best conversion (98%) was observed with dimethyldioxirane (DMDO) which afforded a 
mixture of diastereomers 36a and 36b in 98% yield (2.5:1 ratio). The absolute 
stereochemistry of 36b was assigned utilizing single crystal X-ray. However, 
epoxyketone 36a was not crystalline, so a nucleophilic ring opening of 36a was 
performed with thiophenol to obtain alcohol 37. Again, the absolute configuration of 37 
was assigned using X-ray structure. 
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After having the required epoxyketone in hand, TFA mediated boc-deprotection 
was performed to obtain 22. To construct the final compound LKS01, tripeptide 25 was 
treated with TFA and the resulting product 21 was coupled with epoxyketone 22 to yield 
LKS01 (20). 
 
 
 
Scheme 2.5  Synthesis of right hand epoxyketone fragment (36a) of LKS01 and 
determination of absolute stereochemistry of epoxide utilizing single crystal X-ray.  
Reagents and conditions: (a) N,O-dimethylhydroxylamine hydrochloride (2 equiv), 
HBTU, DIPEA, DCM, rt, 15 hr, 98%; (b) Isopropenyl magnesium bromide, THF, 0°C, 3 
hr, 84%; (c) DMDO (2 equiv), rt, 15 hr, 98%, ratio 4a:4b (3:1); (d) PhSH, Et3N, MeOH, 
rt, overnite, 90%.  (X-ray analysis was performed by Dr. Sean Parkin at Department 
of Chemistry, University of Kentucky) 
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Scheme 2.6 Final coupling of compound 25 and 36a to synthesis LKS01. 
Reagents and conditions: (a) TFA (90% in DCM), 1 hr; (b) TFA-DCM (1:1), 30 min., rt; 
(c) TBTU (1.5 equiv), rt, 3 hr, 70% for 3 steps. 
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2.3.3. Binding Selectivity of LKS01 
Before coupling LKS01 (20) with a fluorescent residue, we wanted to ensure that LKS01 
still maintains the β5i/LMP7 binding selectivity of IPSI (19). To examine this, we choose 
EL4 mouse thymoma cells to perform a mobility shift assay. These cells abundantly 
express all the catalytic subunits of both the immunoproteasome and the constitutive. The 
EL4 cells were incubated with LKS01 at varying concentrations, subsequently the cells 
were lysed and subjected to immunoblotting analyses using antibodies specific for 
different proteasome subunits. As shown in Figure 2.5, there is an upward shift of the 
LMP7 band due to the increased molecular weight of LMP7:LKS01 complex. This 
suggests that LKS01 maintains the ability to bind and modify LMP7. While LKS01 did 
not modify another immunoproteasome-specific subunit LMP2 at the tested 
concentrations, we observed that LKS01 has the ability to modify the X subunit at higher 
concentrations, similar to IPSI (Figure 2.4). Overall, these results indicated that LKS01 
has the ability to modify and bind to LMP7, but the subunit selectivity can be 
concentration-dependent. Similar results were obtained using PANC-1 cells which are 
derived from human pancreatic ductal adenocarcinoma (Figure 2.6A). 
 
 
 
Figure 2.5 Characterization of binding selectivity of LKS01 and IPSI toward the 
proteasome catalytic subunits in EL4 cells. EL4 cells were treated with DMSO 
(vehicle control), epoxomicin (positive control for the shift of LMP7, X and LMP2), 
YU102 (positive control for the LMP2 shift) or increasing concentrations of IPSI or 
LKS01 for 1.5 hr and cell lysates were analyzed by western blotting using antibodies of 
proteasome subunits. An upward shift of a band with respect to the DMSO control 
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indicates an increase in molecular weight due to covalent modifications. (ChemBioChem 
2012, 13, 1899) 
2.3.4. Synthesis and Characterization of fluorescently labeled compound 
 After investigating the binding pattern of LKS01 towards β5i/LMP7, a cbz-deprotection 
of LKS01 was performed utilizing H2/Pd-C, which also resulted in the reduction of 
double bond of indene group at N-terminal. We did not expect any change in binding 
pattern because of the reduction of double bond, so we went ahead and coupled 
BODIPY® 650/665 to dihydro-LKS01 (24) using BODIPY® 650/665-X succinimidyl 
ester to yield LKS01-B650 (39) (Scheme 3). Here, BODIPY® 650/665 was chosen 
because of its near-infrared (NIR) spectral range. NIR-fluorescent probes are known to be 
very effective for non-invasive imaging studies in living cells.  
 
Scheme 2.7 Synthesis of LKS01-B650, a fluorescently labeled LMP7 probe. Reagents 
and conditions: (a) H2-Pd/C, MeOH, rt, 2 hr; (b) 6-(((4,4-difluoro-5-(2-pyrrolyl)-4-bora-
3a,4a-diaza-s-indacene-3-yl)styryloxy)acetyl)aminohexanoic acid, succinimidyl ester, 
THF, rt, 2 hr, 90% for 2 steps.  
              Next, we compared the binding pattern of our fluorescently labeled compound 
LKS01-B650 (39) and its precursor LKS01 (20) towards β5i/LMP7. We performed 
mobility shift assay using Panc-1 human pancreatic cancer cells. The results revealed that 
LKS01-B650 still maintained the ability to modify LMP7 (Figure 2.6). To our surprise, 
the introduction of a large fluorescent residue (BODIPY® 650/665-X) actually improved 
the binding selectivity toward β5i/LMP7. As shown in Figure 2.6B, LKS01-B650 (39) 
modified β5i/LMP7 at 5-10 μM, but not other proteasome subunits including X upto 10 
μM. These results were further confirmed by molecular modeling studies of LKS01-
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B650 (39) with LMP7 (Figure 2.13 in supporting information). Collectively, these results 
suggest that the S2 pocket of LMP7 can accommodate the large BODIPY residue at P3 
without disrupting the interactions of LKS01-B650 with LMP7. 
 
 
Figure 2.6 Selective modification of LMP7 by LKS01-B650. Panc-1 cells were 
incubated with 5, 10 or 15 μM of LKS01-B650 for 1.5 hr and lysed. The resulting cell 
extracts were electrophoresed and subjected to immunoblotting. LKS01-B650 selectively 
modified LMP7, but not other proteasome catalytic subunits at the concentrations tested. 
(This figure is taken from the supporting information of our published work L. K. Sharma 
et al. ChemBioChem 2012, 13, 1899) 
 
2.3.5. Direct In-Gel Visualization of LKS01-B650-bound Subunits‡ 
 
To verify that LKS01-B650 (39) does not label any other catalytic subunits (except 
β5i/LMP7) of proteasome and does not target any other non-proteasomal proteins, we 
explored in-gel fluorescence assay. This assay was performed using immunoproteasome-
expressing parental T1 cells and T1-derived T2 lymphoblast cells which lack 
immunoproteasomes. Extracts from T1 cells pretreated with LKS01-B650 (39) were 
subjected to gel-electrophoresis, and the gel was imaged using Typhoon imaging system. 
To our delight, no significant fluorescent bands except a strong band around 23kD band 
were observed, which corresponds to the proteolytically active proteasomal β-subunits. 
(Figure 2.7, left panel). When the cells were pre-treated with LKS01 (β5i/LMP7 
____________________ 
‡ The in-gel fluorescent assay was performed by Na-Ra Lee. 
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selective inhibitor) or epoxomicin (a broadly acting proteasome inhibitor), this signal at 
23 kD was completely abolished (Figure 2.7, left panel). However, the fluorescent signal 
was not affected by the pre-treatment of cells with YU-102, an LMP2 selective inhibitor 
(Suppl. Figure 2.17), suggesting that the LKS01-B650-labeled protein is most likely 
β5i/LMP7. Importantly, when T2 cell lysates (lacking immunoproteasome-subunits) were 
treated with LKS01-B650 (39), no fluorescent bands were observed (Figure 2.7, right 
panel), indicating that LKS01-B650 does not target catalytic subunits (β1/Y, β2/Z and 
β5/X) of constitutive proteasome. Taken together, all these results strongly support that 
the major target of LKS01-B650 (39) in the concentration range tested is β5i/LMP7-
subunit of immunoproteasome.  
 
 
Figure 2.7 Visualization of LMP7 bound to LKS01-B650 in T1 & T2 lymphoblast 
cell lysate. Cell lysate was pretreated with DMSO, LKS01, YU102, or epoxomicin (epx) 
for 1 hr, followed by incubation of LKS01-B650 for 1 hr at room temperature. LKS01-
B650 binding was then visualized using a Typhoon FLA 9000 imaging system. 
Pretreatment of LKS01, a parent compound of LKS01-B650, or epoxomicin, a general 
proteasome inhibitor, effectively competed away fluorescent signals. In T2 lysates, no 
fluorescent signals were observed at the molecular weights consistent with LMP7. (This 
figure is taken from our published work L. K. Sharma et al. ChemBioChem 2012, 13, 
1899) 
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2.3.6. Visualization of LMP7-subunits in Living Cells¶  
We next addressed whether LKS01-B650 (39) is able to label selectively β5i/LMP7-
catalytic subunit of immunoproteasome in living cells. Panc-1 cells were treated with 
LKS01-B650 (39) and fluorescent images were captured. As shown in Figure 2.8, 
sensitive and specific labeling of β5i/LMP7-subunit was observed in Panc-1 cells. When 
the cells were pretreated with LKS01 fluorescent signals were effectively abolished. This 
competition assay is consistent with the results obtained from the in-gel fluorescence 
assay (Figure 2.8). Collectively, these results suggest that LKS01-B650 (39) can be used 
as an imaging probe to visualize catalytic active β5i/LMP7-subunit of 
immunoproteasome in living cells. 
 
Figure 2.8 Visualization of LMP7 using LKS01-B650 in Panc-1 cells. Cells were 
pretreated with DMSO or LKS01 (5 μM) for 1.5 hr, followed by incubation of LKS01-
B650 (10 μM) for 1.5 hr. LKS01-B650 binding was then visualized via fluorescence 
microscopy. Pretreatment of LKS01, a parent compound of LKS01-B650, effectively 
competed away fluorescent signals. LKS01-B650 (Red, λex = 635 nm, λem = 665 nm), 
DAPI (Blue) = Nucleus. This experiment was performed by Na-Ra Lee. (This figure is 
taken from our published work L. K. Sharma et al. ChemBioChem 2012, 13, 1899) 
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2.3.7. Localization Studies of catalytically active LMP7† 
Next, we investigated the utility of our imaging probe LKS01-B650 to carry out the 
localization studies of immunoproteasome in living cells. At first, we decided to compare 
the localization pattern of immunoproteasome using LKS01-B650 with β5i/LMP7-
antibody. As shown in Figure 2.9A, a diffused localization pattern was observed 
throughout the cell when β5i/LMP7 antibodies were used. While fluorescent signals 
derived from fluorescent probe LKS01-B650 showed a punctate localization. These 
results can be explained based on the fact that the cell contains both active form (mature) 
and inactive form (pre-β5i) of catalytic subunits. Given that LKS01-B650 is an activity 
based probe, therefore it can detect only active form of β5i/LMP7 which is a part of 
immunoproteasome complex. On the other hand, since β5i/LMP7 antibody binds to non-
active site of subunits, it can detect both mature (active) and immature (inactive) 
β5i/LMP7 and thereby showed diffuse fluorescent signals. 
             To confirm that the β5i/LMP7 detected by the LKS01-B650 is a part of the fully 
assembled immunoproteasome, we performed a co-localization study with LKS01-B650 
and UK101-Fluor, a fluorescent probe targeting catalytic active β2i/LMP2 (Carmony et 
al. 2011). As shown in Figure 2.9B, the catalytically active β5i/LMP7 detected by red 
fluorescent signals from LKS01-B650 is colocalized with the green fluorescent signals 
derived from UK101-Fluorescein β2i/LMP2, indicating that LKS01-B650-bound 
β5i/LMP7 is a component of the fully assembled immunoproteasome. 
           Additionally, we examined whether active β5i/LMP7 is colocalized with the 
endoplasmic reticulum (ER), where the assembled immunoproteasome is known to be 
localized (Brooks et al. 2000). As expected, red fluorescent signals derived from LKS01-
B650 (39) appeared to be mostly colocalized with green fluorescent signals derived from 
the calnexin antibody (a marker for ER) (Figure 2.9C).  
 
 
 
_________________________________________________________________________ 
† These experiments were performed by Eun-Ryoung Jang of Dr. Wooin Lee’s group. 
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Figure 2.9 Localization Studies of LKS01-B650-bound β5i/LMP7. Panc-1 cells were 
incubated with LKS01-B650 (10 μM) for 1.5 hr, and subsequently stained with (A) 
antibodies recognizing LMP7 or (B) calnexin (an endoplasmic reticulum marker) or (C) 
treated with UK101-Fluor, a LMP2-specific fluorescent imaging probe. Fluorescent 
signals derived from an anti-LMP7 antibody appear to diffuse throughout the cytoplasm, 
while fluorescent signals from LKS01-B650 appear to be confined to rather limited areas. 
Overlapping signals of LKS01-B650 and calnexin immunofluorescence indicate that 
immunoproteasomes containing LMP7 are mostly localized around the ER. LMP7 
signals are colocalized with signals from LMP2, indicating LKS01-B650-bound-LMP7 is 
found in fully assembled immunoproteasomes. (Portion of figure is taken from: 
ChemBioChem 2012, 13, 1899) 
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2.3.8. FRET-Based Pair  
After successfully showing the application of structure-based design to develop 
fluorescently-labeled ABPs for β5i/LMP7-subunit of immunoproteasome, we next 
focused on developing the imaging agents suitable for FRET studies (Chapter 1, Section 
1.8.1). FRET based energy transfer requires the overlap of the emission spectra of the 
donor to the absorption spectra of acceptor. Greater is the spectral overlap; more efficient 
is the FRET process. In case of Bodipy compounds this spectrum overlap is low and the 
most commonly used fluorophore pair for FRET study is Cy3-Cy5 (Figure 2.10). So, we 
synthesized cyanine derivatives of LKS01 compounds (Figure 2.11), utilizing the same 
synthetic scheme as previously described in this chapter. 
 
Figure 2.10 Spectral overlap of Bodipy dyes and Cyanine dyes  
 
Figure 2.11 Cyanine based LKS01 derivatives. 
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To achieve our objective of exploring FRET studies, utilizing these imaging 
agents, we needed fluorescently labeled ABP selective for β1i/LMP2-subunits of 
immunoproteasome. We decided to use YU102, a LMP2-selective inhibitor in a dose 
dependent manner (Figure 2.15). Utilizing the structure-based design as described in this 
chapter (Sec 2.3), we designed and synthesized YU102-Cy3 and YU102-Cy5 which 
show selectivity towards LMP2-subunits of immunoproteasome (Figure 2.12). These 
compounds were also characterized by mobility shift assay and competition assays as 
described in Sec 2.3.4 and 2.3.6. 
 
 
Figure 2.12  LMP2 selective cyanine dye based fluorescent probes. 
2.4 Summary 
The immunoproteasome, an alternative form of the constitutive proteasome, has been 
implicated in a number of pathological states such as cancer and autoimmune diseases.  
However, the detailed function of the immunoproteasome remains poorly understood. We 
have developed an immunoproteasome-specific near infra-red (NIR) fluorescent probe 
targeting the immunoproteasome catalytic subunit β5i/LMP7. We demonstrated that this 
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peptide epoxyketone-based compound LKS01-B650 (39), selectively binds to 
catalytically active β5i/LMP7, but not inactive or pre-β5i/LMP7. Our results show that 
our probe can be used to visualize the catalytically active β5i/LMP7 in living cells 
providing an ability to monitor, in real-time, the expression/activity of the 
immunoproteasome in living cells. Given the reported implications of the 
immunoproteasome in cancer and other neurodegenerative diseases, this imaging agent 
can be further explored as a potential diagnostic tool for early detection of tumor. We are 
also able to develop cyanine dye-labeled derivatives of LKS01 (β5i/LMP7-selective) and 
YU102 (β1i/LMP2-selecive), that can be further used in FRET-based studies to identify 
intermediate proteasomes as discussed in chapter 1, section 1.8.1. 
 
2.5 Experimental Procedures  
This section of the chapter is taken in parts from the supporting info of our 
published paper: L. K. Sharma et. al. ChemBioChem 2012, 13, 1899. 
 
2.5.1. Synthesis of compounds 
A. General Methods and Materials 
Unless stated otherwise, all reactions were carried out in flame-dried glassware under 
nitrogen atmosphere at room temperature and with anhydrous solvent. All commercial 
reagents were obtained from commercial available sources and used without further 
purification. All reactions were magnetically stirred and monitored by thin-layer 
chromatography (TLC). TLC plates were visualized by exposure to ultraviolet light (254 
nm) and/or by immersion in a staining solution of phosphomolybdic acid (PMA), 
followed by heating on a hot plate. Column or flash chromatography (silica) was 
performed with the indicated solvents using silica gel (particle size 0.032-0.063 mm) 
purchased from Dynamic Adsorbents or MP Biomedicals. All fluorescently labeled 
compounds are purified on a Biotage SP-1 chromatography system. 
Dimethyldioxirane (DMDO) was prepared as described by Murray et al. (1998) 
and generally concentrations in the range of 0.04-0.10 M were obtained. 1H and 13C 
spectra were recorded using 300 or 400 or 500 MHz, using CDCl3 or acetone-d6 as a 
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solvent.  The chemical shifts are reported in parts per million (ppm) relative to internal 
CHCl3 (δ 7.26 ppm for proton NMR and δ 77.23 ppm for carbon NMR) or relative to 
acetone-d6 (δ 2.05 ppm for proton NMR and δ 29.92 ppm for carbon NMR). Coupling 
constants are reported in hertz (Hz). The following abbreviations are used to designate 
the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet.  
X-ray crystallographic structures were obtained by Dr. Sean Parkin of 
Department of Chemistry, University of Kentucky. 
 
B. Experimental Procedures for Reactions and Characterization Data 
Synthesis of Weinreb Amide (ChemBioChem 2012, 13, 1899) 
To a solution of Boc-Phe-OH 33 (5.0 mmol, 1.33 g) in  dry 
methylene chloride (25 ml) was added N,O-
dimethylhydroxylamine hydrochloride (6.0 mmol, 0.585 g) and 
HBTU (5.2 mmol, 1.991 g). After stirring for 5 min at room 
temperature, DIPEA (25.0 mmol, 4.2 ml) was added dropwise at 
0°C and the reaction mixture was stirred for 15 hr at room temperature. The entire 
contents of the reaction mixture was concentrated under reduced pressure and the 
residue was purified by flash column chromatography (10-50% ethyl acetate/hexane 
gradient) to obtain 1.50 g (97%) Weinreb amide 34; 1H NMR (500 MHz, CDCl3): δ 
7.28 (m, 2H), 7.20 (m, 1H), 7.18 (m, 2H), 5.14 (d, J=4.0 Hz, 1H), 4.95 (m, 1H), 3.65 
(s, 3H), 3.16 (s, 3H), 3.04 (dd, J=14.0 Hz, 5Hz, 1H), 2.90 (dd, J=14.0 Hz, 8Hz, 1H), 
1.39 (s, 9H); 13C NMR (75 MHz, CDCl3): δ 172.2, 155.2, 136.6, 129.5, 128.4, 126.8, 
79.7, 61.7, 51.7, 39.0, 32.3, 28.5. 
Preparation of α,β-unsaturated ketone (ChemBioChem 2012, 13, 1899) 
To a solution of the Weinreb amide 34 (1.0 mmol, 0.308 g) in 
THF (5.0 ml) was added dropwise a solution of isopropenyl 
magnesium bromide in THF (2.5 mmol, 0.5 M, 5.0 ml) under 
nitrogen atmosphere at -30°C. After being stirring at 0°C for 
3hr, the reaction was quenched by the addition of sat. aq. NH4Cl solution and was 
diluted with ethyl acetate. The organic layer was separated and wahed with brine, 
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dried over MgSO4 and concentrated under reduced pressure. The resulting residue 
was purified by flash column chromatography on Biotage SP-1 chromatography 
system using a 5-10% ethyl acetate/hexane gradient to afford 0.243 g (84%) of enone 
35; 1H NMR (500 MHz, CDCl3): δ 7.24 (m, 3H), 7.65 (d, J=7.5 Hz, 2H), 6.01 (d, 
J=4.0 Hz, 1H), 5.85 (m, 1H), 5.26 (m, 2H), 3.04 (m, 1H), 2.90 (m, 1H), 1.86 (s, 3H), 
1.41 (s, 9H); 13C NMR (75 MHz, CDCl3): δ 200.0, 155.1, 142.5, 136.2, 129.5, 128.4, 
126.9, 126.7, 79.8, 55.1, 40.1, 28.6, 18.0. 
Epoxidation of enone (ChemBioChem 2012, 13, 1899) 
A DMDO solution (1.06 mmol, 0.06 M, 18 ml) 
was added to enone 35 (0.71 mmol, 0.204 g) 
and the reaction mixture was stirred for 15 hr 
at room temperature. The entire contents were 
concentrated under reduced pressure and the resulting mixture of diasteromers (0.207 
g, 96%) was separated by flash column  chromatography on a Biotage SP-1 
chromatography system using a 0-5% ethyl acetate/hexane gradient. Data for the 
epoxyketone 36a (0.147 g): 1H NMR (500 MHz, CDCl3): δ 7.31-7.22 (m, 3H), 7.15 
(d, J=7.5 Hz, 2H), 4.97 (d, J=8.0 Hz, 1H), 4.57 (m, 1H), 3.28 (d, J=5.0 Hz, 1H), 3.09 
(dd, J=14.0, 5.0 Hz, 1H), 2.89 (d, J=5.0 Hz, 1H), 2.72 (dd, J=14.0 Hz, 8 Hz, 1H), 
1.49 (s, 3H), 1.36 (s, 9H); 13C NMR (125 MHz, CDCl3): δ 208.5, 155.3, 136.0, 129.5, 
128.6, 127.1, 79.9, 59.3, 53.8, 52.5, 37.5, 28.4, 16.7; epoxyketone 36b (0.059 g): 1H 
NMR (500 MHz, CDCl3): δ 7.26 (m, 2H), 7.25 (m, 1H), 7.13 (d, J=7.0 Hz, 2H), 4.89 
(d, J=5.0 Hz, 1H), 4.60 (m, 1H), 3.0 (m, 1H), 2.83 (m, 1H), 2.67 (d, J=4.5 Hz, 1H), 
2.57 (d, J=5.0 Hz, 1H), 1.49 (s, 1H), 1.39 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 
207.8, 155.0, 136.3, 129.6, 128.9, 127.2, 80.3, 59.2, 54.4, 52.0, 38.4, 28.4, 17.4.  
Syntheis of Fmoc-D-Ala-Lys(Z)-OtBu (24) (ChemBioChem 2012, 13, 1899) 
Fmoc-D-Ala-OH (0.5 mmol, 0.156 g), H-Lys(Z)-
OtBu.HCl (0.5 mmol, 0.186 g), HBTU (1.5 equiv) 
and HOBt (1.5 equiv) were dissolved in dry DCM 
(7 ml) and DIPEA (2.5 mmol, 0.41 ml) was added 
dropwise at 0°C. After stirring at room temperature 
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for 3 hr, the reaction mixture was concentrated under reduced pressure and the residue 
was purified by flash column chromatography on a Biotage SP-1 chromatography 
system using a 10-50% ethyl acetate/hexane gradient. to give 0.302 g (96%) of 
compound 24; 1H NMR (500 MHz, CDCl3): δ 7.74 (d, J=7.5 Hz, 2H), 7.57 (d, J=7.25 
Hz, 2H), 7.38 (t, J=7.5 Hz, 2H), 7.30 (m, 7H), 6.74 (bs, 1H), 5.53 (d, J=7 Hz, 1H), 
5.05 (m ,3H), 4.52 (q, J=7 Hz, 1H), 4.38 (m ,2H), 4.29 (m ,1H), 4.18 (m, 1H), 3.14 (s, 
2H), 2.79 (s, 2H), 1.83 (m, 1H), 1.64 (m, 1H), 1.49 (m, 2H), 1.43 (s, 9H), 1.38 (d, 
J=6.5 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 172.1, 171.2, 163.8, 156.5, 155.9, 
143.8, 143.7, 141.2, 136.6, 128.5, 128.1. 127.7. 127.1, 125.1, 120.0, 82.3, 67.2, 66.7, 
52.5, 50.8, 47.2, 40.7, 38.8, 32.2, 29.4, 28.2, 22.3, 19.1.  
 
Synthesis of Ind-D-Ala-Lys(Z)-OtBu (25) (ChemBioChem 2012, 13, 1899) 
A solution of piperidine (20% solution in 
piperidine, 3 ml) was added to 24 (0.35 mmol, 
0.220 g) and stirred for 2 hr at room temperature. 
The reaction mixture was concentrated under 
reduced pressure and used for the next reaction without further purification. The 3-
methylindene-2-carboxylic acid (0.35 mmol, 0.061 g), HBTU (0.52 mmol, 0.199 g) 
and HOBt (0.52 mmol, 0.071 g) were then added to a solution of previous crude in 
DCM (5 ml). After stirring for 15 min at room temperature, DIPEA was added 
dropwise at 0°C and the reaction mixture was stirred for 3 hr at room temperature. 
The reaction mixture was concentrated under reduced pressure and the crude product 
was purified by flash column chromatography on a Biotage SP-1 chromatography 
system using a 10-50% ethyl acetate/hexane gradient  to obtain 0.142 g (95% for 2 
steps) of compound 25; 1H NMR (500 MHz, CDCl3): δ 7.42 (t, J=7.0 Hz, 2H), 7.36-
7.24 (m, 7H), 7.02 (d, J=8.0 Hz, 1H), 6.60 (d, J=7.0 Hz, 1H), 5.11 (m, 1H), 5.07 (s, 
2H), 4.72 (m, 1H), 4.46 (m, 1H), 3.58 (s, 2H), 3.18 (m, 2H), 2.49 (s, 3H), 1.85 (m, 
1H), 1.68 (m, 1H), 1.54 (m, 2H), 1.47 (d, J=7 Hz, 3H), 1.42 (s, 9H), 1.3 (m, 3H); 13C 
NMR (75 MHz, CDCl3): δ 172.4, 171.2, 165.8, 156.6, 147.7, 145.6, 142.2, 136.6, 
131.8, 128.5, 128.1, 127.3, 126.8, 123.9, 120.8, 88.4, 66.7, 52.7, 48.9, 40.8, 38.5, 
32.2, 29.5, 28.2, 22.4, 19.1, 12.6. 
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Synthesis of LKS01 (ChemBioChem 2012, 13, 1899) 
 
 
A solution of TFA-DCM (9:1, 4 ml) was added to compound 25 (0.05 mmol, 0.028 g) 
and stirred for 1h. The reaction mixture was concentrated under reduced pressure and 
purified using flash chromatography to obtain compound 21. Similarly, Boc-
deprotection of 36a (0.05 mmol, 0.015 g) was performed using TFA-DCM (1:1, 3 ml) 
to obtain compound 22. To a solution of compounds 21 and 22 in DCM (2 ml) was 
added HBTU (0.06 mmol, 0.016 g) and HOBt (0.06 mmol, 0.008 g). After stirring for 
15 min DIPEA (0.20 mmol, 0.03 ml) was added dropwise at 0°C. The reaction was 
stirred for 3 hr, after which the entire contents were concentrated under reduced 
pressure. The residue was purified by flash column chromatography on a Biotage SP-
1 chromatography system using a 20-100% EtOAc/hexane gradient to give 0.023 g 
(82%) of LKS01 (20); 1H NMR (500 MHz, CDCl3): δ 7.43 (m, 2H), 7.38-7.28 (m, 
8H), 7.19 (m, 2H), 7.13 (m, 4H), 6.98 (d, J= 7.5 Hz, 1H), 6.59 (d, J= 7.0 Hz, 1H), 
5.17 (t, J= 11.5 Hz, 1H), 5.08 (s, 2H), 5.05 (d, J= 3.5 Hz, 1H), 4.74 (m, 1H), 4.62 (m, 
1H), 4.39 (m, 1H), 3.61 (dq, J= 16.0, 2.0 Hz, 2H), 3.28 (d, J= 5.0 Hz, 1H), 3.12 (m, 
2H), 3.04 (dd, J= 14.0, 4.5 Hz, 1H), 2.79 (d, J= 5.0 Hz, 1H), 2.71 (dd, J= 14.0, 8.5 
Hz, 1H), 2.51 (t, J= 2.0 Hz, 1H), 1.74 (m, 1H), 1.59 (m, 1H), 1.40 (m, 3H), 1.36 (s, 
3H), 1.25 (m, 2H); 13C NMR (125 MHz, CDCl3): δ 207.8, 172.9, 171.5, 166.4, 156.8, 
145.6, 142.4, 136.8, 136.2, 131.8, 129.4, 128.6, 128.2, 127.5, 127.2, 126.9, 124.0, 
121.0, 66.8, 59.5, 53.2, 53.2, 53.0, 52.6, 49.2, 40.4, 38.4, 36.9, 31.5, 29.3, 22.1, 18.5, 
16.6, 12.6, 12.5. 
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Attachement of Bodipy-650 (ChemBioChem 2012, 13, 1899) 
The compound LKS01 (20) (2x10-3 
mmol, 1.4 mg) and Pd-C (5%) were 
dissolved in MeOH (3 ml) in a vessel 
capped with rubber septum. The solution 
was then stirred for 2 hr under a 
hydrogen atmosphere. After the reaction, 
the mixture was filtered using selite and 
the filtered solution was concentrated 
under reduced pressure and used for the following step without further purification. 
The above residue was dissolved in DMF (1 ml) and 6-(((4,4-difluoro-5-(2-pyrrolyl)-
4-bora-3a,4a-diaza-s-indacene-3-yl)styryloxy)acetyl)amino-hexanoic acid, 
succinimidyl ester (2x10-3 mmol, 1.2 mg) was added to the solution. The mixture was 
then stirred for 2 hr at room temperature and concentrated under reduced pressure. 
The remaining residue was purifed by flash column chromatography on Biotage SP-1 
chromatography system using a 5-100% methanol/ethyl acetate gradient to give 1.8 
mg (86%) of LKS01-B650 (39); the compound 39 was confirmed by mass analysis 
(MALDI): molecular ion peak, M+=1090 (observed), 1090 (calculated); 
M++Na=1113(observed), 1113(calculated); M+K=1129 (obsereved), 1129 
(calculated). 
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2.5.2. Molecular Modeling Studies (ChemBioChem 2012, 13, 1899) 
The molecular dynamics (MD) simulation was performed by using the Sander module of 
Amber (version 8). The ligand parameters were prepared with the Antechamber module 
of the Amber using the AM1-BCC method. The protein-ligand binding complex was 
neutralized by adding counter-ions and was solvated in a rectangular box of TIP3P water 
molecules with a minimum solute wall distance of 10 Å. The solvated system was then 
carefully equilibrated and fully energy-minimized. The solvated system was gradually 
heated from T = 10 K to T = 298.15 K in 60 ps before a production MD simulation run 
for 3 ns, making sure that we obtained a stable MD trajectory for the simulated system.  
The time step used for the MD simulation was 2 fs. Periodic boundary condition in the 
NPT ensemble at T = 298.15 K with Berendsen temperature coupling and P = 1 atm with 
isotropic molecule-based scaling was applied. The SHAKE algorithm was used to fix all 
covalent bonds containing hydrogen atoms.  The non-bonded pair list was updated every 
10 steps. The particle mesh Ewald (PME) method was used to treat long-range 
electrostatic interactions. A residue-based cutoff of 12 Å was utilized for the non-
covalent interactions. The time-dependent geometric parameters were carefully examined 
to make sure that we obtained a stable MD trajectory for the simulated protein-ligand 
binding system. The coordinates of the simulated system were collected every 1 ps during 
the simulation. 
(A) Modeling Studies of LKS01-B650 with LMP7 (ChemBioChem 2012, 13, 1899) 
We modeled the binding mode of LKS01-B650 with β5i/LMP7 from the X-ray 
crystal structure (PDB CODE: 3UNF) Huber et al. (2012), by docking with GOLD 
software. The study indicates that the S2 pocket of LMP7 can accommodate the large 
side chain of LKS01-B650 (Figure 2.13). To investigate how far our structure 
predication is in agreement with the effective immnuproteasome structure reported by 
Huber et al (2012), we aligned our previous homology model to the X-ray crystal 
structure of LMP7 (Figure 2.14). The root-mean-square deviation (RMSD) of the atomic 
positions of the homology model from the X-ray crystal structure is 1.41 Å which is very 
small compared to the resolution of the X-ray crystal structure (2.9 Å). The small RMSD 
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value suggests that our previous homology model was reasonable. In fact, both the 
homology model and X-ray crystal structures lead to the same conclusion in the present 
study.  
 
 
Figure 2.13 Binding mode of LKS01-B650 with LMP7 from the X-ray crystal 
structure (PDB CODE: 3UNF). (Molecular modeling was performed by Beilei Lee 
from Zhang’s group in the Department of Pharmaceutical Sciences, University of 
Kentucky) (ChemBioChem 2012, 13, 1899) 
 
 
Figure 2.14 Alignment of homology model (gray) with the X-ray crystal structure 
(green) of LMP7, the active site was circled with a red line. (Molecular modeling was 
performed by Beilei Lee from Zhang’s group in the Department of Pharmaceutical 
Sciences, University of Kentucky) (ChemBioChem 2012, 13, 1899) 
 
Active site 
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2.5.3. Biological Methods (ChemBioChem 2012, 13, 1899) 
Cell Culture  (ChemBioChem 2012, 13, 1899) 
EL4 and Panc-1 cells were maintained in DMEM (Dulbecco’s modified Eagle’s medium, 
Invitrogen) supplemented with 10% horse serum and in DMEM supplemented with 10% 
fetal bovine serum, respectively.  T1 and T2 cells were cultured at 5% CO2 and 37˚C in 
IMDM (Iscove's Modified Dulbecco's Media, Invitrogen) supplemented with 10% fetal 
bovine serum and 20% fetal bovine serum, respectively. All cell lines were kept under an 
atmosphere of 5% CO2 in a humidified 37°C incubator.  
Inhibitor Treatment (ChemBioChem 2012, 13, 1899) 
All the compounds (proteasome inhibitors) were dissolved in DMSO and stored at -20 °C 
before use. EL4 cells were plated on a 12-well plate at a density of 8.0 X 104 cells/well, 1 
hr prior to the compound treatment. Panc-1 cells were plated on a 24-well plate at a 
density of 1.0 X 105 cells/well one day prior to the compound treatment. EL4 and Panc-1 
cells were then treated with DMSO (vehicle control), LKS01, IPSI and LKS01-B650 at 
varying concentrations for 1.5 hr. In addition, cells were treated with the following 
compounds to serve as controls for proteasome subunit binding activities; epoxomicin (1 
μM, a non-selective inhibitor which covalently modifies β1i, β5i and β5 subunits) or 
YU102 (10 μM, a proteasome inhibitor which covalently modifies β1i and β1 subunits).  
In order to verify whether the fluorescent signals associated with LKS01-B650 can be 
effectively competed away by other specific and non-specific proteasome inhibitors; 
LKS01, epoxomicin and YU102 were used as pre-treatments for in-gel fluorescence 
experiments and for experiments in which LKS-B650 fluorescence was detected in living 
cells. For the in-gel fluorescence competition experiment, T1 and T2 cell lysates were 
prepared as described in section 3.4. Cell lysates were pretreated with DMSO, 0.5, 1, 5 
μM of LKS01, 0.1 μM of YU102, or 10 μM of epoxomicin for 1 hr before treatment with 
LKS01-B650 (10 μM) for 1 hr. Samples were then loaded and separated by 
polyacrylamide gel electrophoresis. After separation, gels were imaged using a Typhoon 
FLA 9000 imaging system (λex = 635 nm, λem = 665) to detect LKS-B650 bound to 
proteins. For the competition assay in live cells, 5 μM of LKS01 was used to treat Panc-1 
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cells for 1.5 hr, followed by treatment with LKS01-B650 (10 μM) for 1.5 hr prior to 
fluorescence microscopy as described in section 3.5. 
Immunoblotting (ChemBioChem 2012, 13, 1899) 
Cells were lysed by incubation in ice-cold lysis buffer (50 mM Tris-Cl, 150 mM NaCl, 
1% NP-40, 1% Triton X-100, and 1% protease inhibitor cocktail, Sigma-Aldrich) for 1 
hr. The resulting cell extracts were then cleared by centrifugation (14,000 rpm) at 4°C for 
10 min and supernatants were collected. The protein concentration of the cleared lysates 
were measured using a Bradford protein assay kit (Bio-Rad). The lysates were mixed 
with 2X Laemmli sample buffer (Sigma-Aldrich) and were boiled for 10 min to denature 
protein. Equivalent amounts of total protein were loaded on to 12% (β1i & β1 subunits) 
or 14% (β5i & β5 subunits) polyacrylamide gel and protein were separated by 
electrophoresis. After electrophoresis, proteins were transferred onto PVDF membranes 
(Bio-Rad). The membranes were blocked by incubating with TBST containing 5% w/v 
non-fat milk powder in TBST at room temperature for 1 hr. All primary antibodies were 
diluted in 3% BSA (Fisher) in TBST except for the β5i antibody which was diluted in 3% 
non-fat milk powder in TBST. Membranes were incubated with primary antibodies with 
membranes at room temperature for 2 hrs or at 4°C for overnight. All of the secondary 
antibodies were diluted in 3% non-fat milk in TBST. The membranes were incubated 
with secondary antibodies at room temperature for 1 hr. Polyclonal β1i or β5i antibodies 
were purchased from Abcam; β5 and β1 antibodies were purchased from Affinity 
Bioreagents; monoclonal β-actin antibody was purchased from Novus Biological. Mouse 
or rabbit secondary antibodies conjugated with horseradish peroxidase were purchased 
from GE Healthcare. Protein bands were visualized using enhanced chemiluminescence 
substrates (ECL). 
 In-Gel Fluorescence Study (ChemBioChem 2012, 13, 1899) 
Appropriate concentrations of YU102, LKS01-B650 and epoxomicin (Epx) for in these 
in-gel studies were determined by Western blot analysis of subunit covalent modification. 
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Figure 2.15 Differential modification of β1i (LMP2) and β1 (Y) in T1 cell lysate. 
YU102 covalently modifies β1i (LMP2) partially 0.05 μM with complete modification at 
0.5 μM, while the β1 (Y) subunit is modified at 0.5 μM. Epoxomicin completely 
modified β1i (LMP2), β1 (Y), β5 (X) and β5i (LMP7) at 10 μM. Positive Control for β1i, 
β1: 10μM YU102; Positive Control for β5i, β5: 30μM Epx. (This experiment was 
performed by Na-Ra Lee from Kyung-Bo’s group in the Department of Pharmaceutical 
Sciences, University of Kentucky) (ChemBioChem 2012, 13, 1899) 
 
Figure 2.16  Mobility Shift assay of LKS01-B650 in T1 and T2 cell lysates. In T1 cell 
lysate, LKS01-B650 selectively modifies β5i (LMP7) at a concentration of 5μM, but not 
β1i (LMP2), β1 (Y) or β5 (X) at concentrations of upto 10μM. In T2 cell lysates, none of 
the proteasome subunits were modified at concentrations of 5-10 μM. Positive Control 
for β1i (LMP2), β1 (Y): 10μM YU102; Positive Control for β5i (LMP7) and β5(X): 
30μM Epx (epoxomicine). (This experiment was performed by Na-Ra Lee from Kyung-
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Bo’s group in the Department of Pharmaceutical Sciences, University of Kentucky) 
(ChemBioChem 2012, 13, 1899) 
 
Figure 2.17 Impact of the LKS01, YU102 or epoxomicin pretreatment on in-gel 
fluorescence labeling of LK01-B650. T1 and T2 cell lysates were pretreated with 
DMSO or LKS01, YU102, or epoxomicin (Epx) for 1 hr, followed by incubation with 
10μM LKS01-B650 for 1 hr. LKS01-B650 binding was, then, visualized using a 
Typhoon FLA 9000 imaging system (λex = 635 nm, λem = 665). Pretreatment with 
LKS01, a parent compound of LKS01-B650, effectively competed away fluorescent 
signals consistent with the molecular weight of LMP7 in T1 cell lysate. The non-selecitve 
inhibitor epoxomicin also blocked LKS01-B650 binding. The LMP2-selective inhibitor 
YU102 did not block LKS01-B650 binidng to the major band. Diffuse fluorescent signal 
above 40 kDa is likely due to free LKS-01-B650 which was not removed from samples 
before separation. No fluorescently-labelled bands were observed at the molecular 
weights consistent with non-LMP7 proteasome catalytic subunits. (This experiment was 
performed by Na-Ra Lee from Kyung-Bo’s group in the Department of Pharmaceutical 
Sciences, University of Kentucky) (ChemBioChem 2012, 13, 1899) 
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Figure 2.18 Immunoblotting analysis. The LMP7 antibody detects a specific band (with 
a slight shift following pre-incubation and treatment with LKS01-B650) only in T1 cells, 
but not in T2 cells. T1 and T2 cells were plated onto 6-well plate (2 x 105 cells/well), 24 
h prior to the experiment. The cells were pre-incubated with LKS01 (1 or 5 μM), Epx (5 
μM), YU102 (10 μM) or DMSO (control) for 1.5 hr at 37 °C. Subsequently, cells were 
treated with 15 μM of LKS01-B650 or DMSO (control) for 1.5 hr at 37 °C and cell 
extracts were analyzed by immunoblotting. Pre-incubation of T1 cell lysates with LKS01 
and Epx as well as incubation with LKS01-B650 resulted in an upward shift in the LMP7 
band. (This experiment was performed by Na-Ra Lee from Kyung-Bo’s group in the 
Department of Pharmaceutical Sciences, University of Kentucky) (ChemBioChem 2012, 
13, 1899) 
Preparation of T1 and T2 cell lysates (ChemBioChem 2012, 13, 1899) 
T1 and T2 cells were harvested and cell pellets were washed once with Hank’s Buffered 
Salt Solution (HBSS). The pellets were lysed by incubation in 1X Passive lysis buffer 
(Promega) at room temperature for 15 min with continuous slow inversion of the 
samples. Each of the supernatant was then collected by centrifugation at 14000 rpm at 4 
oC for 10 min. Protein concentrations were determined by the Bradford Assay (Bio-Rad). 
The lysates were then diluted to a total protein concentration 1 μg/μL for pretreatments 
and treatments with proteasome inhibitors.   
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In-Gel Fluorescence Detection (ChemBioChem 2012, 13, 1899) 
Compound-treated cell lysates were denatured as described for immunoblotting and 
electrophoresed on 12% polyacrlyamide gels. In-gel fluorescence signals were recorded  
for gels prepared with lysates from T1 and T2 cells which had been treated with LKS01-
B650 alone or with LKS01-B650 following pretreatment with LKS01, YU102,  
epoxomicin (Epx), or DMSO (vehicle control). Pretreatment with LKS01 or epoxomicin 
competed away a fluorescent signal from LKS01-B650 which was consistent with the 
molecular weight for LMP7. YU102 pretreatment did not have this effect. Again in-gel 
fluorescent signals were captured using a Typhoon FLA 9000 imaging system (λex = 635 
nm, λem = 665).   
Fluorescence Microscopy (ChemBioChem 2012, 13, 1899) 
Panc-1 cells were plated at a density of 1.0 x 105 cells on 4-well chamber slides, 24-48 
hrs prior to treatment of compounds. Following compound treatment, the cells were fixed 
with 4% paraformaldehyde in PBS for 7 min at 37oC and washed extensively with PBST 
to remove unbound compounds. Slides were mounted with coverslips using Prolong Gold 
antifade reagent with DAPI (Invitrogen). For co-localization experiments, fixed cells 
were subjected to permeablization (incubation with 0.2% Triton-X in PBS for 30 min), 
blocking (10% goat serum and 1% BSA for 1 hr), and subsequent incubation with 
primary antibodies (β5i or calnexin). Primary antibodies against β5i (Abcam) or calnexin 
(Cell Signaling) were diluted with DakoCytomation Antibody Dilutant with Background 
Reducing Components and incubated with cells for 1 hr at 37oC. Following washing in 
PBST and incubation with secondary antibody conjugated with a green fluorophore 
Alex488 (Invitrogen), slides were mounted with coverslips. Cells were then visualized 
using an inverted Nikon-Ti-U fluorescence microscope and NIS Element Research image 
analysis software. 
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2.5.4. Copies of NMR and mass spectra (ChemBioChem 2012, 13, 1899) 
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Chapter 3: Development of Bifunctional Cross-linking Agents 
3.1. Overview of the study 
To identify different proteasome subtypes, we decided to use a more traditional 
chemical cross-linking approach to complement the FRET-based method. We therefore 
sought to develop new bifunctional cross-linking agents that are capable of cross-linking 
Thr1Oγ of two catalytic β-subunits within the same proteasome complex (Chapter 1, 
Figure 1.8). The ability of the synthesized bifunctional agents to cross-link catalytic 
subunits can be easily tested by mobility shift assays, which may serve as a direct and 
convincing method to determine the subunit composition of intermediate proteasomes. 
3.2. Introduction 
3.2.1. The chemical crosslinking approach 
A chemical crosslinking approach has been successfully applied to the design of small 
bifunctional molecules, capable of interacting with two or more proteins simultaneously, 
for enhanced or novel biological effects (Uy et al. 1977; Kluger et al. 2004; Agou et al. 
2004; Corson et al. 2008). This approach involves the chemical joining of two different 
proteins in close proximity by a covalent bond. It utilizes cross-linking agents that have at 
least two chemical groups (such as primary amines, sulfhydryls etc.) that react with 
specific functional groups on proteins. If these two reactive groups are identical (homo-
bifunctional), the molecule can crosslink two identical protein monomers; but if two 
reactive groups are non-identical (hetero-bifunctional), two different proteins can be 
cross-linked. This bifunctional cross-linking approach has proved to be useful for 
stabilizing proteins, targeting them to specific sites and for the functional analysis of 
proteins (DeSantis  et al. 1999; Veronese et al. 2001; Kluger et al. 2004). Additionally, 
cross-linking agents have been used to study the tertiary and quaternary structure of 
proteins and to identify the spatial arrangements of the subunits in oligomeric proteins 
(Kluger et al. 2004; Sinz et al. 2006; Corson et al. 2008). 
_________________________________________________________________________ 
* Kinetic assay and mobility shift assays reported in this chapter were performed by 
Kimberly Carmony. 
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3.2.2. Chemical crosslinking in proteasome biology 
The unique arrangement of proteasome and immunoproteasome catalytic subunits makes 
them ideal targets for specific chemical crosslinking. To the best of my knowledge, there 
are only three reports in the literature describing the use of crosslinking agents in the 
context of proteasome biology. In all of these studies, bifunctional compounds were 
developed in attempt to gain to more potent and selective proteasome inhibition. Loidl et. 
al. (1999a) designed a bifunctional inhibitor (Mal-βAla-Val-Arg-H) to inhibit the trypsin-
like (T-L) activity of proteasome. As shown in Figure 3.1, the C-terminal aldehyde group 
of the compound reacts with the N-terminal Thr1 of the β2-subunit, and a maleinimide 
moiety at N-terminus reacts with the thiol group of Cys118 in the S3 binding pocket of 
the trypsin-like (T-L) site. Because of this unique bifunctional nature of Mal-βAla-Val-
Arg-H, it showed high selectivity towards inhibiting the T-L activity of the eukaryotic 
proteasome (IC50 = 0.5μM, T-L activity; IC50 > 100μM, CT-L activity).  
 
Figure 3.1 The hetero-bifunctional structure of Mal-βAla-Val-Arg-H. The aldehyde 
group (blue) reacts with the N-terminal Thr1 and maleinimide group (red) reacts 
with the Cys118 thiol. 
The same research group reported a few peptide aldehyde-based bifunctional inhibitors 
and found them to be twice as potent as the parent peptide aldehyde (Loidl et. al. 1999b; 
Loidl et. al. 2000). For example, the IC50 (T-L) for compound 45 (Figure 3.2) was 
6.4μM, but when the N-termini of two peptide aldehydes were linked with a 
polyoxyethylene (PEG) spacer, the IC50 (T-L) for the resulting compound 46 (Figure 3.2) 
was reduced to 0.071μM. More recently, Maréchal et al. (2012) reported a non-covalent 
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bifunctional proteasome inhibitor that inhibited chymotrypsin like (CT-L) activity 800 
times more efficiently compared to the parent compound (TMC-95A). 
 
 
Figure 3.2 Peptide aldehyde-based bifunctional proteasome inhibitor 46 and the 
parent compound 45.  
 
Figure 3.3  Non-covalent homo-bifunctional proteasome inhibitor.  
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 All previous reports on bifunctional proteasome inhibitors were focused on 
developing more potent inhibitors of CT-L and T-L activities of proteasomes, but none of 
the compounds reported were designed to target specific catalytic subunits of 
constitutive- and immuno-proteasomes. These previous reports encouraged us to develop 
new bifunctional crosslinking agents that can be used to identify different intermediate 
proteasomes (Chapter 1, Scheme 1.8.2). As peptide epoxyketones react with Thr1Oγ in a 
very specific manner by forming a morpholino ring (Chapter 1, Scheme 1.2E), we 
decided to develop the required bifunctional agents with epoxyketone pharmacophores. 
By choosing the appropriate length of the linkers between the two peptide epoxyketones, 
we should be able to cross-link two nearby catalytic subunits (such as β1i and β2i), as 
well as distant subunits (such as β1i and β5i). Mobility shift assays could provide a direct 
and rapid method to analyze the reaction products of the proteasome and bifunctional 
reagents. Therefore, this cross-linking approach may serve as a more convincing method 
to determine the subunit composition of intermediate proteasomes. 
 The overall goal of the study in this chapter is to develop a few homo- and 
hetero-bifunctional agents for a proof-of-concept of crosslinking approach and show 
their ability to crosslink different catalytic subunits of the proteasome by western 
blotting analysis (mobility shift assays).  
 
3.3. Results and Discussion 
3.3.1. Design and synthesis of bifunctional agents 
To develop the required crosslinking agents, we planned to derivatize the following three 
compounds: LKS01 (20), YU102 (48) and epoxomicin (49) (Figure 3.4). The ability of 
LKS01 (20) to selectively targeting the β5i/LMP7 subunit has already been discussed in 
detail in chapter 2 (Figure 2.5). Dr. Kim’s lab group has also identified YU102 (48) as a 
selective inhibitor of the  β1i/LMP2 subunit (Chapter 2, Figure 2.15); while on the other 
hand epoxomicin (49) has been reported to bind to almost all of  the catalytic subunit of 
constitutive- and immuno-proteasome (β2, β5, β1i, β2i and β5i). 
LKS01 (20) already has a lysine group which can be deprotected easily for further 
derivatization. Also, a Boc-derivative (20B) of LKS01 was developed. For YU102 and 
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epoxomicin derivatization, compounds 50, 51 and 52 were synthesized (Figure 3.5) by 
using a similar synthetic approach as described for LKS01 (20) in chapter 2.  
 
Figure 3.4 Chemical structure of the compounds used for design of bifunctional 
agents. 
 
Figure 3.5 Derivatives of YU102: 50, 51; derivative of epoxomicin: 52; and 
derivative of LKS01: 20B. 
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Scheme 3.1 shows the general synthetic scheme used to synthesize all the 
bifunctional crosslinking agents reported in this chapter. The N-hydroxysuccinimide ester 
(NHS) groups of the linkers are reacted with the primary/secondary amine in the side 
chain of the polypeptide compounds to form an amide bond. The resulting intermediate 
can be reacted with the same polypeptide to form homo-bifunctional agents or it can be 
reacted with a different polypeptide compound to develop hetero-bifunctional agents. 
 
Scheme 3.1  General synthetic scheme used to synthesize bifunctional compounds. 
 
 
Figure 3.6  LKS01 and YU102 based hetero-bifunctional agents (53 and 54) with 
short linkers. 
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3.3.2. Bifunctional agents with short linkers  
For our initial studies we synthesized two hetero-bifunctional molecules LKS-7-
YU (53) and LK-6-YU (54) that consist of LKS01 (β5i-targeting) on one end and YU102 
(β1i-targeting) the other end (Figure 3.6). To investigate the ability of these bifunctional 
agents to cross-link two catalytic subunits within the same proteasome complex, mobility 
shift assays were performed using the U266 cell lines, which expresses all of the catalytic 
subunits of both the constitutive proteasome and immunoproteasome. 
 
Figure 3.7 Western blot analysis of bifunctional agents LKS-7-YU (53) using (A) 
β1i-antibody; (B) β5i-antibody and (C) β1i-antibody (competition assay). (D) 
Cartoon showing the cross-linking ability of LKS-7-YU (53). U266 cell lysates were 
treated with DMSO, 5 μM epoxomicin, or 10 μM of each bifunctional compound for 4 
hrs at room temperature and subjected to western blot analysis using a β1i-antibody or a 
β5i-antibody. For the compettion assay cell lysates were pre-incubated with DMSO, 3 
μM NC-012, or 0.1 μM IPSI for 1 hr at room temperature prior to treatment with 5 μM 
epoxomicin, or 10 μM of LKS-7-YU. (Mobility shift assays were performed by Kimberly 
Carmony) 
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As shown in Figure 3.7A and B, both LK-7-YU and LK-6-YU were found to 
maintain the ability to modify both β1i and β5i subunits, detected by the increased 
molecular sizes of bifunctional agent (53 and 54)-conjugated β1i and β5i subunits 
observed between 20-25 kDa. Interestingly, for LK-7-YU a band around 50 kDa was 
detected using the LMP2 antibody (Figure 3.7A) which suggests that LK-7-YU (54) is 
able to covalently cross-link β1i-bound LK7YU with another catalytic subunit (Figure 
3.7A). However, no band around 50 kDa was observed on a western blot for β5i, which 
suggests that β1i is not crosslinked with β5i. Next, we performed a competition assay 
using NC-012 (Ac-Arg-Leu-Arg-ketoepoxide) which is known to be a selective inhibitor 
of β2/β2i (trypsin like) activity (Kisselev et al. 2012). To our delight, the bands at 50 kDa 
completely disappeared in the β1i immunoblot when the cells were pre-treated with NC-
012 (Figure 3.7C), demonstrating that LKS-7-YU cross-linked β1i and β2/β2i subunits 
(Figure 3.7D). This also suggests the presence of intermediate proteasomes containing 
β1i and β2 in U266 cells.  This contradicts the assumption that cells that abundantly 
express all immunoproteasome subunits prefer to cooperatively assemble 
immunoproteasomes as opposed to intermediate proteasomes. 
 
3.3.3. Bifunctional agents with longer linkers  
The initial data obtained with the bifunctional agent LKS-7-YU proved encouraging, and 
we decided to develop a few more bifunctional agents with longer linkers. We selected 
polyoxyethylene glycol (PEG) as linker because of its interesting properties such as water 
solubility, non-toxicity and resistance to proteolysis. Based on the nature of the 
polypeptide at each end, the bifunctional agents developed by us can be characterized as: 
homo-bifunctional agents, hetero-bifunctional agents and cleavable bifunctional 
agents. First, we synthesized homo-bifunctional agents (YU)2-PEG (55), (LKS)2-PEG 
(56), (Epx)2-PEG (57) that are homo-dimers of YU102, LKS01 and epoxomicin, 
respectively (Figure 3.8). In addition to these bifunctional agents that contain PEG as 
linker, we also synthesized a linear alkyl linker-based epoxomicin homo-dimer, (12-Ado-
Epx)2-C10 (58). One hetero-bifunctional agent, LKS-PEG-YU (59), was also synthesized 
that contains LKS01 (β5i-targeting) on one end and YU102 (β1i-targeting) on the other 
end. Two bifunctional agents (YU)2-SS (60) and LKS-SS-YU (61) were also developed 
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that contain disulfide (S-S) cleavable linkers. The disulfide (S-S) bond can be easily 
cleaved by 10-50 mM DTT or TCEP at pH 8.5. The incorporation of cleavable linkers 
into our bifunctional agents might provide additional proof of the ability of bifunctional 
agents to crosslink catalytic subunits of the proteasome. Of note, when coupling of 
compounds 62 and 63 with PEG-linker was investigated, no reaction was observed 
(Scheme 3.2). This suggests that a free amine with a long alkyl chain is not suited for 
coupling with the PEG-linker, and only a free N-terminal amine or the free amine of ε-
lysine can be used to couple the PEG-linker. However, a free amine with a long alkyl 
chain can be reacted easily with the acid group of another alkyl chain; as observed for the 
synthesis of compound 58.  
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Figure 3.8 Homo-bifunctional agents with PEG-linker and alkyl-linker. 
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Figure 3.9 Hetero-bifunctional agent with a PEG-linker. 
 
 
 
Figure 3.10 Cleavable Homo- and Hetero-bifunctional agents with a PEG-linkers 
containing disulfide (S-S) bonds (red). 
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Scheme 3.2  Failed homo-dimerization reaction of compounds 62 and 63. 
 
3.3.4. Proteasome Activity Assay 
To confirm that bifunctional agents inhibit proteasome activity, we performed an activity 
assay using fluorogenic peptide substrates. This assay measures the ability of inhibitors to 
block the hydrolysis of fluorogenic substrates by the proteasome. Several fluorogenic 
substrates have been reported in the literature that can be used to measure proteasome 
activity. For example, the substrate Suc-LLVY-AMC is generally used to measure the 
CT-L activity of the proteasome (i.e. β5 and β5i activity) (Orlowski et al. 2000). 
Similarly, fluorogenic substrates Ac-PAL-AMC and Ac-ANW-AMC have been reported 
as selective substrates for the subunits β1i and β5i,respectively (Blackburn et al. 2010). 
As explained earlier, the bifunctional agent LKS-7-YU (53) was shown to cross-
link β1i with another proteasome subunit (Figure 3.7). Therefore, we first compared the 
ability of LKS-7-YU (53) and its PEG derivative LKS-PEG-YU (59) to inhibit 
proteasome activity. As reported in Table 3.1, both compounds inhibited most β1/β1i and 
β5/β5i activity at 1 μM. Additionally, LK-7-YU (53) was found to be a more potent 
inhibitor of β2/β2i than LKS-PEG-YU (59) as suggested by Boc-LRR-AMC hydrolysis, 
which was inhibited to 68% with 10 μM of LK-7-YU (53) as compared to 81% with 10 
μM of LKS-PEG-YU (59). 
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Next we investigated the inhibition of proteasome activity by the homo-
bifunctional agents: (YU)2-PEG (55), (LK)2-PEG (56) and (12-Ado-Epx)2-C10 (58) 
(Table 3.1). The bifunctional agent (YU)2-PEG (55), which is a homo-dimer of YU102, 
was found to be more potent at inhibiting β1/β1i over other subunits. However, it did not 
inhibit β2/β2i activity significantly at concentrations up to 10 μM. Similarly, LKS01 
homo-dimer (LK)2-PEG (56) more potently inhibited β5i/β5 over other subunits and did 
not inhibit β2/β2i activity until 10 μM. Compound (12-Ado-Epx)2-C10 (58) was found to 
be least potent bifunctional compound. It displayed some selectivity for β5/β5i over other 
subunits. Interestingly, it appeared to have a slight preference for β1 over β2/β2i, unlike 
epoxomicin (Epx). 
 
Table 3.1  Proteasome Activity Assay  
 
 
 
Compound 
Used 
 
Concent-
ration 
(μM) 
Relative Rate of Hydrolysis (% control) 
Suc-LLVY-
AMC 
(β5/β5i) 
Ac-nLPnLD-
AMC 
(β1) 
Ac-PAL-
AMC 
(β1i) 
Ac-ANW-
AMC 
(β5i) 
Boc-LRR-
AMC 
(β2/ β2i) 
DMSO - 100% 100% 100% 100% 100% 
Epx 20 1% 14% 3% 0% 39% 
    
 L
K
S-
7-
Y
U
 1 4% 3% 1% 4% 95% 
5 0% -1% 0% 0% 82% 
10 0% 0% 1% 1% 68% 
 
LK
S-
PE
G
-
Y
U
 
1 3% 13% 5% 4% 105% 
5 0% 0% 0% 0% 98% 
10 0% -1% 0% 0% 81% 
  
(Y
U
)2
-P
EG
 1 34% -1% 1% 44% 103% 
5 3% -1% 0% 18% 98% 
10 1% -2% 0% 15% 95% 
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(L
K
S)
2-P
EG
 
0.5 25% 89% 92% 5% 103% 
1 5% 90% 95% 5% 105% 
5 1% 73% 57% 0% 92% 
10 1% 45% 37% 0% 76% 
  
(1
2-
A
do
-E
px
)-
C
10
 0.5 101% 98% 95% 86% 101% 
1 59% 82% 85% 63% 93% 
5 23% 84% 68% 40% 90% 
10 13% 80% 51% 18% 84% 
 
3.3.5. Mobility Shift Assay 
To analyze the ability of our synthesized bifunctional agents to crosslink proteasome 
subunits, we performed a mobility shift assay using U266 multiple myeloma cells, since 
these cells abundantly express both the immunoproteasome and the constitutive 
proteasome. Specifically, U266 cell lysates were treated with 10μM of LK-7-YU (53), 
LKS-PEG-YU (59), (YU)2-PEG (55), (LKS)2-PEG (56) and (12-Ado-Epx)2-C10 (58). 
The cell lysates were then subjected to immunoblotting analyses using antibodies specific 
for the β1i/LMP2 proteasome catalytic subunit. Interestingly, bands around 45-50 kDa 
were observed for LK-7-YU (53), LKS-PEG-YU (59), (YU)2-PEG (55) and (LKS)2-PEG 
(56) which suggests that these bifunctional agents cross-link β1i/LMP2 with another 
proteasome subunit. 
Next, we performed a mobility shift assay using antibodies specific for β5i/LMP7 
subunits and observed the same band around 45kDa for (YU)2-PEG (55), (LKS)2-PEG 
(56) (Figure 3.11, B), indicating that both homo-bifunctional agents (55, 56) were able to 
cross-link β5i/LMP7-subunit with other proteasome subunit. Of note, no cross-linked 
dimers were observed on the immunoblot using antibodies specific for β2/Z (Figure 
3.11, C). This is consistent with the activity assay results, which showed that these 
bifunctional agents with longer linkers were not potent inhibitors of trypsin-like (T-L) 
activity (Table 3.1). 
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Figure 3.11 Mobility shift assay of selected longer linker bifunctional agents using 
(A) β1i/LMP2-antibody (B) β5i/LMP7-antibody and (C) β2/Z-antibody. U266 cell 
lysates were treated with DMSO, 5 μM epoxomicin, or 10 μM of each bifunctional 
compound for 4 hrs at room temperature and subjected to western blot analysis using a 
β1i-antibody, a β5i-antibody or a β2-antibody. (Mobility shift assays were performed by 
Kimberly Carmony) 
3.4. Summary 
We have successfully synthesized epoxyketone-based bifunctional compounds by 
utilizing homo- or hetero-dimerization of LKS01, YU102 and epoxomicin. The ability of 
these bifunctional agents to inhibit proteasome activity was demonstrated by blocking the 
proteasome-mediated hydrolysis of polypeptide fluorogenic substrates in activity assays. 
Furthermore, mobility shift and competition assays demonstrated that LKS-7-YU (53) 
cross-linked β1i and β2/β2i subunits within the same proteasome complex, which 
provided the proof-of-concept of crosslinking proteasome catalytic subunits by 
epoxyketone-based bifunctional agents. These new bifunctional tools will be helpful in 
identifying the subunit composition of different proteasome subtypes and will lead to new 
insights into fundamental proteasome biology may lead to the development of novel 
proteasome inhibitors that more effectively target specific proteasome subtypes. 
(C) 
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3.5. Experimental Procedures 
3.5.1. Synthesis and Characterization of compounds 
(A) General Procedure 
All reactions were carried out under a nitrogen atmosphere. All commercial reagents 
were obtained from commercially available sources and used without further purification. 
All reactions were magnetically stirred and monitored by thin-layer chromatography 
(TLC). TLC plates were visualized by exposure to ultraviolet light (254 nm) and/or by 
immersion in a staining solution of phosphomolybdic acid (PMA), followed by heating 
on a hot plate. Column or flash chromatography (silica) was performed with the indicated 
solvents using silica gel (particle size 0.032-0.063 mm) purchased from Dynamic 
Adsorbents or MP Biomedicals. 1H and 13C spectra were recorded using 300 or 400 or 
500 MHz, using CDCl3 or acetone-d6 as a solvent.  The chemical shifts are reported in 
parts per million (ppm) relative to internal CHCl3 (δ 7.26 ppm for proton NMR and δ 
77.23 ppm for carbon NMR) or relative to acetone-d6 (δ 2.05 ppm for proton NMR and δ 
29.92 ppm for carbon NMR). Coupling constants are reported in hertz (Hz). The 
following abbreviations are used to designate the multiplicities: s = singlet, d = doublet, t 
= triplet, q = quartet, m = multiplet. 
Identity of all bifunctional compounds was confirmed by mass analysis (Bruker Daltonics 
MALDI-TOFMS). 
Synthesis of compound 52 
 
To a solution of compound A (0.1 mmol, 55 mg) and compound B (0.12 mmol, 18 
mg) in methylene chloride was added HOBt (1.0 equiv) and HBTU (1.0 eq). After 
stirring the reaction mixture for 5 minutes DIPEA was added dropwise. The reaction 
mixture was further stirred for overnite at room temperature. The reaction mixture 
was concentrated and directly loaded to the column. The purification was performed 
with Ethyl acetate/hexane solvent system (25% to 50%), to obtain 53 mg of pure 52 
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(76%) yield; 1H NMR (500 MHz, CDCl3): δ 7.32 (m, 5H), 7.07 (d, J= 8.0 Hz, 1H), 
6.87 (d, J= 6.4 Hz, 1H), 6.65 (d, J= 7.0 Hz, 1H), 4.66 (d, J= 11.6Hz, 1H), 4.51 (m, 
3H), 4.28 (t, J= 6.5 Hz, 1H), 4.15 (m, 2H), 3.34 (d, J= 4.8 Hz, 1H), 2.88 (d, J= 4.8 
Hz, 1H), 2.77 (m, 1H), 2.75 (s, 3H), 2.05 (m, 2H), 1.70 (m, 3H), 1.50 (s, 3H), 1.45 (s, 
9H), 1.16 (d, J= 6.8 Hz, 3H), 0.92-0.82 (m, 18H), 0.78 (d, J= 6 Hz, 3H); 13C NMR (75 
MHz, CDCl3): δ 208.3, 171.6, 171.1, 169.7, 157.2, 138.0, 128.6, 128.1, 128.1, 80.7, 
74.0, 71.7, 63.2, 59.4, 58.6, 56.2, 52.7, 52.6, 50.6, 39.8, 36.3, 31.4, 30.3, 29.9, 28.6, 
25.2, 24.6, 24.4, 23.6, 21.3, 16.9, 16.0, 15.9, 15.1, 11.6, 10.5. 
Synthesis of compound 50 
 
 
HBTU/HOBt/DIPEA mediated peptide coupling was performed to synthesize compound 
50 in 82% yield; 1H NMR (500 MHz, CDCl3): δ 7.21 (m, 5H), 6.93 (d, J= 8.0 Hz, 1H), 
6.57 (d, J= 8.0 Hz, 1H), 5.22 (t, 1H), 4.55 (m, 2H), 4.67 (m, 1H), 4.09 (dd, J= 7.2 Hz, 6.8 
Hz, 1H), 3.80 (dd, J= 5.2 Hz, 5.2 Hz, 1H), 3.68 (dd, J= 4.0 Hz, 3.6 Hz, 1H), 3.29 (m, 
3H), 3.12 (dd, J= 5.2 Hz, 5.2 Hz, 1H), 3.00 (dd, J= 8.8 Hz, 8.2 Hz, 1H), 2.86 (d, J= 4.4 
Hz, 1H), 2.2 (m, 1H), 1.82 (m, 5H), 1.47 (s, 3H), 1.43 (s, 9H), 1.22 (t, J=7.6 Hz, 6H); 13C 
NMR (75 MHz, CDCl3): 208.4, 171.1, 170.9, 169.2, 156.0, 136.9, 129.3, 128.6, 127.2, 
80.2, 60.6, 59.3, 54.1,  54.1, 52.6, 50.5, 50.5, 46.6, 43.2, 40.0, 37.2, 28.6, 27.8, 25.2, 24.8, 
23.6, 21.5, 16.9, 16.9, 14.4. 
 
(B) General Procedure for the synthesis of Homo-bifunctional Compounds 
To a solution of polypeptide (1 equiv) in THF, BS(PEG)9 (0.5 equiv) or DT(PEG)16 was 
added which was followed by dropwise addition of DIPEA (1.5 equiv). The reaction 
mixture was stirred overnite at room temperature and then it was concentrated to dryness. 
The resulting crude was loaded on column and purification was performed using 
methylene chloride/methanol solvent system. 
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Synthesis of (YU)2-PEG (55) 
 
A solution of compound 51 in methylene chloride was treated with TFA. After stirring 
the reaction mixture for 1hr, it was concentrated and put on high vaccum for 3hr. The 
crude product was taken forward for next reaction of coupling with BS(PEG)9 as 
described in general procedure A. The 5 mg of bifunctional compound 55 was obtained 
in overall 80% yield. The identity of compound 55 was confirmed by mass analysis 
(MALDI-TOFMS): molecular ion peak, M+= (not observed), 1649 (calculated); M+Na = 
1672 (observed), 1672 (calculated); M+K = 1688 (observed), 1688 (calculated). 
 
Synthesis of (LKS)2-PEG (56) 
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To a solution of LKS01 (20) in methylene chloride, 1ml TFA was added. The reaction 
mixture was stirred for 1hr at room temperature and then concentrated to dryness. The 
crude then reacted with BS(PEG)9 as described in general procedure A. The 2.0 mg of 
bifunctional compound 56 was obtained in overall 62% yield. The identity of compound 
56 was confirmed by mass analysis (MALDI-TOFMS): M+Na = 1622 (observed), 1622 
(calculated); M+K=1638 (observed), 1639 (calculated). 
 
Synthesis of (LKS)2-PEG (56) 
By following the procedure A as described earlier, 4 mg of bifunctional compound 57 
was obtained in overall 74% yield. The identity of compound 56 was confirmed by mass 
analysis (MALDI-TOFMS): M+Na = 1706 (observed), 1706 (calculated); M+K= 1722 
(observed), 1722 (calculated). 
 
Synthesis of (12-Ado-Epx)2-C10 (58) 
   
Compound 52B was treated with TFA to deprotect Boc group. After treating the reaction 
mixture for 1hr, it was concentrated and the crude was taken forward directly without 
purification. The crude was treated with sebacic acid (0.5 equiv) under 
HBTU/HOBt/DIPEA coupling condition and the reaction mixture was stirred at room 
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temperature for overnite. The purification was done using methylene chloride/methanol 
solvent system to obtain 58 (1 mg, 46% yield). The identity of compound 58 was 
confirmed by mass analysis (MALDI-TOFMS): M+Na = 1788 (observed), 1788 
(calculated). 
Synthesis of (YU)2-SS (60) 
 
 
By following the procedure A, 5 mg of bifunctional compound 57 was obtained in overall 
85% yield. The identity of compound 57 was confirmed by mass analysis (MALDI-
TOFMS): M+Na = 2073 (observed), 2073 (calculated); M+K= 2090 (observed), 2090 
(calculated). 
 
(C) Synthesis of Hetero-bifunctional Compounds 
Synthesis of LKS-PEG-YU (59) 
  
To a solution of LKS01 (20) (1.0 equiv) in ethyl-acetate/methanol (1:1), 10% Pd/C was 
added and reaction mixture was stirred under bubbling hydrogen atmosphere. After 5hr 
the reaction mixture was filtered and concentrated to dryness. The crude was diluted with 
1.0 ml THF and BS(PEG)9 (1equiv) was added which was followed by addition of 
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DIPEA (1.5 equiv). After stirring the reaction mixture for overnite, it was concentrated. 
The resulting crude was purified using methylene-chloride/methanol solvent system to 
obtain LKS-PEG9. The LKS-PEG9 was then dissolved in 1ml THF and reacted with 
deprotected compound 20 (1.0 equiv) and DIPEA (1.5 equiv). The reaction mixture was 
concentrated after overnite stirring and the crude was purified with methylene-
chloride/methanol solvent system to obtain compound 59 (3.0 mg, 64% yield).  
LKS-PEG9: Mass analysis (MALDI-TOFMS): M+Na = 1180 (observed), 1180 
(calculated); M+K = 1196 (observed), 1196 (calculated). 
LKS-PEG-YU (59): Mass analysis (MALDI-TOFMS): M+Na = 1647 (observed), 1647 
(calculated); M+K = 1663 (observed), 1663 (calculated). 
 
Synthesis of LKS-SS-YU (61) 
The same procedure was followed as described above for the synthesis of 59, except that 
cleavable linker DT(PEG)16 was used instead of BS(PEG)9. The identity of compound 58 
was confirmed by mass analysis (MALDI-TOFMS): Molecular ion peak M+ = 2026 
(observed), 2026 (calculated); M+Na = 2049 (observed), 2049 (calculated); M+K = 2065 
(observed), 2065 (calculated). 
 
Synthesis of LKS-7-YU (53) and LKS-6-YU (54) 
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To synthesize compounds 53 and 54, same procedure was followed with disuccinimidyl 
suberate (DSS) linker.  
LKS-7-YU (53): Mass analysis (MALDI-TOFMS): M+Na = 1309(observed), 
1309(calculated). 
LKS-6-YU (54): Mass analysis (MALDI-TOFMS): M+Na = 1196(observed), 
1196(calculated). 
 
3.5.2. Biology methods 
Cell Lysate Preparation: 
? Cells were lysed in Passive Lysis Buffer (Promega, cat. # E194A) according to 
manufacturer’s instructions. 
? Protein assays were performed by the method of Bradford using the Protein Assay 
Dye Reagent Concentrate (Bio-Rad, cat. # 500-0006) and Bovine Serum Albumin 
Standard (Bio-Rad, cat. # 500-0007).  Protein concentrations were measured 
using a GENESYS 10 spectrophotometer. 
 
 
Proteasome Activity Assays: 
? Incubation with bifunctional compounds: 
o Each well (96-well plate) contained 5 μg of U266 lysate in assay buffer 
(total volume per well = 90 μL).   
? Assay Buffer: 20 mM Tris/Cl pH 8.0, 0.5 mM EDTA 
? For all substrates except Boc-LRR-AMC, 0.035% SDS was 
also included in the assay buffer. 
o Lysates were incubated with DMSO, 20 μM epoxomicin, or increasing 
concentrations of bifunctional compounds (0.5, 1, 5, 10 μM) for 1 hr at 
room temperature. 
? Addition of substrates: 
o Suc-LLVY-AMC (CT-L activity), Ac-nLPnLD-AMC (C-L activity, Y-
selective), Ac-PAL-AMC (LMP7-selective), Ac-ANW-AMC (LMP7-
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selective), and Boc-LRR-AMC (T-L activity) were added to obtain a final 
substrate concentration of 100 μM in a final volume/well of 100 μL. 
? Fluorescence was monitored (excitation = 360 nm, emission = 460 nm) over 90 
min using a SpectraMax M5 plate reader and SoftMax Pro software. 
? Reaction velocities were determined using linear regression (GraphPad Prism) 
and normalized to DMSO-treated control. 
Western Blotting 
? U266 lysate was diluted to a concentration of 1 μg/μL in passive lysis buffer 
(Promega, cat. # E194A). 
? Lysates were treated with DMSO, 5 μM epoxomicin, or 10 μM of each 
bifunctional compound for 4 hrs at room temperature. 
? Samples were denatured in 2X Laemmli sample buffer (Sigma-Aldrich, cat. # 
S3401) at 100°C for 20 min. 
? For LMP2, LMP7, X, and Y western blots: Proteins (5 μg/well) were resolved by 
14% SDS-PAGE. 
? Proteins were transferred onto PVDF membranes (Bio-Rad, cat. # 162-0177). 
? Membranes were blocked in 5% milk in tris-buffered saline with 0.05% Tween-
20 (TBST) for 1 hr at room temperature. 
? Membranes were incubated in primary antibody solutions overnight at 4°C. 
o LMP2 antibody: Abcam, cat. # ab3328, diluted 1:1,000 in 3% BSA 
(Sigma-Aldrich, cat. # A3059) in TBST 
o LMP7 antibody: Abcam, cat. # ab3329, diluted 1:1,000 in 3% milk (Bio-
Rad, cat. # 170-6404) in TBST 
o X antibody: Thermo Scientific, cat. # PA1-977, diluted 1:1,000 in 3% 
BSA in TBST 
o Y antibody: Thermo Scientific, cat. # PA1-978, diluted 1:1,000 in 3% 
BSA in TBST 
o β-Actin: Novus Biologicals, cat. # NB600-501 in TBST 
? Membranes were incubated in secondary antibody solutions for 1 hr at room 
temperature. 
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o For LMP2, LMP7, X, and Y: anti-rabbit IgG horseradish peroxidase (GE 
Healthcare, cat. # NA934), diluted 1:20,000 in 3% milk in TBST 
o For β-Actin: anti-mouse IgG horseradish peroxidase (GE Healthcare, cat. 
# NA931), diluted 1:5,000 in 3% milk in TBST 
? Proteins were visualized using SuperSignal West Femto Chemiluminescent 
Substrate (Thermo Scientific, cat. # 34095) and X-ray film (Thermo Scientific, 
cat. # 34090). 
? Competition Assay: 
o U266 lysate was diluted to a concentration of 1 μg/μL in passive lysis 
buffer (Promega, cat. # E194A). 
o Lysates were pre-incubated with DMSO, 3 μM NC-012, or 0.1 μM IPSI 
for 1 hr at room temperature. 
o Lysates were then treated with DMSO, 5 μM epoxomicin, or 10 μM of 
each bifunctional compound for 4 hrs at room temperature. 
o Samples were then denatured and western blotting was performed to 
detect LMP2, as described above. 
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3.5.3. Copies of NMR and mass spectra 
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Compound 53 
M+ = 1286 
M+Na = 1309 
 
Compound 54 
M+ = 1173 
M+Na = 1196 
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Compound 55 
M+ = 1649 
M+Na = 1672 
M+K = 1688 
 
 
Compound 55 
M+ = 1649 
M+Na = 1672 
M+K = 1688 
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Compound 56 
M+ = 1599 
M+Na = 1622 
M+K = 1638 
 
Compound 56 
M+ = 1599 
M+Na = 1622 
M+K = 1638 
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Compound 57 
M+ = 1683 
M+Na = 1706 
M+K = 1722 
 
 
Compound 
57 
M+ = 1683 
M+Na = 
1706 
M+K = 1722 
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Compound 58 
M+ = 1765 
M+Na = 1788 
 
 
Compound 58 
M+ = 1765 
M+Na = 1788 
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Compound 60 
M+ = 2050 
M+Na = 2073 
M+K = 2090 
 
Compound 60 
M+ = 2050 
M+Na = 2073 
M+K = 2090 
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Compound 61 
M+ = 2026 
M+Na = 2049 
M+K = 2065 
Compound 61 
M+ = 2026 
M+Na = 2049 
M+K = 2065 
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LKS-PEG9 
M+ = 1157 
M+Na = 1180 
M+K = 1196 
 
Compound 59 
M+ = 1624 
M+Na = 1647 
M+K = 1663 
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M+ = 838 
M+Na = 861 
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Chapter 4: Studies towards a selective β5i/LMP7-inhibitor: Understanding the 
binding pattern* 
4.1. Overview of the study 
Recent studies have associated the β5i/LMP7-subunit of the immunoproteasome with 
autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease (IBD) 
(Muchamuel et al. 2009; Basler et al. 2010). The treatment of autoimmune diseases with 
proteasome inhibitors represents a large potential market with possibilities for significant 
improvement in patient wellbeing. However, the current proteasome inhibitors in clinical 
use are designed to target both β5 and β5i subunits, which provide the proteasome with 
its chymotrypsin-like activity. As described previously, non-specific inhibition of the 
chymotrpysin-like activity of the proteasome causes cytotoxic effects which would be 
undesirable in the treatment of autoimmune disease. Aside from therapeutic applications, 
the lack of subunit specific inhibitors also limits our understanding of the functional role 
of individual active subunits in cells. The overall goal of the study in this chapter focuses 
on developing a small library of tripeptide compounds to understand the structural 
determinants for binding to and inhibiting catalytic proteasome subunits. This knowledge 
may lead to a more selective inhibitor of the β5i/LMP7 subunit. 
4.2. Introduction: β5i/LMP7-subunit and Human Diseases 
The approval of bortezomib and carfilzomib by the FDA for the treatment of multiple 
myeloma and mantle cell lymphoma has encouraged scientists to investigate the role of 
constitutive- and immuno-proteasomes in other diseases as well. Several studies have 
recently linked the β5i/LMP7 subunit of the immunoproteasome to diseases including 
autoimmune disorders and cancers. 
Autoimmune diseases 
The upregulation of immunoproteasome subunits (β5i and β1i) has been observed in 
_________________________________________________________________________ 
* Kinetic assay and mobility shift assays reported in this chapter were performed by Zach 
Miller. 
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several autoimmune diseases such as rheumatoid arthritis and inflammatory bowel 
disease. A study utilizing two mouse models of rheumatoid arthritis showed that 
administration of PR-957 (a β5i selective inhibitor) resulted in a significant reduction of 
inflammatory infiltration, pro-inflammatory cytokine production and autoantibody 
production (Muchamuel et al. 2009; Ichikawa et al. 2012). Other studies have 
demonstrated that β5i inhibition by PR-957 or deletion of β5i prevents the progression of 
experimental colitis and systemic lupus erythematosus (Basler et al. 2010). These 
findings provide a rational for targeting the β5i-subunit of immunoproteasome in 
autoimmune diseases. 
Cancer 
Several studies have demonstrated high expression level of immunoproteasome subunits 
in various cancer cells lines. In 2009, Parlati et al. showed that neither the selective 
inhibition of β5 nor β5i can cause antitumor activity. However, another study 
demonstrated that a β5i selective inhibitor PR-924 can provoke apoptosis in human 
multiple myeloma cell lines (Singh et al. 2011). These two contradicting reports warrant 
further investigation to validate β5i-subunit as anti-cancer target. 
 
 
 
Figure 4.1  Chemical Structure of PR-924 (IPSI) and PR-957. 
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Figure 4.2 Binding pattern of PR-924 and PR-957 in EL4 cell lines. 
 Even though PR-957 and PR-924 have been reported as selective inhibitors of the 
β5i/LMP7 subunit in a dose dependent manner, our mobility shift assays in EL4 cell lines 
have shown that both PR-957 and PR-924 bind to and covalently modify the β1i/LMP2-
immunosubunit at low concentrations as well (Figure 4.2). Additionally, the study in 
chapter 2 outlined the modifications of PR-924 (IPSI) which produced the inhibitor 
LKS01 and its fluorescent derivative LKS01-B650. Interestingly, the introduction of the 
BODIPY® 650/665 fluorescent group at the P2 position appeared to significantly 
improve the binding specificity of LKS01 towards β5i/LMP7 (Figure 2.6). Taken 
together, our western blot analysis of PR-924, PR-957 and LKS01-B650 suggest that 
there is still room for improvement in the effort to develop a more selective β5i/LMP7-
subunit inhibitor. 
 To understand the binding pattern of proteasome inhibitors with constitutive- and 
immuno-subunits, we decided to carry out a systematic SAR study. A scheme was chosen 
in which each amino acid residue of the β5i/LMP7-targeing tripeptide inhibitor PR-924 
would be modified individually by replacement with other natural and unnatural amino 
acids in order to generate a series of analogs at each position (Figure 4.3B). These 
analogs would then be tested for their ability to inhibit the activity β5i/LMP7 and β5/X 
subunits in purified proteasomes. Our overall goal in this combinatorial positional 
scanning study was to gain insights that will help advance our efforts to develop a more 
selective inhibitor targeting the β5i/LMP7-subunit of the immunoproteasome. 
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Figure 4.3  (A) Interaction of the side chains of IPSI with specificity (S) pockets of 
proteasomal substrate binding channel; (B) Tripeptide epoxyketone. 
4.3. Results and Discussion 
4.3.1. P2 modification 
Our medicinal chemistry efforts began with the development of a series of analogs of 
lead compound, IPSI (PR-924). This initial series of compounds was designed with 
different amino acids at the P2 position while maintaining the parent compound’s 3-
Methylindene-D-Ala-P2-Phe-Ketoepoxide backbone (Figure 4.4). This small library 
contained P2 amino acids with small hydrophobic side chain such as Gly, Ala, Abu, Ile 
and compounds with larger hydrophobic side chains such as Nle, Met and Lys(Boc). 
Compounds with aromatic functionality like Phe, Trp and Lys(Z) were also synthesized. 
 First, the ability of these compounds to inhibit the β5i/LMP7-subunit was 
analyzed by measuring the hydrolysis of the selective fluorogenic substrate Ac-ANW-
AMC (Blackburn et al. 2010). Compounds with an aromatic ring in the P2 side chain 
(Phe, Lys(Z) and Trp)  were found to inhibit the β5i/LMP7 subunit more potently than 
other compounds. Compounds containing small and large hydrophobic resides (Gly, Ala, 
Abu, Ile, Nle and Lys(Boc)) generally did not produce potent activity (Figure 4.5). 
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Figure 4.4 P2 modification with a 3-Methylindene-D-Ala-P2-Phe-Ketoepoxide 
backbone. 
 Interestingly, the compound containing Met at P2 (65F) was found to be more 
potent inhibitor of β5i/LMP7 as compared to the carbon analog Nle at P2 (65E) 
suggesting a role for the sulfur heteroatom in β5i/LMP7 inhibition. Additionally, the 
compound containing the D-Lys(Z) side chain (65I) was found to be nearly inactive 
against the β5i/LMP7-subunit, clearly indicating the importance of L-amino acid 
stereochemistry at the P2 position. In addition to monitoring the β5i inhibitory potency of 
these P2-derivative compounds, we also assessed these compounds for inhibition of the 
β5/X-subunit by using the selective substrate Ac-WLA-AMC. Compounds containing 
small hydrophobic residue such as Gly, Ala and Abu at P2 position were found to be 
much more potent inhibitors of the β5/X-subunit as compared to Nle, Ile and Met P2 
derivatives. Interestingly the inhibitor containing Phe at the P2 position was a potent 
β5/X inhibitor whereas the analog containing Trp at this position had minimal activity at 
this subunit. This suggests that the size or properties of the tryptophan bicycle somehow 
influence selectivity for β5i/LMP7 over β5/X.  
 Taken together, these initial assays utilizing selective fluorogenic substrates 
and a series of P2 analogs suggest that amino acids with an aromatic residue at the 
P2 position are more suitable for the development of highly selective β5i/LMP7 
inhibitor.  
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Figure 4.5 Inhibition of β5i/LMP7- and β5/X-specific fluorogenic substrate 
hydrolysis by treatment with 0.3 and 1.0 ?M of P2-series analogs respectively. (This 
assay was performed by Zachary C. Miller of Kyung-Bo’s group) 
4.3.2. P3 modification 
The known β5i/LMP7-selective ketoepoxide inhibitor IPSI (Parlati et al. 2010) contains a 
small methyl chain at its P3 position. Another known β5i/LMP7-selective inhibitor, PR-
957, has similarities with IPSI and also contains a methyl side chain at its P3 position. 
Specifically, PR-957 contains L-Ala while both IPSI and LKS01-B650 contain D-Ala at 
their P3 positions. To investigate the impact of P3 position stereochemistry on 
proteasome inhibition, we synthesized inhibitors containing stereoisomers of the 
hydrophobic amino acids alanine, 2-aminobutyric acid (Abu), and norleucine (Nle) at P3 
position with backbone of 3-Methylindene-P3-Nle-Phe-Ketoepoxide (Figure 4.6). An 
analog containing D-Phenylalanine was also synthesized to investigate the size of the P3 
pockets of the β5i/LMP7 subunit as it has been reported to be quite restrictive based upon 
X-ray crystallography (Huber et. al. 2012). 
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Figure 4.6 P3 modification with a 3-Methylindene-R3-Nle-Phe-Ketoepoxide 
backbone. 
 Fluorogenic substrate hydrolysis assays using purified proteasomes treated with 
these compounds revealed that both D-Ala (65E) and D-Abu (66A) were more potent 
inhibitors of β5i/LMP7 as compared to their L-isomers. This pattern was reversed with 
the larger hydrophobic residue norleucine. The difference in potency due to 
stereochemistry appeared smallest with the Abu-containing inhibitors. We could imagine 
that the D and L stereochemistry allow our side chains to access two different portions of 
the P3 pocket which have different requirements. This could perhaps explain the lack of a 
clear structure-activity relationship (SAR) in this data set. Notably the larger and 
aromatic D-Phe analog actually showed better activity that the D-Ala compound 
suggesting that the P3 pocket of the β5i/LMP7 is sufficiently spacious to accommodate a 
benzyl group. Interestingly, a large difference in the β5/X potency of these P3- derivative 
inhibitors was observed. Importantly, L-Ala at P2 was found to be many times more 
potent inhibitor of β5/X compared with the D-isomer. This suggests that replacing the 
proteinogenic L-alanine with its D-isomer has a very large impact on selectivity. The L-
isomers of both Abu and Nle were also found to be slightly more potent inhibitors of 
β5/X as compared to D-isomers. Intriguingly, increasing the side chain’s length from that 
of Ala to that of Abu greatly increased β5/X inhibition but increasing from Abu to Nle 
decreased activity. As with β5i/LMP7, we find evidence of an unexpectedly complex 
structure activity-relationship.  
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 Collectively, the analysis of in vitro β5i/LMP7 and β5/X inhibition by P3 
derivatives suggests that small amino acid with D-isomer will be more suitable for 
the design of β5i/LMP7-slective inhibitors. 
 
 
Figure 4.7 Inhibition of β5i/LMP7- and β5/X-specific fluorogenic substrate 
hydrolysis by treatment with 0.3 and 1.0 ?M of P3-series analogs. (This assay was 
performed by Zachary C. Miller of Kyung-Bo’s group) 
4.3.3. P1 and N-cap modification 
Next, we investigated the effect of amino acid choice at the P1 position utilizing a 
backbone of 3-Methylindene-D-Ala-Lys(Z)-P1-Ketoepoxide. Previous studies have 
indicated that both the β5i/LMP7 and β5/X subunits prefer to bind peptides with large 
hydrophobic amino acids in their P1 positions. A derivative with a homophenylalanine 
(hPhe) group in its P1 side chain (67A) was synthesized as a slightly larger analog of the 
existing Phe-containing compound (20) to see what influence a slight increase in size 
would have on activity. The branched amino acid side chain leucine has been reported as 
being a preferred substrate for both β5/X and β1i/LMP2 but may also be suitable for 
binding to β5i/LMP7 (Huber et al. 2012). In addition the presence of OTBDMS ether at 
the C1 carbon has been reported to decrease β5/X-binding by steric hindrance (Beilei et 
al. 2010). For this reason we synthesized compounds containing leucine (67B) and 
leucine with the OTBMDS ether at the P1 position (67C). 
75.6% 
1.4% 
68.3% 
8.5% 
1.3% 0.3% 
35.8% 
15.0% 
3.2% 
16.1% 
7.3% 
40.2% 
4.6% 4.7% 
0%
20%
40%
60%
80%
100%
D-Ala D-Abu D-Nle D-Phe L-Ala L-Abu L-Nle
Pe
rc
en
t A
ct
iv
ity
 R
em
ai
ni
ng
 
X
LMP7
 
104 
 
Figure 4.8  P1 modification with a 3-Methylindene-D-Ala-Lys(Z)-R1-Ketoepoxide 
backbone 
 As shown in Figure 4.9, compound 67B containing  the amino acid Leu at P1 
position showed less ability to inhibit substrate hydrolysis by the β5i/LMP7 as compared 
to the Phe-P1 derivative (20). Additionally, Leu-P1 (67B) showed higher potency to 
inhibit β5/X activity; which is consistent with the previous crystallographic studies 
(Huber et al. 2012). The TBDMS-containing compound (67C) had weaker activity 
against both β5/X and β5i/LMP7 suggesting that binding to both β5/X and its homologue 
β5i/LMP7 is impeded by the bulky silyl ether. Interestingly, Homo-Phe at the P1 position 
(compound 67A) afforded very weak inhibition of both β5i/LMP7 and β5/X activity, 
suggesting that S1 pocket of both of these subunits is too small to accommodate homo-
Phe.  
 Together, the above results further suggest that a P1 Phe group confers 
β5i/LMP7-specificity to peptide-based ketoepoxide inhibitors. 
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Figure 4.9  Inhibition of β5/X and β5i/LMP7 by 1.0 and 0.3 ?M of P1- and N-Cap-
Modified Compounds. (This assay was performed by Zachary C. Miller of Kyung-Bo’s 
group)
 
Figure 4.10  N-cap modification with N-Cap-D-Ala-Trp-Phe-Ketoepoxide Backbone. 
 Three compounds with N-terminal modifications from the 3-methylindene-
containing inhibitor IPSI (19) were synthesized (Figure 4.10). Notably, the 
carbobenzyloxy-containing compound 68C inhibited β5i/LMP7 with a potency similar to 
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that of the parent compound (Figure 4.9) Despite this, β5/X activity was increased by a 
large factor. This result seems suspect because of the similarity of these two compounds 
but perhaps the protruding methyl side chain of 3-methylindene provides steric 
hinderance in a key location needed to block binding to β5/X. Alternatively it is possible 
that the additional oxygen heteroatom found in compound 68C interacts favorable with a 
residue lining the β5/X pocket. Additional analogs of these two seemingly similar 
compounds should be made to explore the determinants for selectivity in the N-cap. Two 
heterocycle-containing N-cap compounds were also made, one containing the 5-methyl-
3-isoxazole group which has been successfully incorporated into several proteasome 
inhibitors designed at Proteolix, Inc. (Huber  et al. 2012), and the pyrazinoic acid group 
found in the potent β5/X and β5i/LMP7 inhibitor bortezomib (add a reference). 
Interestingly, both heterocyclic N-cap compounds (68A and 68B) demonstrated poor 
β5i/LMP7 activity as well as poor selectivity. Again, further compounds are additional 
tests are needed to understand the N-terminal structural requirements for potent and 
selective β5i/LMP7 inhibition. 
4.4. Summary 
Recent studies have indicated the therapeutic potential of β5i/LMP7-subunit of 
immunoproteasome as a drug target in the treatment of autoimmune diseases. In our 
efforts to develop a more selective inhibitor of β5i/LMP7-subunit, we have developed a 
small library of compounds based on combinatorial positional scanning approach. The 
synthesized proteasome inhibitors were characterized for their potency and specificity by 
fluorogenic substrate hydrolysis assays. Although in some cases a clear structure-activity 
relationship was not forthcoming, enzyme inhibition assays have shed light on some of 
the factors needed for to generate a selective inhibitor of the β5i/LMP7 subunit. 
Specifically, we have identified the following structural requirements: 
? P1 position: Phe or a smaller aromatic residues (no extended phenylalanine 
analogs) 
? P2 position: A larger, aromatic ring-containing residue 
? P3 position: small D-amino acid  
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4.5. Supporting Info 
4.5.1. Kinetic assay protocol 
The hydrolysis of the X, LMP7, and LMP2-specific substrates Ac-WLA-AMC, Ac-
ANW-AMC, and Ac-PAL-AMC respectively, was measured at room temperature in the 
presence of 0.5 ug/mL purified 20S human constitutive or immunoproteasome. 
Experiments were carried out in 96-well polystyrene microplates with a 100 uL reaction 
volume containing 20 mM Tris-HCl, 0.5 mM EDTA, 0.035% w/v SDS, and ≤3% v/v 
DMSO. Substrates were present at 20 ?M for Ac-WLA-AMC and 100 ?M each for Ac-
ANW-AMC and Ac-PAL-AMC. 20S proteasomes were exposed to various 
concentrations of inhibitors for sixty minutes before the addition of substrate. After 
substrate addition, the fluorescence of the liberated AMC was measured using an 
excitation wavelength of 360 nm and an emission wavelength of 460 nm. Each well was 
read once per minute over a 90 minute time period. A linear regression was then 
performed to quantify the rate of substrate hydrolysis. These rates were normalized to 
positive control wells to obtain “percent activity remaining” values which represent the 
percentage of proteasome active sites not inhibited by 60 minute exposure to an 
irreversible inhibitor.  
4.5.2. General Procedure, Synthetic Scheme and Characterization data 
All the reactions are performed as mentioned in chapter 2, supporting information. After 
purification, all the compounds are characterized using 1H NMR, 13C NMR and mass 
analysis. 
The general synthetic scheme used to synthesize the compounds reported in chapter 4 is 
following: 
 
The tripeptide A is prepared by HBTU/HOBt mediated peptide coupling as reported in 
chapter 2, supporting information. Synthesis of epoxyketone B is also reported in chapter 
2, supporting information. 
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Characterization Data (1H NMR, 13C NMR and mass analysis): 
 
1H NMR (400 MHz, CDCl3): δ 7.40 (m, 2H), 7.32 (m, 2H), 7.22 (m, 3H), 7.13 (m, 3H), 
6.96 (t, J= 7.2 Hz, 1H), 6.51 (d, J= 8.5 Hz, 1H), 4.77 (m, 1H), 4.57 (m, 1H), 3.85 (d, J= 
7.0 Hz, 1H), 3.57 (m, 3H), 3.25 (d, J= 6.5 Hz, 1H), 3.08 (dd, J= 13.5, 5.5 Hz, 1H), 2.80 
(m, 2H), 2.49 (s, 3H), 1.43 (d, J= 7.2 Hz, 3H),  1.41 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ 208.0, 173.4, 169.1, 166.6, 145.5, 142.3, 136.0, 131.3, 
131.2, 129.5, 128.7, 127.6, 127.3, 126.9, 124.0, 121.1, 59.5, 53.4, 52.7, 49.4, 38.3, 37.0, 
21.3, 18.2, 16.7, 12.6. 
Mass analysis (MALDI): M++Na = 512.2 (observed), 512.23 (calculated); M+K = 
528.2 (observed), 528.23 (calculated). 
 
1H NMR (400 MHz, CDCl3): δ 7.45 (m, 2H), 7.34 (m, 2H), 7.24 (m, 3H), 7.16 (m, 
4H), 6.81 (d, J= 9.5 Hz, 1H), 4.78 (m, 1H), 4.60 (m, 1H), 3.56 (d, J= 3 Hz, 1H), 3.49 
(dd, J= 7.5, 4.0 Hz, 1H), 3.32 (dd, J= 10.5, 6.0 Hz, 1H), 3.14 (m, 1H), 2.90 (m, 1H), 
2.76 (m, 2H), 2.51 (t, J= 3.0 Hz, 3H), 1.50 (d, J= 10.0 Hz, 3H), 1.36 (d, J= 8.5 Hz, 
1H), 1.27 (d, J= 9.0 Hz, 3H), 1.22 (m, 2H). 
13C NMR (100 MHz, CDCl3): δ 207.6, 172.5, 166.0, 148.5, 148.2, 145.7, 142.3, 
135.9, 131.6, 131.4, 129.6, 129.5, 128.7, 127.3, 124.1, 121.1, 59.5, 53.1, 52.9, 48.5, 
48.3, 38.5, 38.3, 18.4, 18.1, 16.8, 12.6. 
Mass analysis (MALDI): M++Na=526.24 (observed), 526.24 (calculated). 
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1H NMR (400 MHz, CDCl3): δ 7.47 (m, 2H), 7.35 (m, 2H), 7.22 (m, 3H), 7.13 (m, 
2H), 6.99 (d, J= 8.0 Hz, 1H), 6.97 (d, J= 7.2 Hz, 1H), 6.56 (d, J= 7.2 Hz, 1H), 4.78 
(m, 1H), 4.63 (m, 1H), 4.32 (m, 1H), 3.70 (m, 1H), 3.63 (m, 1H), 3.28 (d, J= 5.2 Hz, 
1H), 3.13 (m, 1H), 3.06 (dd, J= 14, 4.8 Hz, 1H), 2.87 (m, 1H), 2.78 (m, 1H), 2.53 (t, 
J= 1.8 Hz, 3H),  1.81 (m, 1H), 1.56 (m, 1H), 1.47 (m, 8H). 
13C NMR (100 MHz, CDCl3): δ 207.7, 172.8, 171.5, 166.4, 148.4, 145.6, 142.4, 
136.2, 131.6, 129.5, 128.6, 127.6, 127.2, 126.9, 124.0, 121.0, 59.4, 54.6, 52.9,  49.2, 
43.4, 38.4, 37.2, 25.4, 18.8, 17.4, 16.6, 12.7. 
Mass analysis (MALDI): M++Na = 540.3 (observed), 540.26 (calculated); M+K = 
556.3 (observed), 556.26 (calculated). 
 
30% racemization was observed during the final reaction. 
1H NMR (400 MHz, CDCl3): δ 7.47 (m, 2H), 7.36 (m, 2H), 7.29 (m, 2H), 7.21 (m, 
3H), 6.93 (d, J= 8.5 Hz, 1H), 6.72 (d, J= 7.5 Hz, 1H), 6.42 (d, J= 7.0 Hz, 1H), 4.80 
(m, 1H), 4.63 (m, 1H), 4.39 (dd, J= 8.5, 4.5 Hz, 1H), 3.61 (s, 2H),  3.36 (d, J= 5.0 Hz, 
1H), 3.16 (dd, J= 14, 5 Hz, 1H), 2.88 (d, J= 5Hz, 1H), 2.76 (dd, J=10.5, 3.5 Hz, 1H), 
2.54 (t, J= 3 Hz, 3H), 1.84 (m, 1H), 1.45 (s, 3H), 0.83 (t, J= 6.5, 3H), 0.71 (d, J= 7 
Hz, 3H). 
13C NMR (100 MHz, CDCl3): δ 207.8, 172.6, 171.3, 166.5, 148.8, 145.7, 142.4, 
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136.1, 131.7, 129.5, 128.8, 127.7, 127.3, 127.1, 124.0, 121.0, 59.5, 58.0, 56.7, 53.2, 
52.6, 49.2, 38.8, 37.1, 26.4, 18.3, 16.8, 15.6, 12.6 11.8. 
Mass analysis (MALDI): M++Na = 568.03 (observed), 568.29 (calculated); M+K = 
584.3 (observed), 584.29 (calculated). 
 
1H NMR (400 MHz, CDCl3): δ 7.47 (m, 2H), 7.36 (m, 2H), 7.20 (m, 2H), 7.12 (m, 
3H), 6.70 (d, J= 7.5 Hz, 1H), 6.61 (d, J= 7.6 Hz, 1H), 6.34 (d, J= 6.8 Hz, 1H), 4.77 
(m, 1H), 4.58 (m, 1H), 4.32 (m, 1H), 3.64 (m, 2H), 3.28 (d, J=5.2 Hz, 1H), 3.05 (dd, 
J= 14.0, 4.8 Hz, 1H), 2.85 (s, 2H), 2.54 (t, J= 2.8 Hz, 3H), 1.71 (m, 2H), 1.44 (d, J= 
6.8 Hz, 3H), 1.40 (s, 3H), 1.25 (m, 7H). 
13C NMR (100 MHz, CDCl3): δ 207.6, 172.5, 171.5, 166.5, 148.6, 145.7, 142.4, 136.0, 
131.5, 129.5, 128.6, 127.6, 127.2, 127.0, 124.0, 121.1, 59.4, 53.5, 52.8, 52.6, 49.1, 38.4, 
37.3, 31.7, 27.6, 22.5, 18.1, 16.7, 14.1, 12.6. 
Mass analysis (MALDI): M++Na = 568.03 (observed), 568.29 (calculated); M+K = 
584.3 (observed), 584.29 (calculated). 
 
1H NMR (400 MHz, CDCl3): δ 7.44 (m, 2H), 7.34 (m, 3H), 7.21 (m, 2H), 7.15 (m, 
3H), 7.07 (d, J= 7.5 Hz, 1H), 6.56 (d, J= 7.0 Hz, 1H), 4.74 (m, 1H), 4.59 (m, 2H), 
3.60 (m, 2H), 3.29 (d, J=4.5, 1H), 3.07 (dd, J= 14.0, 4.5 Hz, 1H), 2.85 (d, J= 4.5 Hz, 
1H), 2.72 (dd, J= 13.5, 8.5 Hz, 1H), 2.50 (m, 5H), 2.04 (s, 3H), 1.94 (m, 2H), 1.43 (d, 
J= 7.0 Hz, 3H), 1.41 (s, 3H).  
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13C NMR (100 MHz, CDCl3): δ 207.7, 173.0, 171.2, 166.4, 148.6, 145.6, 142.4, 
135.9, 131.5, 129.4, 128.7, 127.6, 127.2, 126.9, 124.0, 121.0, 59.5, 53.4, 52.7, 52.3, 
49.2, 38.8, 38.8, 36.9, 30.9, 30.1, 18.4, 16.6, 12.5.  
Mass analysis (MALDI): M++Na=586.2 (observed), 568.25 (calculated); M+K= 
602.2 (observed), 602.25 (calculated). 
 
1H NMR (400 MHz, CDCl3): δ 7.43 (m, 2H), 7.♥32 (m, 3H), 7.19 (m, 2H), 7.12 (m, 
3H), 6.98 (d, J= 7.6 Hz, 1H), 6.85 (d, J= 7.2 Hz, 1H), 6.47 (d, J= 7.5 Hz, 1H), 4.72 
(m, 2H), 4.56 (m, 1H), 4.31 (m, 1H), 3.68 (m, 1H), 3.62 (m, 1H), 3.28 (d, J= 5.5 Hz, 
1H), 3.13 (m, 1H), 3.04 (m, 3H), 2.83 (d, J= 6 Hz, 1H), 2.72 (m, 1H), 2.50 (t, J=2 Hz, 
3H), 1.72 (m, 1H), 1.58 (m, 1H), 1.417 (m, 14H), 1.37 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ 207.8, 172.9, 171.6, 166.5, 156.4, 145.6, 142.4, 
136.2, 131.6, 129.5, 128.8, 128.6 ,127.6, 127.2, 126.9, 124.0, 121.0, 79.4, 59.5, 55.7, 
53.2, 52.7, 49.3, 43.7, 40.0, 38.8, 38.4, 36.9, 31.4, 29.6, 28.6, 22.4, 18.2, 16.6, 12.7.  
Mass analysis (MALDI): M++Na = 683.4 (observed), 683.35 (calculated); M+K = 
699.4 (observed), 699.35 (calculated). 
 
1H NMR (500 MHz, acetone-d6): δ 7.08 (d, J = 7.5Hz, 1H), 7.60 (d, J = 8.5 Hz, 1H), 
7.49 (m, 2H), 7.36-7.28 (m, 5H), 7.235 (m, 3H), 7.20 (m, 3H), 7.14 (m, 2H), 4.72 (m, 
1H), 4.67 (m, 1H), 4.44 (m, 1H), 3.67 (s, 2H), 3.35 (d, J = 5.5 Hz, 1H), 3.20 (dd, J= 
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14.0, 4.5 Hz, 1H), 3.06 (dd, J= 14.0, 4.0 Hz, 1H), 2.94 (d, J=5.5 Hz, 1H), 2.80 (m, 
2H), 2.47 (t, J= 3.0 Hz, 3H), 1.39 (s, 3H), 1.30 (d, J= 6.5 Hz, 3H).  
13C NMR (125 MHz, acetone-d6): δ 208.1, 173.4, 172.1, 166.7, 147.5, 146.6, 143.5, 
138.7, 138.4, 133.6, 130.3, 130.2, 130.2, 129.2, 129.0, 128.9, 127.8, 127.5, 127.5, 
127.2, 124.7, 121.4, 59.9, 54.7, 52.7, 50.5, 39.0, 38.8, 38.0, 36.9, 18.0, 16.8, 12.5.  
Mass analysis (MALDI): M++Na = 602.3 (observed), 602.3 (calculated); M+K = 
618.3 (observed), 618.27 (calculated). 
 
1H NMR (400 MHz, CDCl3): δ 7.38 (m, 2H), 7.33 (m, 2H), 7.20 (m, 3H), 7.15 (m, 
2H), 6.76 (d, J= 7.6 Hz, 1H), 6.54 (d, J= 7.2 Hz, 1H), 6.32 (d, J= 7.6 Hz, 1H), 4.81 
(m, 1H), 4.57 (m, 1H), 4.27 (m, 1H), 3.71 (m, 2H), 3.31 (d, J= 4.8 Hz, 1H), 3.16 (m, 
2H), 2.90 (d, J= 5.2 Hz, 1H), 2.53 (t, J = 2.4, 3H), 1.48 (d, J = 6.0 Hz, 3H), 1.45 (m, 
5H), 1.26 (m, 4H), 0.78 (t, J = 7.2 Hz, 3H). 
13C NMR (100 MHz, CDCl3): δ 207.6, 172.7, 171.5, 166.3, 148.7, 145.6, 142.3, 
135.8, 131.3, 129.5, 128.8, 127.7, 127.4, 127.1, 124.1, 121.1, 59.5, 53.6, 48.9, 43.9, 
38.8, 37.3, 31.7, 27.6, 22.5, 18.8, 18.1, 16.7, 13.9, 12.7. 
Mass analysis (MALDI): M++Na = 644 (observed), 568.29 (calculated); M+K = 660 
(observed), 584.29 (calculated). 
 
1H NMR (400 MHz, CDCl3): δ 7.46 (m, 2H), 7.35 (m, 2H), 7.19 (m, 2H), 7.13 (m, 
3H), 6.88 (d, J= 8.5 Hz, 1H), 6.85 (d, J= 8..5 Hz, 1H), 6.54 (d, J= 7.5 Hz, 1H), 4.77 
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(m, 1H), 4.53 (m, 1H), 4.40 (m, 1H), 3.64 (m, 2H), 3.29 (d, J= 5.0 Hz, 1H), 3.05 (dd, 
J= 14.0, 4.5 Hz, 1H), 2.84 (d, J= 5.0 Hz, 1H),  2.73 (dd, J= 13.0, 8.5 Hz, 1H),  2.54 (t, 
J=2.0 Hz, 3H), 1.97 (m, 1H), 1.75 (m, 2H), 1.52 (m, 1H), 1.38 (s, 3H), 1.24 (m, 4H), 
0.96 (t, J= 7.0 Hz, 3H), 0.85 (t, J=7.0 Hz, 3H). 
13C NMR (100 MHz, CDCl3): δ 207.6, 171.9, 171.5, 166.6, 148.2, 145.7, 142.4, 
136.0, 131.8, 129.5, 128.6, 127.5, 127.2, 126.9, 124.0, 121.0, 59.5, 54.8, 53.4, 52.9, 
52.6, 38.5, 37.2, 31.8, 27.6, 25.6, 22.6, 16.6, 14.0, 12.1, 10.2. 
Mass analysis (MALDI): M+Na = 582.3 (observed), 582.30 (calculated); M+K = 
598.3 (observed), 598.30 (calculated). 
 
1H NMR (400 MHz, CDCl3): δ 7.46 (t, J= 6.0 Hz, 2H), 7.35 (m, 2H), 7.22 (m, 3H), 
7.15 (d, J = 7.5 Hz, 2H), 6.75 (d, J = 7.5 Hz, 1H), 6.61 (d, J = 7.5 Hz, 1H), 6.38 (d, J 
= 7.5 Hz, 1H), 4.84 (m, 1H), 4.50 (m, 1H), 4.34 (m, 1H), 3.62 (s, 2H), 3.30 (d, J = 5.0 
Hz, 1H), 3.13 (dd, J = 9.0, 5.5 Hz, 1H), 2.90 (d, J = 4.5 Hz, 1H),  2.81 (dd, J = 14.0, 
8.0 Hz, 1H),  2.53 (t, J = 2.0 Hz, 3H), 1.90 (m, 1H), 1.73 (m, 2H), 1.54 (m, 1H), 1.48 
(s, 3H), 1.2 (m, 4H), 0.91 (t, J = 7.5 Hz, 3H), 0.85 (t, J = 7.5 Hz, 3H). 
13C NMR (100 MHz, CDCl3): δ 207.6, 172.0, 171.5, 166.4, 148.2, 145.7, 142.3, 
135.8, 131.7, 129.5, 128.8, 127.5, 127.3, 127.0, 124.0, 121.0, 59.4, 54.4, 53.5, 52.7, 
52.7, 38.5, 37.3, 31.9, 27.6, 25.7, 22.5, 16.7, 14.0, 12.5, 10.2. 
Mass analysis (MALDI): M+Na=582.3 (observed), 582.30 (calculated); M+K=598.3 
(observed), 598.30 (calculated). 
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1H NMR (400 MHz, CDCl3): δ 7.47 (m, 2H), 7.36 (m, 2H), 7.20 (m, 3H), 7.13 (m, 
2H), 6.67 (d, J = 7.6 Hz, 1H), 6.58 (d, J = 8.0 Hz, 1H), 6.32 (d, J = 7.6 Hz, 1H), 4.77 
(m, 1H), 4.46 (m, 1H), 4.35 (m, 1H), 3.64 (m, 2H), 3.28 (t, J = 2.8 Hz, 1H), 3.05 (dd, 
J = 13.6, 5.2 Hz, 1H), 2.85 (d, J = 4.8 Hz, 1H),  2.73 (dd, J = 13.6, 8.0 Hz, 1H),  2.54 
(t, J = 2.0 Hz, 3H), 1.94 (m, 1H), 1.73 (m, 2H), 1.47 (m, 1H), 1.38 (s, 3H), 1.30 (m, 
2H), 1.25 (m, 6H), 0.90 (m, 3H), 0.85 (t, J = 7.5 Hz, 3H). 
13C NMR (100 MHz, CDCl3): δ 207.6, 172.0, 171.5, 166.4, 148.2, 145.7, 142.3, 
135.7, 131.7, 129.5, 128.8, 127.5, 127.3, 127.0, 124.0, 121.0, 59.4, 53.7, 53.5, 52.9, 
52.6, 38.5, 37.2, 31.9, 31.7, 27.9, 27.6, 22.7, 22.5, 16.6, 14.1, 14.1, 12.6.  
Mass analysis (MALDI): M+Na = 610.3 (observed), 610.34 (calculated); M+K = 
626.3 (observed), 626.34 (calculated). 
 
 
 
1H NMR (400 MHz, CDCl3): δ 7.47 (m, 2H), 7.34 (m, 2H), 7.22 (m, 3H), 7.14 (m, 
2H), 6.76 (d, J = 7.0 Hz, 1H), 6.72 (d, J = 8.0 Hz, 1H), 6.41 (d, J = 7.5 Hz, 1H), 4.78 
(m, 1H), 4.51 (m, 1H), 4.36 (m, 1H), 3.66 (m, 2H), 3.29 (t, J = 4.5 Hz, 1H), 3.05 (dd, 
J = 14, 4.5 Hz, 1H), 2.84 (d, J = 5.0 Hz, 1H),  2.75 (dd, J = 14, 8.5 Hz, 1H),  2.54 (t, J 
= 2.0 Hz, 3H), 1.95 (m, 1H), 1.73 (m, 2H), 1.53 (m, 1H), 1.38 (s, 3H), 1.33 (m, 2H), 
1.26 (m, 6H), 0.89 (m, 3H), 0.85 (t, J = 7.5 Hz, 3H). 
13C NMR (100 MHz, CDCl3): δ 207.6, 172.1, 171.5, 166.6, 148.3, 145.7, 142.4, 
136.1, 131.7, 129.5, 128.6, 127.6, 127.2, 126.9, 124.0, 121.0, 59.4, 53.7, 53.4, 52.9, 
52.6, 38.5, 37.2, 32.0, 31.8, 27.9, 27.6, 22.7, 22.5, 16.6, 14.1, 14.0, 12.5. 
Mass analysis (MALDI): M+Na = 610.3 (observed), 610.34 (calculated); M+K = 
626.3 (observed), 626.34 (calculated). 
 
 
115 
 
1H NMR (400 MHz, CDCl3): δ 7.41 (m, 1H), 7.36-7.14 (m, 10H), 7.11 (m, 3H), 6.76 
(d, J = 7.5 Hz, 1H), 6.52 (d, J = 7.6 Hz, 1H), 4.75 (m, 2H), 4.24 (m, 1H), 3.56 (m, 
2H), 3.26 (d, J = 5.2 Hz, 1H), 3.12 (d, J = 7.6 Hz, 2H), 3.01 (dd, J = 14.0, 4.8 Hz, 
1H), 2.82 (d, J = 4.8 Hz, 1H), 2.74 (m, 1H), 2.46 (s, 3H), 2.09 (t, J = 12.4 Hz, 3H), 
1.36 (s, 3H), 1.16 (m, 2H), 0.95 (m, 2H), 0.79 (t, J = 7.2 Hz, 3H). 
13C NMR (100 MHz, CDCl3): δ 172.9, 165.5, 147.4, 145.8, 142.3, 132.1, 127.3, 
126.8, 123.9, 123.9, 120.9, 120.8, 82.3, 65.2, 54.5, 48.7, 48.7, 38.5, 38.3, 28.2, 19.2, 
19.1, 17.8, 17.4, 12.4, 12.3. 
Mass analysis (MALDI): M++Na = 644 (observed), 644.32 (calculated); M+K = 660 
(observed), 660.32 (calculated). 
 
1H NMR (400 MHz, CDCl3): δ 7.41 (m, 3H), 7.32 (m, 6H), 7.18 (m, 3H), 7.10 (m, 
4H), 6.92 (d, J = 7.6 Hz, 1H), 6.45 (d, J = 6.8 Hz, 1H), 5.14 (m, 1H), 5.07 (m, 3H), 
4.63 (m, 1H), 4.51 (m, 1H), 4.41 (m, 1H), 3.49 (m, 2H), 3.20 (m, 3H), 2.64 (m, 1H), 
2.55 (m, 1H), 2.46 (t, J = 2.4 Hz, 3H), 2.06 (m, 1H), 1.88 (m, 1H), 1.70 (m, 1H), 1.52 
(d, J = 6.4, 1H), 1.47 (m, 4H), 1.42 (m, 1H), 1.38 (m, 4H). 
13C NMR (100 MHz, CDCl3): δ 208.1, 173.2, 171.8, 166.5, 156.9, 145.6, 142.4, 
140.7, 136.7, 131.4, 128.6, 128.6, 128.3, 127.6, 126.9, 126.4, 124.0, 121.0, 99.7, 66.8, 
59.4, 53.2, 52.4, 49.3, 40.4, 38.8, 38.3, 32.6, 31.3, 29.3, 22.4, 18.4, 17.6, 16.7, 12.6.  
Mass analysis (MALDI): M++Na = 731 (observed), 731.35 (calculated); M+K = 747 
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(observed), 747.35 (calculated). 
 
1H NMR (400 MHz, CDCl3): δ 7.41 (m, 2H), 7.33-7.29 (m, 8H), 7.19 (d, J = 8.0 Hz, 
1H),  6.80 (d, J = 7.6 Hz, 1H), 6.59 (d, J = 7.2 Hz, 1H), 5.20 (m, 1H), 5.05 (s, 2H), 
4.64 (m, 1H), 4.47 (m, 2H), 3.60 (m, 2H), 3.25 (d, J = 5.2 Hz, 1H), 3.15 (m, 2H), 2.48 
(t, J = 2.0 Hz, 3H), 1.82 (m, 1H), 1.62 (m, 3H), 1.46 (m, 1H), 1.44 (m, 4H), 1.39 (m, 
4H), 1.34 (m, 1H), 1.24 (m, 1H), 0.84 (t, J = 6.4Hz, 6H). 
13C NMR (100 MHz, CDCl3): δ 208.7, 173.0, 171.9, 166.3, 156.9, 148.4, 145.6, 
142.4, 136.7, 131.4, 128.7, 128.3, 127.5, 126.9, 124.0, 121.0, 66.8, 59.4, 53.0,  50.8, 
49.2, 40.4, 39.6, 38.4, 31.6, 29.3, 25.4, 23.4, 22.3, 21.3, 21.3, 18.6, 16.8, 12.5.  
Mass analysis (MALDI): M++Na = 683 (observed), 683.35 (calculated); M+K = 699 
(observed), 699.35 (calculated). 
 
Mass analysis (MALDI): M++Na = 813.4 (observed), 813.43 (calculated); M+K = 
829.4 (observed), 829.43 (calculated). 
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Mass analysis (MALDI): M++Na = 591 (observed), 591.24 (calculated); M+K = 607 
(observed), 607.24 (calculated). 
 
Mass analysis (MALDI): M++Na = 619 (observed), 619.29 (calculated); M+K = 635 
(observed), 635.29 (calculated). 
 
Mass analysis (MALDI): M++Na = 594 (observed), 594.23 (calculated); M+K = 610 
(observed), 610.24 (calculated). 
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4.5.3. Copies of Mass Spectra 
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Chapter 5: A Concise Synthetic Approach to 1-Azaspirocyclic Compounds† 
5.1. Overview of the Study 
In drug-discovery research, structural modification is an important tool that facilitates the 
understanding and enhancement of the specific biological activity of small molecules. 
The development of a concise and flexible synthetic route is a fundamental prerequisite 
for said structural modification. The study in this chapter focuses on the development of a 
concise approach towards the synthesis of 1-azaspirocyclic ring systems. These structural 
motifs have captivated the synthetic community for many years, as a result of their 
presence as structural subunits in biologically active and structurally diverse natural 
products. We have developed a new and step-economical approach to 1-azaspirocyclic 
ring system formation via an efficient tandem semi-pinacol/Beckmann rearrangement. 
The reaction constructs a tertiary carbon center adjacent to the nitrogen functionality and 
a spirocyclic ring system in a single synthetic operation. During this endeavour, an 
environmentally benign, microwave-assisted, and solvent-free self-condensation of 
carbonyl compounds has also been developed. 
5.2. Introduction 
 
5.2.1. 1-Azaspirocyclic Ring System in Natural Products 
 
Figure 5.1  1-Azaspirocyclic Ring Systems 
 1-azaspirocyclic systems comprise two rings fused in spiro fashion that contain a 
nitrogen atom adjacent to ring the junction. 1-azaspiro[4.4]-nonane (69), 1-
azaspiro[4.5]decane (70), and 6-azaspiro[4.5]decane (71) ring systems are some 
____________________ 
† The studies reported in this chapter are started under the supervision of Dr. Gregory I. 
Elliott.   
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representative examples of 1-azaspirocyclic  systems  (Figure 1). The 1-azaspirobicyclic 
core has been observed in a variety of alkaloid natural products. Notable examples 
include (–)-histrionicotoxin (72), lepadiformine (73), halichlorine (74), pinnaic acid (75), 
tauropinnanic acid (76) as well as many others (Figure 5.2). 
 
 
Figure 5.2  Alkaloids that contain 1-azaspirocycle motifs 
 The histrionicotoxins are a group of alkaloids isolated from the skin extracts of 
the Colombian “poison dart” frog Dendrobates histrionicus (Daly et al. 1971). They 
differ primarily in the degree and nature of unsaturation in the side chains. (–)-
histrionicotoxin (72a) and its hydrogenated derivative perhistrionicotoxin (72b) were 
originally isolated by Witkop and co-workers in 1971. They were among the first 
alkaloids shown to act as noncompetitive inhibitors of neuromuscular, ganglionic and 
central neuronal nicotinic acetylcholine receptors (Takahashi et al. 1982; Daly et al. 
1991). These types of biological activity of this type give these compounds antiarrythmic 
properties. Histrionicotoxin and perhistrionicotoxin are both useful biochemical tools for 
probing the mechanism of transynaptic transmission of neuromuscular impulses. The 
parent compound’s low abundance in nature (>200 μg/frog), interesting biological 
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activity and unique spiropiperidine structure make histrionicotoxins attractive synthetic 
targets. 
                     In 1994, Lepadiformine (73) was isolated from Clavelina lepadiformis and 
exhibits moderate in vitro cytotoxicity against nasopharynx carcinoma (KB) and non-
small-cell lung carcinoma (NCSLC-N6) (Biard et al. 1994). When the alkaloid was tested 
in rats, it caused induction of bradycardia, prolongation of ECG parameters and a 
transient fall in blood pressure (Juge et al. 2001).  
 Halichlorine (74), a marine alkaloid isolated from the marine sponge 
Halichondria okadai Kadota by Uemura and co-workers in 1996 (Kuramoto et al. 1996),  
has been shown to inhibit the expression of vascular cell adhesion molecule-1 (VCAM-1) 
with an IC50 of 7μg/ml. VCAM-1 is a peptide involved in the recruitment and trafficking 
of leukocytes to site of tissue trauma (Chou et al. 1996), making it a potential target for 
the treatments of a wide variety of diseases believed to arise from extreme inflammatory 
and autoimmune responses such as atherosclerosis, rheumatoid arthritis, organ transplant 
rejection and a wide number of autoimmune conditions. 
 Later, the structurally similar compounds pinnaic acid (75) and tauropinnanic acid 
(76), which were isolated from the Okinawan bivalve Pinna muricata, were shown to 
exhibit inhibitory activity against cPLA2 (cytosolic phospholipase A2) (Chou et al. 
1996), This enzyme cleaves arachidonic acid from phospholipids in the cell membrane, 
thus allowing for its conversion into prostaglandins and making these compounds of 
potential value for the treatment of inflammatory diseases. 
5.2.2. Previous approaches for the construction of 1-azaspirocyclic motifs 
In addition to the interesting biological activities of these alkaloids, their complex 
structures have attracted synthetic chemists for the development of a number of synthetic 
strategies towards the core 1-azaspirocyclic ring systems. An outstanding review by Dake 
provides a comprehensive overview of the previous approaches for the construction of 1-
azaspirocyclic ring system (Dake et al. 2006). Additionally, reviews by Weinreb and 
Sinclair provide a good read and highlights various approaches for the synthesis of 
histrinicotin and cylindricine/lepadiformine respectively (Weinreb et al. 2006; Sinclair et 
al. 2007). 
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 Most of the previous strategies have proven to be innovative and provide good 
yields, but they have also been target-molecule oriented. As Dake noted “In most cases, a 
method was developed in order to solve a specific synthetic problem, generally within the 
context of a total synthesis exercise” (Dake, G. 2006). So, in the context of my 
dissertation, I decided to briefly review only those previous azaspirocyclization 
approaches that were shown to have general applicability.  
(A) Ring Expansions 
In 2001, Dake and co-workers reported a semipinacol-based acid-mediated ring 
expansion of cyclobutanols to produce azaspirocyclic ketones (Fenster et al. 2001). 
Mechanistically, the reaction of enamines 77 with camphorsulfonic acid (CSA) produced 
the transient azacarbenium ion intermediate 78 (Scheme 5.1). Finally, ring expansion of 
the adjacent cyclobutane with carbonyl bond formation furnished azaspirocyclic ring 
systems 79a and 79b. However, the same ring expansion reaction of cyclopentanols 
derivatives was found to be unsuccessful. An alternate strategy was suggested for the ring 
expansion of cyclopentanol-derived substrates to their corresponding cyclohexanones. 
The reaction required a siloxy-epoxide derivative 81 and treatment with a lewis acid 
resulted in epoxide ring opening. The resulting transient intermediate 82 generated the 
ring expansion product 83 as single observable diastereomer.  
 
Scheme 5.1  Dake’s ring expansion approach 
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(B) Conjugated Diene-Iminium Ion Spirocyclization 
Kibayashi’s group efficiently used N-acyliminium ion-based spirocyclizations for the 
synthesis of 1-azaspiro[4.4]nonane and 1-azaspiro[4.5]decane ring systems (Abe et al. 
2005). These reactions started with the acyclic ketoamide 84 which on treatment with 
formic acid initiated the in situ generation of the cyclic N-acyliminium ion 85 (Scheme 
5.2). Subsequently, the attack of formate anion on the conjugated diene resulted in 
azaspirocyclization to form 87. This methodology was successfully used for the 
enantioselective total synthesis of the tricyclic marine alkaloids (-)-lepadiformine (73) 
and the structurally similar compounds: (+)-cyclindricine C and (-)-fasicularin. 
 
 
  
Scheme 5.2  Kibayashi’s approach via intramolecular conjugate azaspirocyclization 
(C) Dearomatization 
In 2004, Wardrop’s group expanded the concept of the electrophilic addition process 
originally developed by Glover for the synthesis of the (+)-Kishi lactum utilizing 
nitrenium ion as electrophile (Glover et al.1987; Wardrop et al. 2004). The 
spirocyclisation was achieved by using a hypervalent iodine reagent, 
phenyliodinebis(trifluoroacetate) (PIFA) to obtained a 9:1 mixture of C6 epimers 89a and 
89b (Scheme 5.3). This method was successfully adopted to generate intermediates used 
in the synthesis of the natural product fasicularin (Wardrop et al. 2004). 
 
133 
  
Scheme 5.3  Electrophilic addition to arenes (Wardrop route) 
(D) Cycloaddition 
Funk’s research group demonstrated the applicability of the cycloaddition approach for 
the synthesis of azaspirocyclic ring systems (Funk et al. 1987). The [3+2] cycloaddition 
of the exocyclic nitrone 92 and the unsaturated ester 93 resulted in the formation of the 
isoxazolidine intermediate 94 (Scheme 5.4). N-O bond cleavage by hydrogenolysis of 94 
initiated the spontaneous lactamization to yield the azaspirocyclic product 95. 
 
 
Scheme 5.4   [3+2] Cycloaddtion approach 
 
(E) Radical Cyclization 
The Ihara group reported the development of a radical cyclization approach for the 
synthesis of halichlorine 74 and pinnaic acids 75 (Takasu et al. 2003). The reaction of 96 
with tri-n-butyltin hydride and AIBN generated an aryl radical. A 1,5 hydrogen atom 
transfer generated radical 97 which cyclized in a 5-exo fashion to produce the 
azaspirocycles 98a and 98b. 
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 Scheme 5.5  The Ihara radical cyclization approach 
(F) Intramolecular Aza-Piancatelli Rearrangement 
Recently, Palmer and Alaniz demonstrated an Aza-Piancatelli rearrangement of 
furylcarbinols 99 for the construction of 1-azaspirocylic ring system (Palmer et al. 2011). 
The reaction was catalyzed by dysprosium (III) triflate to form exclusively trans 
diastereomer azaspirocyclic framework 101. 
 
 
Scheme 5.6  Aza-Piancatelli rearrangement approach 
5.3. Our Approach to Azaspirocyclic Compounds 
The preceding schemes provide clear evidences for the interest of synthetic organic 
chemists in architecturally complex 1-azaspirocyclic compounds. Structurally, the 1-
azaspirocyclic framework contains a carbocyclic ring and a heterocyclic ring joined in a 
spiro fashion. The two main synthetic problems associated with this structural motif are: 
(1) the construction of a tertiary carbon center adjacent to the nitrogen functionality and 
(2) the formation of the spirocyclic ring system. Most of the previous reported syntheses 
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first construct the tertiary center adjacent to N-atom, then during the end stages either 
close the heterocyclic ring (path a), or close the carbocyclic ring (path b) to form the core 
azaspirocyclic ring system. There have been only a few synthetic strategies reported that 
combine the generation of tertiary carbon center and spirocyclic ring formation within a 
single synthetic step (Dake, G. 2006). 
 
 
Scheme 5.7  Our approach to 1-azaspirocylic ring system 
 In developing a conceptually different and concise approach to the 1-
azaspirocyclic framework, we envisioned a new synthesis of histrionicotoxin (72a) from 
lactam 102. The amide group and carbonyl moiety in compound 102 were seen to 
provide a perfect platform for further derivatization to launch the total synthesis of 
histrionicotoxin (72a) and its perhydroderivative perhistrionicotxin (72b). The 
spirocyclic compound 102 was envisioned to obtain from rearrangements of epoxy-oxime 
103. Specifically, we intended to use a semipinacol rearrangement of the epoxide to 
explore ring expansion reaction for the formation of the spirocyclic ring system. The 
amide bond in 102 was envisioned to be synthesized from a Beckmann rearrangement of 
corresponding oxime. We planned to synthesize this required epoxy-oxime 103 from 
corresponding cyclic enone 104 (Scheme 5.7). Similarly, the 1-azaspirocyclic core of 
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other natural products, having different ring sizes, could be synthesized from the 
corresponding cyclic enones using the same series of reactions. This approach should 
provide a general method that will enable the synthesis of azaspirocyclic compounds with 
different heterocycle or carbocycle ring sizes. 
 
5.4. Results and Discussion  
Our initial task focused on the synthesis of 2-cyclopentylidene-cyclopentaone (104) from 
an aldol condensation of cyclopentanone. The aldol condensation is a classic and well-
known carbon-carbon bond forming reaction. The reaction involves the removal of an 
acidic α-hydrogen from an aldehyde or ketone to generate an enolate or enol (donor) 
which then reacts with another molecule of same aldehyde or ketone (acceptor). The 
resulting β-hydroxycarbonyl compound can then undergo dehydration to produce an α,β-
unsaturated carbonyl compound. 
 The aldol condensation of alkyl aldehydes is a very rapid process (Watanabe et al. 
2010 and references therein). However, ketones show poor reactivity as aldol acceptors 
due to steric hindrance, especially in case of cyclic and higher molecular weight ketones 
(Mestres, R. 2004). Additionally, ketones are moderate carbonacids and thus require 
strong bases like lithium diisopropylamide (LDA) and sodium hydride for their self-
condensation (Mestres, R. 2004). These strong bases require special reaction conditions 
such as aprotic solvents and complete exclusion of moisture and oxygen. Alternative 
methods reported for the self-aldol condensation of ketones require two to three 
equivalents of strong acids like hydrochloric acid and polyphosphoric acid (Nielsn, A. T. 
1968). The cationic rhodium complex [Cp*Rh(η6-C6H6)](BF4)2] (Terai et al. 2006) and 
the W(CO)6/CCl4/UV system  (Bozkurt et al. 2000) are also known to promote self-
condensation of cyclic ketones. Aldol condensation of aromatic and aliphatic ketones has 
been reported using organometallic reagents (Nakano et al. 1987; Danen et al. 1940) and 
titanium alkoxide (Yatluck et al. 2004). 
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5.4.1 A microwave assisted solvent-free self-condensation of cyclic ketones† 
In 2006, Arnold et. al. observed a very slow self-condensation of cyclopentanone while 
researching the synthesis of arylidene and alkylidene carbonyl compounds. A decent 
conversion of cyclopentanone to the self-condensed product 104 was observed over a 
period of 11 days with two molar equivalents of lithium perchlorate and catalytic amount 
of triethylamine. When we investigated the same reaction, the dilakylated product 105 
was also observed along with required monoalkylated product 104. We decided to further 
study the self-condensation of cyclic ketones using cyclopentanone as model substrate. 
As microwave irradiation is known to provide an efficient energy source to accelerate 
organic transformations, we planned to investigate self-condensation reaction using a 
Biotage microwave reactor under solvent-free conditions (Scheme 5.8). 
 
Scheme 5.8  Self-condensation of cyclopentanone 
(A) Effect of effect of LiClO4 and Et3N on the ratio of monoalkylated 104) and 
dialkylated (105) products.  
First, we decided to investigate whether Lewis acid (LiClO4) is required for the reaction 
or not. When the self-condensation of cyclopentanone was carried out in the absence of 
lithium perchlorate, even an equivalent amount of triethylamine failed to give the 
required product. To further investigate the effect of lithium perchlorate, the self-
condensation was carried out at different mol% amounts of lithium perchlorate while 
keeping the concentration of Et3N at 20 mol%. It was observed that the increase in the 
mol% of lithium perchlorate resulted into the formation of more dialkylated product 105 
(Table 5.1, Entry 1-4.).  
____________________ 
† A report of this work has been published. Portions taken in part from:  Lalit Kumar Sharma, 
Kyung Bo Kim and Gregory I. Elliott: Green Chem. 2011, 13, 1546-1549.  
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Table 5.1 Effect of LiClO4 on self-condensation of cyclopentanone 
Entry LiClO4 (mol%) Et3N (mol%) Ratio (104:105)a Yield of 104 (%)b 
1 50 20 5.4:1 68 
2 20 20 88:1 66 
3 10 20 14.3:1 56 
4 5 20 28.6:1 31 
5 0 20 - 0 
a Ratio based on the peak integration of 1H NMR (500 MHz) b Isolated yield. 
  
Next we studied the effect of triethylamine and as we expected no reaction was 
observed in the absence of triethylamine (Table 5.2, Entry 5). Next the self-
condensation was carried out at different mol% amount of triethylamine while keeping 
the concentration of lithium perchlorate at 10 mol%. Surprisingly, no effect on the yield 
or ratio of the two products was observed after addition of extra equivalent of 
triethylamine relative to lithium perchlorate (Table 5.2, Entry 1-3). 
Table 5.2 Effect of Et3N on self-condensation of cyclopentanone 
Entry Et3N (mol%) LiClO4 (mol%) Ratio (104:105)a Yield of 104 (%)b 
1 30 10 14.3:1 55 
2 20 10 14.3:1 56 
3 10 10 14.3:1 52 
4 5 10 20.0:1 30 
5 0 10 ‒ 0 
 
a Ratio based on the peak integration of 1H NMR (500 MHz) 
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b Isolated yield. 
(B) Optimization studies of self-condensation of cyclopentanone 
After closely looking at the previous data of Table 5.1 and Table 5.2, we observed that 
best yield and selectivity for 2-cyclopentylidene-cyclopentaone (104) was obtained when 
equal equivalents of lithium perchlorate and triethylamine were used. So, we further 
studied the self-condensation reaction with equal equivalents of lithium perchlorate and 
triethylamine (Table 5.3). The best yield (80%) with good selectivity was obtained using 
40 mol% of each triethylamine and lithium perchlorate (Table 5.3, Entry 5). To our 
delight, the self-condensation of cyclopentanone was also accomplished on 
100 mmol scale without any observable loss in yield or selectivity. 
Table 5.3 Optimization of self-condensation of cyclopentanone (Green Chem. 2011, 
13, 1546-1549) 
Entry Et3N (mol%) LiClO4 (mol%) Ratio (104:105)a Yield of 104 (%)b 
1 10 10 93:7 50 
2 20 20 88:12 69 
3 25 25 86:14 72 
4 30 30 86:14 77 
5 40 40 90:10 80 
6 50 50 88:12 75 
7 60 60 86:14 71 
8 70 70 85:15 75 
9 100 100 88:12 61 
 
a Ratio based on the peak integration of 1H NMR (500 MHz) 
b Isolated yield. 
*Entry 2-6 are average of two runs 
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(C) Mechanistic studies                          
For mechanistic investigation, other additives were also examined for their effect on the 
self-condensation of cyclopentanone. The reactions with lithium 
trifluoromethanesulfonate and lithium perchlorate trihydrate were found to work 
efficiently (Table 5.4, Entry 3 and 4). Interestingly, we also observed that lithium 
perchlorate, lithium perchlorate trihydrate, and lithium trifluoromethane-sulfonate are all 
soluble in cyclopentanone at 120 °C. While the other additives that were found to be 
ineffective for self-condensation reactions are insoluble in cyclopentanone at 120 °C. 
Therefore, it can be concluded that mutual solubility of the reactants is a major factor for 
the reaction to proceed. This observation was also made previously by Rothenberg et al. 
with respect to very similar reactions (Rothenberg, G. 2001). 
 The role of LiClO4 in the reaction may be realized through coordination of 
lithium ion with the carbonyl oxygen, making it more susceptible to nucleophilic attack 
by the enolate generated by triethylamine. Also, anhydrous lithium perchlorate acts as a 
dehydrating agent, thus helping in aldol dehydration. 
Table 5.4 Investigation of other additivesa (Green Chem. 2011, 13, 1546-1549) 
 
Entry Additive Ratio (104:105)b Yield of 104 (%)c 
1 LiSO4 ‒ 0 
2 LiCl ‒ 0 
3 LiCF3SO3 92:8 71 
4 LiClO4.3H2O 94:6 51 
5 NaClO4 ‒ 0 
6 KClO4 ‒ 0 
aReactions were carried out with 40 mol% of LiClO4 and 40mol% of Et3N at 120 °C. 
b Ratio based on the peak integration of 1H NMR (500 MHz). 
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c Isolated yield. 
           Next we compared the efficiency of microwave irradiation with conventional 
heating. To effectively compare these two sets of conditions, all reactions were initiated 
after reaching the designated temperature in oil-bath and were carried out in sealed 
Biotage microwave vails. When the reaction was carried out with an oil bath held at 
120±0.5 °C using 40 mol% each of LiClO4 and Et3N, only 17% of the desired cyclic 
enone 104 was obtained (Table 5.5, Entry 1). After performing the reaction for periods 
of time, yield of required compound 104 increased but selectivity for compound 104 
dropped fourfold with a threefold increase in reaction time (Table 5.5, Entry 2-4). 
Table 5.5 Reaction using conventional heating (Green Chem. 2011, 13, 1546-1549) 
Entry Time Ratio (104:105)b Yield of 104 (%)c 
1 20min 95:5 17 
2 1h 85:15 46 
3 2h 80:20 68 
4 4h 70:30 54 
aAll reactions were started after reaching the designated temperature in oil-bath and were 
carried out in sealed Biotage microwave vails with 40 mol% of LiClO4 and 40mol% of Et3N 
at 120 °C. 
b Ratio based on the peak integration of 1H NMR (500 MHz). 
c Isolated yield. 
 
(D) Substrate Scope (Green Chem. 2011, 13, 1546-1549) 
Further studies were conducted to explore the substrate scope of our microwave-assisted 
solvent-free reaction (Table 5.6). First, we attempted the solvent-free condensation of 1-
indanone 109 and 5,6-dimethoxy-1-indanone 113 under optimized conditions. NOE 
experiments showed that the reaction exclusively gave the E-isomer (Table 5.6, Entry 2 
and 3). The self-condensation of 2-indanone 114 yielded the mono-condensed product 
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115 as the major product (Table 5.6, Entry 4). While, the same reaction of 1,3-
indandione 117 was completed in 5 min giving dione 118 as the major product (Table 
5.6, Entry 5). Of note, an increase in the yield of truxenequinone 119 was observed when 
the reaction was allowed to run for a longer time. Truxenequinone 119 has been reported 
to be useful for the synthesis of fullerenes compounds (Diederich, F. 1992, Rabideau, P. 
W. 1996). Interestingly, the reaction of six membered cyclic ketones such as 
cyclohexanone 120 and beta-tetralone 121 gave the β,γ-unsaturated isomer (Table 5.6, 
Entry 6 and 7). However, the reaction was successfully applied to the six-membered 
α,β-unsaturated ketone 125 (Table 5.6, Entry 8). Unfortunately, the self-condensation 
reaction of larger ring systems such as cycloheptanone and cyclooctanone (Table 5.6, 
Entry 9) failed under our optimized conditions.  
 We also investigated the implication of our method towards the self-condensation 
of various aldehydes. It was found that the method afforded the desired self-condensation 
products in excellent yields and with high selectivity towards E-isomers (Table 5.7, 
Entries 1-7). It is noteworthy that the self-condensation of aldehydes also does not 
proceed in the absence of lithium perchlorate (Table 5.7, Entry 2). For the practical 
conversion to the self-condensed products of acyclic ketones, higher temperatures and 
longer reaction times were required (Table 5.7, Entry 8-9). 
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Table 5.6 Substrate Scope a  
Entry Substrate Major Product Minor Product Ratiob 
(major: 
minor) 
Yield of 
Major (%)c 
 
1 
 
 
 
 
 
90:10 
 
80 
 
 
2    
 
 
99:1 
 
 
73 
 
 
3d 
 
 
 
 
_ 
 
 
 
NAe 
 
 
70 
 
 
 
4  
 
 
 
 
75:25 
 
 
71 
 
 
5f 
 
 
 
 
 
 
99:1 
 
 
 
92 
 
6 
   
 
98:2 
 
 
50 
 
 
7  
 
 
 
 
_ 
 
 
NA 
 
 
61 
 
 
8 
 
 
 
 
 
 
 
50:50 
 
 
40 
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9 
 
 
 
_ 
 
 
_ 
 
 
NA 
 
 
No 
reaction 
a Reaction were carried out with 40 mol% of LiClO4 and 40 mol% of Et3N at 120 ˚C. 
 b Ratio based on the peak integration of 1H NMR (500 MHz). c Isolated Yield. 
 d Reaction temperature was 150 °C. 
e Not Applicable.  
 f  Reaction time was 5 min. 
 
Table 5.7 Self-condensation of acyclic aldehydes and ketones (Green Chem. 2011, 13, 
1546-1549) 
 
Entry R1 R2 Yield (%)a E:Zb 
1 C5H11 H 95 98:2 
2 C4H9 H 93(0)c 97:3 
3 C3H7 H 90 95:5 
4 C2H5 H 90 98:2 
5 (CH3)2CHCH2 H 85 94:6 
6 PhCH2 H 92 98:2 
7 PhCH2CH2 H 89 97:3 
8 H 4-Me-C6H4 15 >99:1 
9 H 4-Me-C6H4 42d 50:50 
a Isolated Yield. 
b Ratio based on the peak integration of 1H NMR (500 MHz). c Reaction without LiClO4.  
d  Reaction was done at 200 ˚C for 4 hr. 
 
 
 
145 
5.4.2. Studies towards the synthetic 1-azaspirocyclic ring system 
After achieving our initial goal of synthesizing 2-cyclopentylidenecyclopentanone 104 
from cyclopentanone 106, we focused our attention on the development of a concise 
synthetic strategy to obtain the 1-azaspiroctyclic ring system. 
(A) Sequential Semi-pinacol and Beckmann rearrangements to synthesize 1-
azaspirocyclic ring system 
We began with the investigation of the epoxidation reaction of 2-cyclopentylidene-
cyclopentaone (104). Several epoxidation reaction conditions using reagents such as 
MCPBA, H2O2/NaOH and HBO3 were investigated and the best yield was obtained with 
dimethyldioxirane (DMDO) which afforded the corresponding oxide 128 in 98% yield 
(Scheme 5.9). DMDO provided a mild and neutral reaction condition and produced easily 
removable acetone as the only byproduct. Importantly, no purification was required for 
the DMDO-mediated epoxidation reaction. The epoxyketone 128 was then treated with 
hydroxylamine hydrochloride to obtain oxime 129 in 97% yield. The oxime formation 
reaction selectively produced the E-isomer as revealed by the X-ray analysis of oxime 
129 (Figure 5.3). The E-isomer was required for the late stage Beckmann rearrangement. 
 Next, we investigated the ring expansion reaction required to generate the 
spirocyclic ring system. Several Lewis acids such as Bi(OTf)3, In(OTf)3, La(OTf)3 and 
BF3.Et2O were investigated for the semipinacol-type ring expansion of epoxy-oxime 129 
and the best results were obtained using 10 mol% of Sc(OTf)3 in DCM, affording spiro 
keto-oxime 130 in 91% isolated yield. Finally, a PPSE (polyphosphoric acid 
trimethylsilyl ester) mediated Beckman rearrangement provided an efficient method for 
the isomerization of oxime 130 to amide 131. The structure of this 1-azaspirolactam 131 
was confirmed by X-ray crystallography (Figure 5.3). 
  Overall, our approach in Scheme 5.9 provided 1-azaspirolactam 131 in five 
sequential steps starting from the cheap and commercially available precursor 
cyclopentanone with high atom efficiency. Since the conversion of 1-azaspirolactam 131 
into (±)-perhistrioniocotoxin 72b has already been reported, our synthesis of 1-
azaspirolactam 131 also constitutes a formal synthesis of (±)-perhistrioniocotoxin. 
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Scheme 5.9 Synthesis of azaspiro lactam 10 utilizing sequential semi-pinacol and 
Beckmann rearrangements.  
Reagents and conditions: (a) LiClO4 (0.4 equiv), Et3N (0.4 equiv), 120°C, 20 min., 
microwave irradiations, 80%; (b) DMDO (1.5 equiv), rt, 15 hr, 98%; (c) NH2OH.HCl 
(1.5 equiv), NaOAc (1.5 equiv), MeOH, 30 min, rt, 88%; (d) Sc(OTf)3 (0.1 equiv), DCM, 
rt, 4hr, 91%; (e) PPSE, 80°C, 12 hr, 75%.  
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Figure 5.3  X-ray crystal structure of 129 (left) and 131 (right). (X-ray analysis was 
performed by Dr. Sean Parkin at Department of Chemistry, University of Kentucky) 
(B) Tandem Semi-pinacol and Beckmann rearrangements 
Scheme 5.9 clearly demonstrated the efficiency of our synthetic strategy for the 
construction of the 1-azaspirocyclic ring system. The key sequential reactions in our 
approach were a Lewis acid catalyzed semi-pinacol rearrangement and a PPSE-mediated 
Beckmann rearrangement. As both of these reactions are known to proceed using acids 
also, we envisaged that it might be possible to use both the above reactions in one 
synthetic step to construct an azaspirocyclic ring system. 
                                                                                                                                                             
Table 5.8 Tandem Semi-pinacol/Beckmann rearrangements. 
 
Entry Reagents Temp (°C) Time (h) Yield (%)a 
1 TiCl4, DCM  -78 0.5 10 
2 AlCl3, CH3CN reflux 2.5 trace 
3 SOCl2, rt, 6h 25 6.0 0 
4 PPA 130 0.5 84 
5 Eaton’s reagent 100 1.0 77 
6 PPE 100 2.0 20 
7 PPSE 80 12 10 
a Isolated Yield.  
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We started by investigating the feasibility of tandem semi-pinacol/Beckmann 
rearrangements. When we attempted use TiCl4 and AlCl3, which are commonly 
employed strong Lewis acids in Beckmann rearrangements, for the conversion of epoxy 
ketone 129 to required product 131, yields were poor. However, moderate yields were 
observed in the case of strong acids such as Eaton’s reagent and PPE (Polyphosphate 
Ester). To our delight, a smooth expansion to 1-azaspirocycle 131 was observed when 
PPA (polyphosphoric acid) was used. To the best of my knowledge, this reaction 
provides the first example of tandem semi-pinacol/Beckmann rearrangements in the 
literature. This tandem reaction allows the formation of a tertiary carbon adjacent to the 
N functionality and the spirocyclic ring system within one synthetic operation.      
 
(C) One pot synthesis of sterically hindered α,β-dicyclic enone and corresponding 
epoxides 
After successfully showing the application of the tandem semi-pinacol/Beckmann 
rearrangements for the synthesis of 1-azaspirolactam 131, we next focused on the 
application of tandem semi-pinacol/Beckmann rearrangements on other systems (Scheme 
5.10). For the synthesis of α,β-dicyclic enones having different ring sizes, we decided to 
investigate a procedure previously reported by Bach et al. (1985). Initially, thiol 132 was 
chosen as a model substrate for our studies. A Lewis acid catalyzed α-thioalkylation of 
silyl enol ether resulted in the desired carbon–carbon bond formation of the two cyclic 
fragments to obtain thiol 132 (Reetz, M. T. 1981). Bach et al. reported in their paper that 
treatment of 132 with sodium periodate at 0 °C produced the required α,β-unsaturated 
cyclic enone 134a. However, we were unable to reproduce this oxidative 
dehydrosulfenylation reaction. Even a 24 hr reaction at room temperature did not go to 
completion and yielded sulfone 133 as major product. After further digging into the 
literature we found that heating of β-ketosulfone in CCl4 is known to produce unsaturated 
ketones (Paterson, I. 1979). The reaction provided an isomeric mixture of products 134a 
and 134b whose separation was difficult and an extensive chromatography was required 
to purify the products; thus affording a low yield of the required enone 134a. Hence, we 
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turned our attention towards modification of this route to synthesize the cyclic enone 
more efficiently. 
 
Scheme 5.10  Investigation of previously reported method to synthesize α,β-dicyclic 
enones 
 First, we decided to investigate the oxidation of thiol 132 to sulfone 133. 
Dimethyldioxirane (DMDO) being a powerful electrophilic oxidant is known to oxidize 
aliphatic sulfides to sulfinic acids. Also, DMDO provides a mild and neutral reaction 
condition for transfer of oxygen atoms; and produces a fairly innocuous and easily 
removable acetone as the only byproduct. When we carried out the oxidation of thiol 132 
with DMDO, a complete conversion to required product 133 was observed within 30 
min. Next, we investigated the selective elimination reaction for the conversion of 
compound 133 to enone 134a. Several amine bases such as DMAP, imidazole, Et3N, 
DABCO and DIPEA provided unsatisfactory results and 1,8-diazabicyclo[5.4.0]undec-7-
ene (DBU) was found to be the best one giving enone 134a in 95% yield.  
 In Scheme 5.9 we showed the application of DMDO for the epoxidation of enone 
and for the oxidation of sulphide we used DMDO also. So, we envisioned a one pot 
synthesis of epoxy-ketone 135 from thiol 132.  
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Scheme 5.11  One pot thiol-oxidation/elimination/epoxidation 
 The one-pot procedure consists of the reaction of thiol 132 (1 equiv) with DMDO 
(2.5 equiv). After complete consumption of starting material, the reaction mixture was 
concentrated to remove acetone. The concentrate was diluted with methylene chloride (2 
ml) and DBU was added dropwise at 0°C and the reaction was monitored. After 
completion of the elimination reaction 1.5 equiv DMDO was added and the reaction 
mixture was stirred for 15 hr at room temperature. The reaction mixture was again 
concentrated and the product was extracted with ethyl acetate in pure form. The epoxy-
ketone 135 was thus obtained in a one-pot fashion with an overall yield of 95% (Scheme 
5.11).  
(D) Application of tandem semi-pinacol/Beckmann rearrangements 
 With the straightforward synthesis of the trispiro epoxyketone in hand, we next 
focused on the application of the tandem semi-pinacol/Beckmann rearrangement to 
another system. The treatment of hydroxylamine hydrochloride with epoxyketone 141 
afforded epoxy-oxime 142 which was further transformed into lactam 143 by a PPA 
mediated tandem semi-pinacol/Beckmann rearrangement; thus validating our 
straightforward strategy for the rapid construction of the 1-azaspriocyclic ring system 
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(Scheme 5.12). The structure of lactam 143 was confirmed by X-ray crystallography 
(Figure 5.4). 
 
Scheme 5.12  Substrate Scope of tandem semi-pinacol/Beckmann rearrangement 
 
Figure 5.4  X-ray structure of 1-azaspirocycle 143. (X-ray analysis was performed by 
Dr. Sean Parkin at Department of Chemistry, University of Kentucky) 
5.5. Summary 
A new concise approach for the construction of 1-azaspirocyclic ring system has been 
developed via tandem rearrangements of an α,β-epoxy oxime. The synthetic strategy 
demonstrated the first example of tandem semi-pinacol/Beckman rearrangements and 
generated a tertiary carbon center and a spirocyclic ring within a single synthetic step. 
The method also highlighted an efficient one-pot reaction for the construction of highly 
strained trispiro epoxyketone epoxides. Additionally, an environmentally benign, 
microwave-assisted, and solvent-free self-condensation of carbonyl compounds has also 
been developed. 
 
152 
5.6. Supporting Information 
5.6.1. General Methods (Green Chem. 2011, 13, 1546-1549) 
All reactions were carried out in flame-dried glassware under nitrogen atmosphere with 
anhydrous solvent. The microwave reactions were carried out in sealed tubes in Biotage 
InitiatorTM Microwave Synthesizer. Unless otherwise noted, all commercial reagents 
were obtained from commercially available sources and used without purification. Flash 
column chromatography was performed on a Biotage SP-1 chromatography system. TLC 
plates were visualized by exposure to ultraviolet light (254 nm) and/or by immersion in a 
staining solution of vanillin, followed by heating on a hot plate. Dimethyldioxirane 
(DMDO) was prepared as described by Murray et al. Generally, concentrations in the 
range of 0.04-0.10 M were obtained. 1H and 13C spectra were recorded using 300 or 400 
or 500 MHz, using CDCl3 as a solvent.  The chemical shifts are reported in parts per 
million (ppm) relative to CHCl3 (δ 7.26 ppm for proton NMR and δ 77.23 ppm for carbon 
NMR). Coupling constants are reported in hertz (Hz). The following abbreviations are 
used to designate the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet. 
 
5.6.2. Synthesis 
(A) Self-condensation of ketones 
Reaction Procedure A: (Green Chem. 2011, 13, 1546-1549) 
To a 0.2-0.5 ml microwave vial containing ketone (1 mmol) was added anhydrous 
LiClO4 (0.043 g, 40 mol %) and Et3N (0.056 mL, 40 mol %). The vial was sealed and 
the reaction mixture was stirred for 20 min. at 120 °C (or as specified conditions) in 
the microwave reactor. After cooling, the microwave vessel was uncapped and 15mL 
of sat. NH4Cl was added. The product was extracted with (2x20 mL) ethyl acetate. 
The organic layer was dried over MgSO4, filtered, and evaporated to dryness under 
reduced pressure to obtain the crude. All the liquid products were purified using 
distillation while the solid products were purified either by crystallization or by silica 
gel column chromatography. 
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Self-condensation of cyclopentanone: (Green Chem. 2011, 13, 1546-1549) 
                                     
Reaction procedure A was followed to obation crude. The crude was distilled to 
obtain the enone 104 (80%) as colorless liquid, while the remaining solid was 
crystalized using hexane-ethyl acetate (3:1) to yield 105 in pure form.  
2-cyclopentylidenecyclopentan-1-one (104): IR (ν, cm-1): 2955, 2870, 1706, 1636, 
725;       1H NMR (500 MHz, CDCl3): δ 2.77 (m, 2H), 2.51 (m, 2H), 2.29 (m, 4H), 
1.90 (m, 2H), 1.76-1.64 (m, 4H); 13C NMR (125 MHz, CDCl3): δ 207.6, 158.8, 128.1, 
40.0, 34.5, 32.7, 27.2, 26.9, 25.4, 20.3.                                                    
 2,5-Dicyclopentylidenecyclopentaone (105): White solid; mp=83-84 °C;  IR (ν, cm-1): 
2952, 2862, 1689, 1637, 1617, 1260, 1173, 767; 1H NMR (500 MHz, CDCl3): δ 2.87 (t, J 
= 6.5 Hz, 4H), 2.52 (bs, 4H), 2.28 (t, J = 6.5 Hz, 4H), 1.76-1.64 (m, 8H); 13C NMR (125 
MHz, CDCl3): δ 196.06, 157.76, 131.37, 34.31, 32.45, 27.32, 26.16, 25.47. 
 
Self-condensation of 1-indanone: (Green Chem. 2011, 13, 1546-1549) 
                                                                                                              
  
 
Reaction procedure A was followed to obtain solid crude. 1H NMR of crude product 
showed the formation of very small amount of 110. The crude was crystallized using 
hexane-ethyl acetate (3:1) to obtain 110 (73%) in pure form (compound 111 was not 
isolated). 
trans-2-(1-indanylidene)indan-1-one (110): White solid; mp=143-144 °C; IR (ν, cm-1): 
3064, 2918, 1673, 1597, 1325, 733; 1H NMR (500 MHz, CDCl3): δ 7.83 (d, J = 7.5 Hz, 
1H), 7.82 (d, J = 7.5 Hz, 1H), 7.60-7.80 (m, 2H), 7.44-7.34 (m, 4H), 4.03 (s, 2H), 3.58 (t, 
J = 6.5 Hz, 2H), 3.14 (t, J = 6.5 Hz, 2H); 13C NMR (125 MHz, CDCl3): δ 195.5, 155.3, 
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151.9, 148.7, 141.1, 139.8, 133.8, 130.6, 127.5, 127.1, 126.5, 126.2, 126.2, 126.0, 123.8, 
33.3, 31.8, 31.2. 
 
 
Self-condensation of 5,6-dimethoxy-1-indanone: (Green Chem. 2011, 13, 1546-
1549) 
 
 
Reaction procedure A was followed to obtain solid. Purification of silica gel (50% 
EtOAc/hexane) afforded 113 in 70% yield. 
Dione 113: Yellow solid; IR (ν, cm-1): 3064, 2918, 1673, 1597, 1325, 733; 1H NMR (500 
MHz, CDCl3): δ 7.29 (s, 1H), 7.27 (s, 1H), 7.18 (s, 1H), 7.00 (s, 1H), 4.00 (s, 3H), 3.97 
(s, 3H), 3.95 (s, 6H), 3.91 (s, 2H), 3.57 (t, J = 6.0 Hz, 2H), 2.68 (t, J = 6.0 Hz, 2H); 13C 
NMR (125 MHz, CDCl3): δ 194.2, 154.5, 154.4, 151.9, 149.5, 148.7, 143.0, 133.4, 108.1, 
107.8, 107.7, 107.3, 105.2, 104.7, 104.3, 56.4, 56.3,  56.3, 56.2, 32.5, 32.3, 31.1. 
 
Self-condensation of 2-indanone: (Green Chem. 2011, 13, 1546-1549) 
 
 
Reaction procedure A was followed to obtain solid crude. Purification by silica gel 
(3% EtOAc/hexane) afforded dione 115 in 71% yield and 116 in 8% yield. 
Dione (115): Yellow solid; mp=160-162 °C, IR (ν, cm-1): 3027, 2906, 1707, 1625, 1393, 
731; 1H NMR (500 MHz, CDCl3): δ 7.63 (d, J = 5.0 Hz, 1H), 7.42-7.38 (m, 4H), 7.33 (d, 
J = 10.0 Hz, 1H), 7.28-7.26 (m, 2H), 4.42 (s, 2H), 4.01 (s, 2H), 3.51 (s, 2H); 13C NMR 
(125 MHz, CDCl3): δ 204.3, 154.4, 141.4, 140.4, 139.5, 137.6, 129.9, 127.7, 127.5, 
127.3, 126.9, 125.4, 124.9, 124.6, 123.7, 42.6, 41.5, 41.0. 
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Compound (116): Green solid; mp=178-180 °C, IR (ν, cm-1): 3022, 2900, 1700, 
1625, 1390, 722; 1H NMR (500 MHz, CDCl3): δ 7.69 (m, 2H), 7.41 (m, 6H), 7.27 (m, 
4H), 4.58 (s, 4H), 4.25 (s, 4H). 
 
Self-condensation of 1,3-indandione: (Green Chem. 2011, 13, 1546-1549) 
 
Reaction procedure A was followed for only 5 minutes to obtain solid crude and crude 
was crystallized using hexane-ethyl acetate (3:1) to obtain  118 (92%) in pure form.  
When the reaction was conducted for 20 min, truxenequinone 119 was obtained in 55% 
yield while compound 118 was obtained in 25% yield by column chromatography (5% 
Ethyl acetate/hexane).                                                                         
1-(indan-1,3-dione-2-ylidene)indan-3-one (118): Yellow solid; IR (ν, cm-1): 3020, 
2901, 1707, 1680, 1340, 931; 1H NMR (500 MHz, CDCl3): δ 9.64 (d, J=8.0 Hz, 1H), 
8.00 (m, 1H),  7.96-7.90 (m, 2H), 7.88-7.74 (m, 3H), 7.72 (1.75, J=6.5Hz, 1H), 4.11 (s, 
2H); 13C NMR (125 MHz, CDCl3): δ 201.1, 191.2, 189.5, 155.5, 146.1, 141.8, 141.4, 
140.6, 135.5, 134.3, 131.8, 126.0, 123.7, 123.6, 123.2, 43.6.  
Truxenequinone (119): Yellow solid; 1H NMR (500 MHz, CDCl3): δ 9.30 (d, J= 10 Hz, 
3H), 7.87 (d, J= 10.0 Hz, 3H), 7.72 (t, J = 10.0 Hz, 3H), 7.85 (t, J = 10.0 Hz,  3H). 
 
 
Self-condensation of cyclohexanone: (Green Chem. 2011, 13, 1546-1549) 
                        
Reaction procedure A was followed to obtain crude as yellow oil. The crude was distilled 
to obtain 121 (50%) and 122 (2%) in pure form.                                                       
[1,1'-bi(cyclohexylidene)]-2-one (121): Colorless oil; IR (ν, cm-1): 2922, 2851, 1675, 
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1639, 1444, 729; 1H NMR (500 MHz, CDCl3): δ 5.38 (t, J=10 Hz, 1H), 2.88 (dd, 
J=11.2 and 5.0Hz, 1H), 2.42-2.36 (m, 1H), 2.34-2.26 (m, 1H), 2.06-1.96 (m, 4H), 
1.96-1.80 (m, 4H), 1.74-1.52 (m, 6H); 13C NMR (125 MHz, CDCl3): δ 211.8, 136.1, 
123.8, 58.9, 42.3, 31.0, 27.8, 27.5, 25.5, 25.1, 23.1, 22.6.                                                                               
1'-hydroxy-[1,1'-bi(cyclohexan)]-2-one (122): Colorless oil; IR (ν, cm-1): 3300, 
1670, 1429; 1H NMR (500 MHz, CDCl3): δ 3.64 (s, 1H), 2.39 (dd, J=12.0 and 5Hz, 
1H), 2.36-2.28 (m, 2H), 2.22-2.16 (m, 1H), 2.10-2.04 (m, 1H), 1.96-1.90 (m, 1H), 
1.74-1.54 (m, 8H), 1.46-1.38 (m, 3H), 1.30-1.12 (m, 2H); 13C NMR (125 MHz, 
CDCl3): δ 216.6, 72.2, 59.2, 44.1, 36.5, 33.5, 29.2, 28.5, 26.1, 25.7, 21.9, 21.6. 
 
Self-condensation of β-tetralone: (Green Chem. 2011, 13, 1546-1549) 
 
 
Reaction procedure A was followed to obtain solid crude and crude was crystallized 
using hexane-ethyl acetate (3:1) to obtain 19 (61%) in pure form.   
1',3,4,4'-tetrahydro-[1,2'-binaphthalen]-2(1H)-one (124): White solid; IR (ν, cm-1): 
2918, 2842, 1678, 1629, 1451, 780; 1H NMR (500 MHz, CDCl3): δ 7.30-7.20 (m, 3 
H), 7.15-7.05 (m, 4H), 6.97 (d, J=6.0 Hz, 1H), 6.27 (s, 1H), 3.68 (s, 2H), 3.36-3.26 
(m, 2H), 3.13 (dd, J=14.0, 4.5 Hz, 1H), 2.90-2.68 (m, 2H), 2.36-2.18 (m, 2H); 13C 
NMR (125 MHz, CDCl3): δ 209.6, 138.2, 136.1, 134.9, 134.2, 133.1, 128.2, 127.9, 
127.4, 127.2, 127.1, 127.0, 126.6, 126.1, 125.7, 55.4, 45.2, 33.7, 28.2, 26.1.  
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Self-condensation of 3,3-dimethylcyclohexenone: (Green Chem. 2011, 13, 1546-
1549) 
                      
                                        
Reaction procedure A was followed to obtain crude. Purification of silica gel (3% 
EtOAc/hexane) afforded a mixture of (126) and (126) as colorless oil (40% yield); 1H 
NMR (500 MHz, CDCl3): δ 7.11 (d, J = 10.0 Hz, 1H), 6.57 (d, J = 2.5 Hz, 1H), 6.55 
(d, J = 2.5 Hz, 1H), 6.33 (d, J = 10.0 Hz, 1H), 5.93 (d, J = 10.0 Hz, 1H), 5.89 (d, J = 
1.5 Hz, 1H), 5.87 (d, J = 1.5 Hz, 1H), 5.79 (d, J = 10.5 Hz, 1H), 2.86 (t, J = 6.5 Hz, 2 
H), 2.60 (s, 2H), 2.57 (s, 2H), 2.44 (t, J = 6.5 Hz, 2H), 1.62 (t, J = 7.0 Hz, 2H), 1.52 
(t, J = 7.0 Hz, 2H), 1.13 (s, 6H), 1.12 (s, 6H), 1.04 (s, 6H), 1.03 (s, 6H); 13C NMR 
(125 MHz, CDCl3): δ 192.2, 191.9, 157.3, 157.2, 147.5, 145.3, 143.0, 142.2, 129.8, 
129.6, 127.3, 126.9, 123.9, 122.6, 42.3, 41.5, 36.9, 36.6, 36.2, 35.8, 32.4, 32.2, 28.6, 
28.5, 27.9, 27.9, 25.0, 24.2. 
 
Self-condensation of 4-methylacetophenone (Table V, Entry 8): 
 
 
Reaction procedure A was followed to obtain crude. The condensation product was 
isolated by column chromatography on silica gel (3% EtOAc/hexane). 1H NMR (500 
MHz, CDCl3): δ 8.01 (d, J=5.0 Hz, 2H), 7.59 (d, J=5.0 Hz, 2H), 7.37 (d, J=8.0 Hz, 2H), 
7.33 (d, J=8.0 Hz, 2H), 2.69 (s, 3H), 2.52 (s, 3H), 2.50 (s, 3H); 13C NMR (75 MHz, 
CDCl3): δ 191.6, 163.8, 154.5, 143.2, 139.9, 139.3, 136.9, 129.4, 129.3, 128.5, 126.5, 
121.5, 21.9, 21.5, 19.0. 
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(B) Self-condensation of aldehydes 
Reaction Procedure B: (Green Chem. 2011, 13, 1546-1549) 
To a 0.2-0.5 ml microwave vial containing substrate (1mmol) was added anhydrous 
LiClO4 (0.043 g, 40 mol %) and Et3N (0.056 ml, 40 mol %). The vial was sealed and 
the reaction mixture was stirred for 20 min. at 120 °C in microwave reactor. After 
cooled to ambient temperature, saturated NH4Cl (10 ml) was added and extraction 
was done using ether. The organic layer was dried over MgSO4, filtered, and 
evaporated to dryness under reduced pressure to obtain crude. The condensation 
product was purified by distillation. 
 
Self-condensation of heptanal (Table V, Entry 1): (Green Chem. 2011, 13, 1546-
1549) 
1H NMR (500 MHz, CDCl3): δ 9.35 (s, 1H), 6.43 (t, J=7.5 Hz, 1H), 2.36 (m, 2H), 
2.22 (t, J=7.4 Hz, 2H), 1.36-1.22 (m, 10H), 0.92-0.84 (m, 6H); 13C NMR (125 MHz, 
CDCl3): δ 195.4, 155.4, 143.9, 31.9, 31.8, 29.1, 29.0, 28.7, 28.6, 24.0, 22.7, 22.4, 
14.1, 14.1.  
Self-condensation of hexanal (Table V, Entry 2): (Green Chem. 2011, 13, 1546-
1549) 
1H NMR (500 MHz, CDCl3): δ 9.36 (s, 1H), 6.44 (t, J=7.5 Hz, 1H), 2.40-2.16 (m, 
4H), 1.60-1.25 (m, 10 H), 0.92-0.88 (m, 6H); 13C NMR (125 MHz, CDCl3): δ 195.5, 
155.5, 143.8, 31.7, 31.1, 29.0, 28.5, 23.8, 22.9, 22.5, 14.0, 13.8. 
Self-condensation of pentanal (Table V, Entry 3): (Green Chem. 2011, 13, 1546-
1549) 
1H NMR (500 MHz, CDCl3): δ 9.36 (s, 1H), 6.48 (t, J=7.5 Hz, 1H), 2.35 (m, 2H), 
2.21 (t, J=7.5 Hz, 2H), 1.54-1.26 (m, 6H), 0.94-0.88 (m, 6H); 13C NMR (125 MHz, 
CDCl3): δ 195.4, 155.6, 143.7, 31.0, 28.8, 26.1, 22.6, 22.1, 14.2, 14.1. 
Self-condensation of butanal (Table V, Entry 4): (Green Chem. 2011, 13, 1546-
1549) 
1H NMR (500 MHz, CDCl3): δ 9.35 (s, 1H), 6.40 (t, J=7.5 Hz, 1H), 2.35 (t, J=7.5 Hz, 
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2H), 2.24 (q, J=7.5 Hz, 2H), 1.54 (m, 2H), 1.0-0.92 (m, 6H); 13C NMR (125 MHz, 
CDCl3): δ 195.1, 154.6, 145.4, 30.7, 22.0, 17.2, 13.9, 13.4. 
Self-condensation of isovaleraldehyde (Table V, Entry 5): (Green Chem. 2011, 13, 
1546-1549) 
1H NMR (500 MHz, CDCl3): δ 9.31 (s, 1H), 6.33 (t, J=7.5 Hz, 1H), 2.90-2.80 (m, 
1H), 2.5 (t, J=7.5 Hz, 2H),  1.82-1.75 (m, 1H), 1.15 (d, J=7 Hz, 6H), 0.95 (d, J=7 Hz, 
6H); 13C NMR (125 MHz, CDCl3): δ 195.6, 152.9,  137.1, 46.3, 43.7, 41.8, 37.6, 33.5. 
Self-condensation of phenylacetaldehyde (Table V, Entry 6): (Green Chem. 2011, 
13, 1546-1549) 
1H NMR (500 MHz, CDCl3): δ  9.45 (s, 1H), 7.30-7.10 (m, 10H), 6.65 (t, J=7.4, 1H), 
3.42 (d, J=7 Hz, 2H); 13C NMR (125 MHz, CDCl3): δ 195.1, 154.7, 142.6, 140.4, 
128.8, 128.5, 128.4, 128.3, 128.2, 128.1, 126.3, 126.0, 35.0. 
Self-condensation of 3-phenyl propionaldehyde (Table V, Entry 7): (Green Chem. 
2011, 13, 1546-1549) 
1H NMR (500 MHz, CDCl3): δ 9.45 (s, 1H), 7.32-7.10 (m, 10H), 6.65 (t, J=7.0, 1H), 
3.58 (s, 2H), 2.80-2.70 (m, 4H); 13C NMR (125 MHz, CDCl3): δ 194.8, 155.1, 142.7, 
140.5, 139.0, 128.6, 128.5, 128.5, 128.3, 126.4, 126.2, 34.4, 31.1, 29.6.  
 
Note: All the spectral data of self-condensation of aldehydes are consistent with the 
data given in Green Chem., 2010, 12, 384-386. 
 
(C) Synthesis spirocyclic ring systems 
Preparation of 2-Cyclopentylidenecyclopentan-1-one Oxide (128)  
To a solution of 104 (0.779 g, 5.2 mmol) in CH2Cl2 (5 ml) was added 
rapidly a solution of 0.053 M DMDO in acetone (28 ml, 1.5 eq) under 
nitrogen. The reaction mixture was stirred at room temperature for 15 h. 
The solvent was removed in vacuo and extraction was done using CH2Cl2 
to obtain epoxide 128 (0.846 g, 98%) as colorless oil. IR (ν, cm-1): 2962, 2871, 1746, 
1406, 1206, 1164, 960; 1H NMR (500 MHz, CDCl3): δ 2.42-2.28 (m, 2H), 2.19-2.02 (3H, 
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m, 3H), 1.96-1.50 (m, 9H); 13C NMR (125 MHz, CDCl3): δ 214.5, 76.9, 68.1, 37.3, 32.1, 
29.7, 27.5, 25.6, 25.0, 18.1. 
 
Preparation of (1E)-11-oxadispiro[4.0.4.1]undecan-1-one oxime (129) 
 
Epoxide 128 (0.392 g, 2.4 mmol) was treated with NH2OH.HCl (1.1 
equiv) and sodium acetate (2.2 equiv) in methanol (10ml/g of 
NH2OH.HCl) at 0oC for 1hr. CH2Cl2 was added and aqueous phase was 
extracted several times with CH2Cl2. The combined aqueous phases 
were washed with brine and dried over MgSO4, filtered, and evaporated to dryness under 
reduced pressure to yield 129 (0.421 g, 97%) as white solid. NMR of crude suggested 
that no further purification is required. In order to get mp of the compound 
recrystallization was done with hot hexane. mp: 115-117 °C; IR (ν, cm-1 ) : 3224, 2960, 
1469, 1428, 930, 754; 1H NMR (500 MHz, CDCl3): δ 2.66 ̶ 2.42 (m, 2H), 1.44 ̶ 2.20 
(15H, m); 13C NMR (125 MHz, CDCl3): δ 161.4, 76.4, 68.2, 32.3, 30.4, 30.3, 26.8, 25.5, 
25.3, 19.9. 
 
 
Preparation of (1E)-spiro[4.5]decane-1,6-dione 1-oxime (130) 
 
To a solution of oxime 129 (0.181 g, 1.0 mmol) in 5 ml CH2Cl2, Sc(OTf)3 
(0.049 g, 0.1 eq) was added. The reaction mixture was stirred for 4h at 
room temperature and 20 ml of saturated NaHCO3 solution was added to 
quench the reaction. The product was extracted with 2 x 50 ml ethyl ether. 
The organic phase was washed with 50 ml brine and dried (MgSO4). The solvent was 
then removed, and recrystallization of the crude from a hot solution of hexane-CH2Cl2 
(5:1) yielded ketoxime 130 (0.165 g, 91%). mp: 94-95 °C; IR (ν, cm-1): 3284, 2948, 1704, 
1451, 1416, 906; 1H NMR (500 MHz, CDCl3): δ 9.20 (bs, 1H), 2.62 ̶ 2.52 (m, 1H), 2.52 ̶ 
2.28 (m, 3H), 2.08 ̶ 1.98 (m, 1H), 1.98 ̶ 1.84 (m, 1H), 1.84 ̶ 1.70 (m, 2H), 1.70 ̶ 1.44 (m, 
6H); 13C NMR (125 MHz, CDCl3): δ 210.8, 167.8, 60.1, 39.5, 37.2, 36.8, 27.7, 27.0, 
21.8, 21.2. 
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Preparation of 1-azaspiro[5.5]undecane-2,7-dione (10) 
A viscous mixture of 0.050 g (0.28 mmol) of epo-oxime 130 and 1.0 g of 
PPA was heated at 130°C for 5 min. The mixture was cooled and the 
viscous oil was allowed to stand at room temperature overnight, and then 
diluted with ice water. Neutralization was done with 30ml of 50% 
sodium hydroxide with cooling. The product was separated with CHCl3 and 
recrystallization from CHCl3 gave 1-azaspirolactam 131 (0.042 g, 84%). mp: 152-154 °C; 
IR (ν, cm-1): 3183, 2928, 1712, 1650, 1407; 1H NMR (500 MHz, CDCl3):  δ 6.35 (bs, 
1H), 2.54-2.46 (m, 2H), 2.34-2.24 (m, 2H), 2.18-2.10 (m, 1H), 2.10-2.00 (m, 2H), 1.90-
1.54 (m, 7H); 13C NMR (125 MHz, CDCl3): δ 209.7, 172.4, 65.4, 40.9, 38.7, 30.9, 29.4, 
27.4, 21.8, 17.2. 
 
 
Preparation of 2-(1-(ethylthio)cycloheptyl)cyclopentanone (132a) 
 
To a round bottom flask containing 20 ml of anhydrous CH2Cl2 at -60°C, SnCl4 (10 ml, 1 
M in CH2Cl2) was added. A cooled (-60°C) solution of cycloheptane-1,1-
diylbis(ethylsulfane) (2.18 g, 10.0 mmol) in 5 ml anhydrous CH2Cl2 was added dropwise. 
Immediately, a cooled (-60°C) solution of (cyclopent-1-en-1-yloxy)trimethylsilane 
(1.56g, 10.0 mmol) in 5.0 ml CH2Cl2. After stirring the reaction mixture at -60°C for 45 
min, reaction was quenched with 100 ml ice water. Extraction was done using CH2Cl2 
and organic layer was washed with 10% aqueous NaHCO3 (100 ml), water (100 ml) and 
dried over MgSO4. The filtrate was concentrated under reduced pressure to obtain 
compound 132a (2.1 g, 87% yield); IR (ν, cm-1): 2926, 2864, 1694, 1447; 1H NMR (500 
MHz, CDCl3):  δ 2.44 (m, 2H), 2.30-2.22 (m, 3H), 2.20-2.12 (m, 3H), 2.00 (m, 1H), 1.92 
(m, 1H), 1.85 (m, 1H), 1.72-1.56 (m, 6H), 1.52-1.42 (m, 4H), 1.14 (t, J=7.5 Hz, 3H); 13C 
NMR (125 MHz, CDCl3): δ 219.3, 56.5, 54.8, 41.4, 39.2, 36.4, 29.9, 29.5, 27.2, 23.1, 
23.1, 22.5, 20.4, 14.5. 
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Preparation of 2-cycloheptylidenecyclopentanone (133a) 
 
To a solution of compound 132a (0.24 g, 1 mmol) in MeOH-H2O (9:1, 
10 ml), NaIO4 (1.0 mmol) was added. The reaction mixture was stirred 
in the dark for 16 h, water (15 ml) was added and extraction was done 
with CH2Cl2. The organic phase was dried and concentrated to give a 
mixture of sulphoxide and eliminated products. The crude was warmed in CCl4 at 60 °C 
for 24h and chromatography on silica gel (99:1 hexane/EtOAc) yielded 133a (0.11 g, 
62%). IR (ν, cm-1): 2926, 2854, 1702, 1620, 1447, 1250, 1173, 1083; 1H NMR (500 
MHz, CDCl3):  δ 2.97 (t, J=5.5 Hz, 2H), 2.59 (t, J=7.5 Hz, 2H), 2.32 (t, J=8 Hz, 4H), 
1.86 (m, 2H), 1.68-1.58 (m, 4H), 1.54-1.48 (m, 4H); 13C NMR (125 MHz, CDCl3): 206.6, 
156.7, 129.8, 40.2, 35.2, 30.3, 29.3, 29.1, 28.8, 26.8, 25.8, 19.0. 
 
13-oxadispiro[4.0.6.1]tridecan-1-one (141) 
 
A DMDO solution (2.5 equiv, 12.5mmol) was added to a round bottom 
flask containing compound 132a (1.2 g, 5.0 mmol). The reaction 
mixture was stirred and monitored with TLC using vanillin stain. After 
complete consumption of SM (in 1 hr), the reaction mixture was concentrated to remove 
acetone. The concentrate was diluted with methylene chloride (2 ml) and DBU (1 equiv) 
was added dropwise at 0°C and the reaction was carefully monitored using TLC. After 
completion of elimination reaction, 1.5 equiv DMDO solution was added and the reaction 
mixture stirred for 15 hr at room temperature. The reaction mixture was concentrated and 
product was extracted with methylene chloride. The oxide 141 was obtained in a one-pot 
fashion with an overall yield of 92% (0.89 g). IR (ν, cm-1): 2924, 2855, 1740, 1455. 1405, 
1168, 997, 751; 1H NMR (500 MHz, CDCl3):  2.44-2.28 (2H, m), 2.22-1.88 (6H, m), 
1.82-1.46 (9H, m), 1.34-1.22 (1H, m); 13C NMR (125 MHz, CDCl3): 214.1, 71.8, 69.8, 
36.9, 34.7, 29.8, 29.2, 28.5, 26.6, 24.5, 24.3, 17.8. 
 
 (1E)-13-oxadispiro[4.0.6.1]tridecan-1-one oxime (142) 
Epoxide 141 (0.246 g, 1.27 mmol) was treated with NH2OH.HCl 
(1.1equiv) and sodium acetate (2.2 equiv) in methanol (10ml/g of 
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NH2OH.HCl) at 0°C. After stirring the reaction mixture at 0°C for 30 min, CH2Cl2 was 
added and aqueous phase was extracted several times with CH2Cl2. The combined 
aqueous phases were washed with brine and dried over MgSO4, filtered, and evaporated 
to dryness under reduced pressure to yield 142 (0.252, 95% yield); IR (ν, cm-1): 3120, 
2919, 2852, 1448, 960; 1H NMR (500 MHz, CDCl3): 8.45 (1H, bs), 2.74-2.64 (m, 1H), 
2.54-2.46 (m, 1H), 2.04-1.34 (16H, m); 13C NMR (125 MHz, CDCl3): 161.6, 70.9, 70.4, 
35.0, 30.7, 29.5, 29.4, 28.8, 26.2, 24.7, 24.5, 19.8. 
 
1-azaspiro[5.7]tridecane-2,7-dione (143) 
 
 A viscous mixture of 0.037g (0.18 mmol) of epoxy-oxime 142 in 1 
g of PPA was heated at 130°C for 5 min with manual stirring. The 
mixture was cooled and the viscous oil was allowed to stand at 
room temperature overnight, and then diluted with ice water. 
Neutralization was done with 30ml of 50% sodium hydroxide with 
cooling. The product was separated with CHCl3 and 
recrystallization from CHCl3 gave lactam 143 (0.030g, 80% yield); IR (ν, cm-1): 3211, 
2932, 1702, 1655, 1403; 1H NMR (500 MHz, CDCl3): δ 6.02 (s, 1H), 2.72 (td, J = 11 Hz, 
J = 4 Hz, 1H),  2.44-2.24 (m, 4H), 1.96-1.84 (m, 3H), 1.84-1.68 (m, 4H), 1.68-1.42 (m, 
4H), 1.40-1.24 (m, 1H), 1.02-0.88 (m, 1H); 13C NMR (125 MHz, CDCl3): δ 214.7, 172.6, 
66.5, 36.7, 34.8, 30.9, 30.8, 30.1, 25.9, 24.4, 22.8, 17.3. 
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5.6.3. Copies of 1H and 13C NMR spectra (Green Chem. 2011, 13, 1546-1549) 
 
 
 
 
165 
 
 
 
166 
 
 
 
 
 
 
167 
 
 
 
 
 
 
168 
 
 
 
169 
 
 
 
 
 
 
 
 
170 
 
 
 
 
 
 
171 
 
 
 
172 
 
 
173 
 
 
 
174 
 
 
 
175 
Table 5.7, entry 8 
 
 
 
 
 
176 
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